{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:49:05Z","timestamp":1776872945386,"version":"3.51.2"},"reference-count":792,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-025-01294-9","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:45:52Z","timestamp":1759596352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elucidating the risk factors and oncogene drivers of acute myeloid leukemia"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9493-3669","authenticated-orcid":false,"given":"Daniel Ruben Akiola","family":"Sanya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djamila","family":"On\u00e9sime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"issue":"4","key":"1294_CR1","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000496097","volume":"141","author":"BJ Bain","year":"2019","unstructured":"Bain BJ, B\u00e9n\u00e9 MC. Morphological and Immunophenotypic Clues to the WHO categories of acute Myeloid Leukaemia. Acta Haematol. 2019;141(4):232\u201344.","journal-title":"Acta Haematol"},{"key":"1294_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.blre.2019.03.007","volume":"36","author":"L Naymagon","year":"2019","unstructured":"Naymagon L, Marcellino B, Mascarenhas J. Eosinophilia in acute myeloid leukemia: overlooked and underexamined. Blood Rev. 2019;36:23\u201331.","journal-title":"Blood Rev"},{"issue":"7","key":"1294_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ajh.25484","volume":"94","author":"BC Medeiros","year":"2019","unstructured":"Medeiros BC, et al. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol. 2019;94(7):803\u201311.","journal-title":"Am J Hematol"},{"issue":"12","key":"1294_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"1294_CR5","doi-asserted-by":"publisher","first-page":"15815","DOI":"10.1038\/s41598-025-99258-4","volume":"15","author":"Y Dong","year":"2025","unstructured":"Dong Y, et al. Machine learning approaches reveal methylation signatures associated with pediatric acute myeloid leukemia recurrence. Sci Rep. 2025;15(1):15815.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3324\/haematol.2020.260331","volume":"107","author":"BZ Carter","year":"2022","unstructured":"Carter BZ, et al. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Haematologica. 2022;107(1):58\u201376.","journal-title":"Haematologica"},{"issue":"1","key":"1294_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-025-01251-7","volume":"15","author":"W Fiskus","year":"2025","unstructured":"Fiskus W, et al. Superior preclinical efficacy of co-treatment with BRG1\/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood Cancer J. 2025;15(1):40.","journal-title":"Blood Cancer J"},{"issue":"16","key":"1294_CR8","doi-asserted-by":"publisher","first-page":"1559033","DOI":"10.3389\/fmicb.2025.1559033","volume":"16","author":"S An","year":"2025","unstructured":"An S, et al. Significant changes in gut microbiota and SCFAs among patients with newly diagnosed acute myeloid leukemia. Front Microbiol. 2025;16(16):1559033.","journal-title":"Front Microbiol"},{"issue":"1","key":"1294_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40164-025-00661-4","volume":"14","author":"N Kapandji","year":"2025","unstructured":"Kapandji N, et al. Unravelling neutropenic enterocolitis: insights from gut microbiota, and intestinal barrier analyses. Exp Hematol Oncol. 2025;14(1):74.","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"1294_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. \u2018Acute myeloid leukemia: a comprehensive review and 2016 update.\u2019 Blood Cancer J. 2016;6(7):e441\u2013e441.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1294_CR11","first-page":"277","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277\u2013300.","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"1294_CR12","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"20","key":"1294_CR13","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"2","key":"1294_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch JS, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264\u201378.","journal-title":"Cell"},{"issue":"4","key":"1294_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"key":"1294_CR16","doi-asserted-by":"crossref","unstructured":"Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New England Journal of Medicine, 2013. 368(22): 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"issue":"16","key":"1294_CR17","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","volume":"28","author":"CJ Harrison","year":"2010","unstructured":"Harrison CJ, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674\u201381.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1294_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/pbc.23179","volume":"57","author":"PA Ho","year":"2011","unstructured":"Ho PA, et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2011;57(2):204\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1294_CR19","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s42003-023-04732-2","volume":"6","author":"C-K Cheng","year":"2023","unstructured":"Cheng C-K, et al. Deep genomic characterization highlights complexities and prognostic markers of pediatric acute myeloid leukemia. Communications Biology. 2023;6(1):356.","journal-title":"Communications Biology"},{"issue":"8","key":"1294_CR20","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","volume":"26","author":"B Izar","year":"2020","unstructured":"Izar B, et al. A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020;26(8):1271\u20139.","journal-title":"Nat Med"},{"issue":"12","key":"1294_CR21","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","volume":"117","author":"M Levis","year":"2011","unstructured":"Levis M, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):3294\u2013301.","journal-title":"Blood"},{"issue":"1","key":"1294_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41408-024-01077-9","volume":"14","author":"A Kaur","year":"2024","unstructured":"Kaur A, et al. Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024;14(1):99.","journal-title":"Blood Cancer J"},{"key":"1294_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02668-6","author":"SJ Skuli","year":"2025","unstructured":"Skuli SJ, et al. Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02668-6.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.1996.tb00483.x","volume":"57","author":"I Olsson","year":"1996","unstructured":"Olsson I, et al. Cell differentiation in acute myeloid leukemia. Eur J Haematol. 1996;57(1):1\u201316.","journal-title":"Eur J Haematol"},{"issue":"10","key":"1294_CR25","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1074\/jbc.M113.498253","volume":"289","author":"S Hou","year":"2014","unstructured":"Hou S, et al. CD226 protein is involved in immune synapse formation and triggers natural killer (NK) cell activation via its first extracellular domain *. J Biol Chem. 2014;289(10):6969\u201377.","journal-title":"J Biol Chem"},{"issue":"5","key":"1294_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1074-7613(00)80136-3","volume":"11","author":"K Shibuya","year":"1999","unstructured":"Shibuya K, et al. Physical and functional association of LFA-1 with DNAM-1 adhesion molecule. Immunity. 1999;11(5):615\u201323.","journal-title":"Immunity"},{"issue":"1","key":"1294_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115122","volume":"44","author":"L Melo Garcia","year":"2025","unstructured":"Melo Garcia L, et al. Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell Rep. 2025;44(1):115122.","journal-title":"Cell Rep"},{"issue":"1","key":"1294_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s42003-024-06453-6","volume":"7","author":"C Sauter","year":"2024","unstructured":"Sauter C, et al. Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia. Commun Biol. 2024;7(1):753.","journal-title":"Commun Biol"},{"key":"1294_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114433","volume":"152","author":"C Yang","year":"2025","unstructured":"Yang C, et al. UBTF facilitates acute myeloid leukemia development and immune escape via PD-L1 regulation. Int Immunopharmacol. 2025;152:114433.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"1294_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.4161\/epi.4.6.9449","volume":"4","author":"E Sanij","year":"2009","unstructured":"Sanij E, Hannan RD. The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin. Epigenetics. 2009;4(6):374\u201382.","journal-title":"Epigenetics"},{"issue":"1","key":"1294_CR31","doi-asserted-by":"publisher","first-page":"14862","DOI":"10.1038\/s41598-025-99038-0","volume":"15","author":"L Yang","year":"2025","unstructured":"Yang L, et al. A bioinformatics analysis and experimental validation of PDGFD as a promising diagnostic biomarker for acute myeloid leukemia. Sci Rep. 2025;15(1):14862.","journal-title":"Sci Rep"},{"issue":"16","key":"1294_CR32","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/bloodadvances.2023010476","volume":"7","author":"A Quagliano","year":"2023","unstructured":"Quagliano A, Gopalakrishnapillai A, Barwe SP. Tetraspanins set the stage for bone marrow microenvironment\u2013induced chemoprotection in hematologic malignancies. Blood Adv. 2023;7(16):4403\u201313.","journal-title":"Blood Adv"},{"issue":"5","key":"1294_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102476","volume":"20","author":"J Lu","year":"2025","unstructured":"Lu J, et al. CD37 regulates the self-renewal of leukemic stem cells via integrin-mediated signaling in acute myeloid leukemia. Stem Cell Reports. 2025;20(5):102476.","journal-title":"Stem Cell Reports"},{"issue":"19","key":"1294_CR34","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood.2023022202","volume":"143","author":"H Gu","year":"2024","unstructured":"Gu H, et al. PI3K\u03b3 maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood. 2024;143(19):1965\u201379.","journal-title":"Blood"},{"issue":"12","key":"1294_CR35","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1182\/blood-2005-01-0050","volume":"105","author":"PG Heller","year":"2005","unstructured":"Heller PG, et al. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood. 2005;105(12):4664\u201370.","journal-title":"Blood"},{"issue":"9","key":"1294_CR36","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.3390\/ijms22095013","volume":"22","author":"D Venney","year":"2021","unstructured":"Venney D, Mohd-Sarip A, Mills KI. The impact of epigenetic modifications in myeloid malignancies. Int J Mol Sci. 2021;22(9):5013.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1294_CR37","first-page":"45","volume":"90","author":"J Donadieu","year":"2005","unstructured":"Donadieu J, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French severe chronic neutropenia study group. Haematologica. 2005;90(1):45\u201353.","journal-title":"Haematologica"},{"issue":"9","key":"1294_CR38","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/cncr.22233","volume":"107","author":"B Deschler","year":"2006","unstructured":"Deschler B, L\u00fcbbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099\u2013107.","journal-title":"Cancer"},{"issue":"1","key":"1294_CR39","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.1038\/s41467-023-42585-9","volume":"14","author":"RN Ptashkin","year":"2023","unstructured":"Ptashkin RN, et al. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing. Nat Commun. 2023;14(1):6895.","journal-title":"Nat Commun"},{"issue":"9","key":"1294_CR40","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1158\/2159-8290.CD-19-0152","volume":"9","author":"Z Gu","year":"2019","unstructured":"Gu Z, et al. Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation. Cancer Discov. 2019;9(9):1228\u201347.","journal-title":"Cancer Discov"},{"issue":"1","key":"1294_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97\u2013105.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1294_CR42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1471-2407-12-304","volume":"12","author":"A Murati","year":"2012","unstructured":"Murati A, et al. Myeloid malignancies: mutations, models and management. BMC Cancer. 2012;12(1):304.","journal-title":"BMC Cancer"},{"issue":"3","key":"1294_CR43","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.molcel.2017.12.029","volume":"69","author":"L Chen","year":"2018","unstructured":"Chen L, et al. The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations. Mol Cell. 2018;69(3):412-425.e6.","journal-title":"Mol Cell"},{"issue":"18","key":"1294_CR44","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1158\/0008-5472.CAN-17-3970","volume":"78","author":"HD Nguyen","year":"2018","unstructured":"Nguyen HD, et al. Spliceosome mutations induce R loop-associated sensitivity to ATR inhibition in myelodysplastic syndromes. Cancer Res. 2018;78(18):5363\u201374.","journal-title":"Cancer Res"},{"issue":"9","key":"1294_CR45","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1038\/s41375-020-0753-9","volume":"34","author":"S Singh","year":"2020","unstructured":"Singh S, et al. SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications. Leukemia. 2020;34(9):2525\u201330.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR46","first-page":"90","volume":"142","author":"S Bamezai","year":"2023","unstructured":"Bamezai S, et al. A noncanonical enzymatic function of PIWIL4 maintains genomic integrity and leukemic growth in AML. Blood. 2023;142(1):90\u2013105.","journal-title":"Blood"},{"key":"1294_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114869","author":"RE Wagner","year":"2024","unstructured":"Wagner RE, et al. SRSF2 safeguards efficient transcription of DNA damage and repair genes. Cell Rep. 2024. https:\/\/doi.org\/10.1016\/j.celrep.2024.114869.","journal-title":"Cell Rep"},{"issue":"18","key":"1294_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184576","volume":"20","author":"X Yang","year":"2019","unstructured":"Yang X, Wong MPM, Ng RK. Aberrant DNA methylation in acute myeloid leukemia and its clinical implications. Int J Mol Sci. 2019;20(18):4576.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1294_CR49","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/1878-0261.12744","volume":"14","author":"P Blecua","year":"2020","unstructured":"Blecua P, Martinez-Verbo L, Esteller M. The DNA methylation landscape of hematological malignancies: an update. Mol Oncol. 2020;14(8):1616\u201339.","journal-title":"Mol Oncol"},{"issue":"1","key":"1294_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01002-y","volume":"13","author":"M Cabez\u00f3n","year":"2021","unstructured":"Cabez\u00f3n M, et al. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Clin Epigenetics. 2021;13(1):9.","journal-title":"Clin Epigenetics"},{"issue":"10149","key":"1294_CR51","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(18)31268-6","volume":"392","author":"Y Dor","year":"2018","unstructured":"Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. The Lancet. 2018;392(10149):777\u201386.","journal-title":"The Lancet"},{"key":"1294_CR52","doi-asserted-by":"publisher","first-page":"1571332","DOI":"10.3389\/fimmu.2025.1571332","volume":"16","author":"M Li","year":"2025","unstructured":"Li M, et al. Impact of single nucleotide polymorphisms of immunomodulatory factors on treatment response and prognosis in acute myeloid leukemia. Front Immunol. 2025;16:1571332.","journal-title":"Front Immunol"},{"issue":"7","key":"1294_CR53","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1002\/cam4.5549","volume":"12","author":"Z Wu","year":"2023","unstructured":"Wu Z, et al. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia. Cancer Med. 2023;12(7):8956\u201369.","journal-title":"Cancer Med"},{"key":"1294_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100850","volume":"50","author":"E O'Reilly","year":"2021","unstructured":"O\u2019Reilly E, Zeinabad HA, Szegezdi E. Hematopoietic versus leukemic stem cell quiescence: challenges and therapeutic opportunities. Blood Rev. 2021;50:100850.","journal-title":"Blood Rev"},{"issue":"12","key":"1294_CR55","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","volume":"129","author":"DA Pollyea","year":"2017","unstructured":"Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129(12):1627\u201335.","journal-title":"Blood"},{"issue":"1","key":"1294_CR56","doi-asserted-by":"publisher","first-page":"6369","DOI":"10.1038\/s41467-025-61567-7","volume":"16","author":"D Fu","year":"2025","unstructured":"Fu D, et al. Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33\/IL1RL1 pathway. Nat Commun. 2025;16(1):6369.","journal-title":"Nat Commun"},{"key":"1294_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110676","volume":"131","author":"D Xue","year":"2020","unstructured":"Xue D, Zhou X, Qiu J. Emerging role of NRF2 in ROS-mediated tumor chemoresistance. Biomed Pharmacother. 2020;131:110676.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"1294_CR58","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859\u201366.","journal-title":"Nat Med"},{"issue":"13","key":"1294_CR59","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189\u201399.","journal-title":"N Engl J Med"},{"issue":"9","key":"1294_CR60","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","volume":"5","author":"M Heuser","year":"2021","unstructured":"Heuser M, et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv. 2021;5(9):2294\u2013304.","journal-title":"Blood Adv"},{"issue":"12","key":"1294_CR61","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1038\/leu.2014.211","volume":"28","author":"MR Corces-Zimmerman","year":"2014","unstructured":"Corces-Zimmerman MR, Majeti R. Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis. Leukemia. 2014;28(12):2276\u201382.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR62","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1038\/s41467-025-60521-x","volume":"16","author":"S Zhu","year":"2025","unstructured":"Zhu S, et al. An improved reference library and method for accurate cell-type deconvolution of bulk-tissue miRNA data. Nat Commun. 2025;16(1):5508.","journal-title":"Nat Commun"},{"issue":"2","key":"1294_CR63","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41590-024-02063-w","volume":"26","author":"BM Barton","year":"2025","unstructured":"Barton BM, et al. IRE1\u03b1\u2013XBP1 safeguards hematopoietic stem and progenitor cells by restricting pro-leukemogenic gene programs. Nat Immunol. 2025;26(2):200\u201314.","journal-title":"Nat Immunol"},{"issue":"5","key":"1294_CR64","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ajhg.2020.03.008","volume":"106","author":"S Choufani","year":"2020","unstructured":"Choufani S, et al. DNA Methylation Signature for <em>EZH2<\/em> Functionally Classifies Sequence Variants in Three PRC2 Complex Genes. Am J Hum Genet. 2020;106(5):596\u2013610.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"1294_CR65","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","volume":"24","author":"P Desai","year":"2018","unstructured":"Desai P, et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018;24(7):1015\u201323.","journal-title":"Nat Med"},{"issue":"1","key":"1294_CR66","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41467-024-46134-w","volume":"15","author":"Y Kubota","year":"2024","unstructured":"Kubota Y, et al. Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting. Nat Commun. 2024;15(1):1832.","journal-title":"Nat Commun"},{"issue":"2","key":"1294_CR67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood-2015-07-655860","volume":"128","author":"R Moschoi","year":"2016","unstructured":"Moschoi R, et al. Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood. 2016;128(2):253\u201364.","journal-title":"Blood"},{"issue":"3","key":"1294_CR68","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2020.07.009","volume":"32","author":"N van Gastel","year":"2020","unstructured":"van Gastel N, et al. Induction of a timed metabolic collapse to overcome cancer Chemoresistance. Cell Metab. 2020;32(3):391-403.e6.","journal-title":"Cell Metab"},{"key":"1294_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115151","author":"LE Lisi-Vega","year":"2025","unstructured":"Lisi-Vega LE, et al. Bone marrow mesenchymal stromal cells support translation in refractory acute myeloid leukemia. Cell Rep. 2025. https:\/\/doi.org\/10.1016\/j.celrep.2024.115151.","journal-title":"Cell Rep"},{"issue":"1","key":"1294_CR70","doi-asserted-by":"publisher","first-page":"17179","DOI":"10.1038\/s41598-025-01711-x","volume":"15","author":"Y Gu","year":"2025","unstructured":"Gu Y, et al. Leukemia cells remodel bone marrow stromal cells to generate a protumoral microenvironment via the S100A8-NOX2-ROS signaling pathway. Sci Rep. 2025;15(1):17179.","journal-title":"Sci Rep"},{"issue":"3","key":"1294_CR71","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3390\/ijms24032086","volume":"24","author":"T Pecchillo Cimmino","year":"2023","unstructured":"Pecchillo Cimmino T, et al. Nox dependent ROS generation and cell metabolism. Int J Mol Sci. 2023;24(3):2086.","journal-title":"Int J Mol Sci"},{"key":"1294_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106084","volume":"176","author":"X Sun","year":"2022","unstructured":"Sun X, et al. Connexin32 ameliorates epithelial-to-mesenchymal-transition in diabetic renal tubular via inhibiting NOX4. Pharmacol Res. 2022;176:106084.","journal-title":"Pharmacol Res"},{"issue":"9","key":"1294_CR73","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/1878-0261.13200","volume":"16","author":"P Garc\u00eda-G\u00f3mez","year":"2022","unstructured":"Garc\u00eda-G\u00f3mez P, et al. Nox4 regulates TGF\u03b2-induced proliferation and self-renewal in glioblastoma stem cells. Mol Oncol. 2022;16(9):1891\u2013912.","journal-title":"Mol Oncol"},{"issue":"1","key":"1294_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09690-9","volume":"15","author":"J Sun","year":"2025","unstructured":"Sun J, et al. Nox4 serves as a pan-cancer prognostic biomarker and therapeutic target in tumorigenesis. Sci Rep. 2025;15(1):24612.","journal-title":"Sci Rep"},{"issue":"12","key":"1294_CR75","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","volume":"129","author":"D Thomas","year":"2017","unstructured":"Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129(12):1577\u201385.","journal-title":"Blood"},{"issue":"9","key":"1294_CR76","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert K, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17(9):1086\u201393.","journal-title":"Nat Med"},{"issue":"4","key":"1294_CR77","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ccell.2015.03.009","volume":"27","author":"AH Shih","year":"2015","unstructured":"Shih AH, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 2015;27(4):502\u201315.","journal-title":"Cancer Cell"},{"issue":"12","key":"1294_CR78","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079\u201389.","journal-title":"N Engl J Med"},{"key":"1294_CR79","doi-asserted-by":"crossref","unstructured":"Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New England Journal of Medicine, 2013. 369(1): 98\u201398.","DOI":"10.1056\/NEJMx130028"},{"issue":"7728","key":"1294_CR80","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526\u201331.","journal-title":"Nature"},{"issue":"1","key":"1294_CR81","doi-asserted-by":"publisher","first-page":"19811","DOI":"10.1038\/s41598-024-65345-1","volume":"14","author":"P Miao","year":"2024","unstructured":"Miao P, et al. Establishment and verification of a TME prognosis scoring model based on the acute myeloid leukemia single-cell transcriptome. Sci Rep. 2024;14(1):19811.","journal-title":"Sci Rep"},{"issue":"11","key":"1294_CR82","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1038\/s41588-024-01929-x","volume":"56","author":"A Stiff","year":"2024","unstructured":"Stiff A, et al. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024;56(11):2434\u201346.","journal-title":"Nat Genet"},{"issue":"7","key":"1294_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06865-6","volume":"15","author":"H Qin","year":"2024","unstructured":"Qin H, et al. A novel LGALS1-depended and immune-associated fatty acid metabolism risk model in acute myeloid leukemia stem cells. Cell Death Dis. 2024;15(7):482.","journal-title":"Cell Death Dis"},{"key":"1294_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114835","volume":"158","author":"L Liu","year":"2025","unstructured":"Liu L, et al. Galectin-1: an important regulator in myeloid differentiation and acute myeloid leukemia as well as a promising prognostic indicator and therapeutic target. Int Immunopharmacol. 2025;158:114835.","journal-title":"Int Immunopharmacol"},{"key":"1294_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02428-y","author":"Z Li","year":"2024","unstructured":"Li Z, et al. The epigenetic state of the cell of origin defines mechanisms of leukemogenesis. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-024-02428-y.","journal-title":"Leukemia"},{"issue":"2","key":"1294_CR86","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41375-023-02097-3","volume":"38","author":"Y Chen","year":"2024","unstructured":"Chen Y, et al. RAB27B-regulated exosomes mediate LSC maintenance via resistance to senescence and crosstalk with the microenvironment. Leukemia. 2024;38(2):266\u201380.","journal-title":"Leukemia"},{"issue":"18","key":"1294_CR87","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","volume":"11","author":"A van Rhenen","year":"2005","unstructured":"van Rhenen A, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11(18):6520\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1294_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55643-7","volume":"16","author":"T Kong","year":"2025","unstructured":"Kong T, et al. RSK1 is an exploitable dependency in myeloproliferative neoplasms and secondary acute myeloid leukemia. Nat Commun. 2025;16(1):492.","journal-title":"Nat Commun"},{"issue":"2","key":"1294_CR89","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"issue":"3","key":"1294_CR90","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12185-022-03374-0","volume":"116","author":"Y Arai","year":"2022","unstructured":"Arai Y, et al. FLT3-targeted treatment for acute myeloid leukemia. Int J Hematol. 2022;116(3):351\u201363.","journal-title":"Int J Hematol"},{"issue":"6","key":"1294_CR91","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"PD Kottaridis","year":"2001","unstructured":"Kottaridis PD, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752\u20139.","journal-title":"Blood"},{"issue":"6","key":"1294_CR92","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/leu.2015.320","volume":"30","author":"GE Nybakken","year":"2016","unstructured":"Nybakken GE, et al. Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. Leukemia. 2016;30(6):1422\u20135.","journal-title":"Leukemia"},{"issue":"20","key":"1294_CR93","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","volume":"120","author":"A Sexauer","year":"2012","unstructured":"Sexauer A, et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML. Blood. 2012;120(20):4205\u201314.","journal-title":"Blood"},{"issue":"10","key":"1294_CR94","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/bloodadvances.2018029496","volume":"3","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019;3(10):1581\u20135.","journal-title":"Blood Adv"},{"issue":"7","key":"1294_CR95","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory <em>FLT3<\/em>-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984\u201397.","journal-title":"Lancet Oncol"},{"issue":"18","key":"1294_CR96","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"2","key":"1294_CR97","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312\u201322.","journal-title":"Cancer Sci"},{"issue":"1","key":"1294_CR98","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58.","journal-title":"Mol Cancer"},{"issue":"1","key":"1294_CR99","first-page":"108","volume":"4","author":"T Kong","year":"2023","unstructured":"Kong T, et al. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nature Cancer. 2023;4(1):108\u201327.","journal-title":"Nature Cancer"},{"issue":"1","key":"1294_CR100","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41408-024-01187-4","volume":"14","author":"T Kong","year":"2024","unstructured":"Kong T, et al. Rsk1 dependency in FLT3-ITD acute myeloid leukemia. Blood Cancer J. 2024;14(1):207.","journal-title":"Blood Cancer J"},{"issue":"7330","key":"1294_CR101","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343\u20139.","journal-title":"Nature"},{"issue":"4","key":"1294_CR102","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1084\/jem.20181276","volume":"216","author":"F Basheer","year":"2019","unstructured":"Basheer F, et al. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. J Exp Med. 2019;216(4):966\u201381.","journal-title":"J Exp Med"},{"issue":"13","key":"1294_CR103","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1073\/pnas.1202258109","volume":"109","author":"T Neff","year":"2012","unstructured":"Neff T, et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A. 2012;109(13):5028\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1294_CR104","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1182\/blood-2011-11-394932","volume":"120","author":"S Tanaka","year":"2012","unstructured":"Tanaka S, et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood. 2012;120(5):1107\u201317.","journal-title":"Blood"},{"issue":"2","key":"1294_CR105","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","volume":"125","author":"B Xu","year":"2015","unstructured":"Xu B, et al. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood. 2015;125(2):346\u201357.","journal-title":"Blood"},{"issue":"2","key":"1294_CR106","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41375-023-02131-4","volume":"38","author":"PJ Sung","year":"2024","unstructured":"Sung PJ, et al. FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia. Leukemia. 2024;38(2):291\u2013301.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR107","doi-asserted-by":"publisher","first-page":"11444","DOI":"10.1038\/s41598-022-15020-0","volume":"12","author":"F Wang","year":"2022","unstructured":"Wang F, et al. PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K\u2013AKT signaling pathway. Sci Rep. 2022;12(1):11444.","journal-title":"Sci Rep"},{"key":"1294_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2025.102476","author":"J Lu","year":"2025","unstructured":"Lu J, et al. CD37 regulates the self-renewal of leukemic stem cells via integrin-mediated signaling in acute myeloid leukemia. Stem Cell Reports. 2025. https:\/\/doi.org\/10.1016\/j.stemcr.2025.102476.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"1294_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11971","volume":"7","author":"Y Hao","year":"2016","unstructured":"Hao Y, et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nat Commun. 2016;7(1):11971.","journal-title":"Nat Commun"},{"issue":"1","key":"1294_CR110","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"key":"1294_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.559576","volume":"11","author":"AJ Highton","year":"2020","unstructured":"Highton AJ, et al. High metabolic function and resilience of NKG2A-educated NK Cells. Front Immunol. 2020;11:559576.","journal-title":"Front Immunol"},{"issue":"21","key":"1294_CR112","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-19-2095","volume":"26","author":"L Borst","year":"2020","unstructured":"Borst L, van der Burg SH, van Hall T. The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment. Clin Cancer Res. 2020;26(21):5549\u201356.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1294_CR113","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41392-025-02228-5","volume":"10","author":"J Xie","year":"2025","unstructured":"Xie J, et al. Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia. Signal Transduct Target Ther. 2025;10(1):143.","journal-title":"Signal Transduct Target Ther"},{"key":"1294_CR114","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.critrevonc.2015.10.001","volume":"98","author":"MCJ Bosman","year":"2016","unstructured":"Bosman MCJ, Schuringa JJ, Vellenga E. Constitutive NF-\u03baB activation in AML: causes and treatment strategies. Crit Rev Oncol Hematol. 2016;98:35\u201344.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1294_CR115","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1172\/JCI68101","volume":"124","author":"Y Kagoya","year":"2014","unstructured":"Kagoya Y, et al. Positive feedback between NF-\u03baB and TNF-\u03b1 promotes leukemia-initiating cell capacity. J Clin Invest. 2014;124(2):528\u201342.","journal-title":"J Clin Invest"},{"issue":"8","key":"1294_CR116","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1038\/s41375-023-01953-6","volume":"37","author":"S Hou","year":"2023","unstructured":"Hou S, et al. PHF6 maintains acute myeloid leukemia via regulating NF-\u03baB signaling pathway. Leukemia. 2023;37(8):1626\u201337.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR117","doi-asserted-by":"publisher","first-page":"32428","DOI":"10.1038\/srep32428","volume":"6","author":"J-Y Chen","year":"2016","unstructured":"Chen J-Y, et al. The oncometabolite R-2-hydroxyglutarate activates NF-\u03baB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells. Sci Rep. 2016;6(1):32428.","journal-title":"Sci Rep"},{"issue":"24","key":"1294_CR118","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1182\/bloodadvances.2019032029","volume":"3","author":"S Al-Kershi","year":"2019","unstructured":"Al-Kershi S, et al. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia. Blood Adv. 2019;3(24):4252\u201363.","journal-title":"Blood Adv"},{"issue":"1","key":"1294_CR119","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s41467-025-55923-w","volume":"16","author":"R Ma","year":"2025","unstructured":"Ma R, et al. NKp46 enhances type 1 innate lymphoid cell proliferation and function and anti-acute myeloid leukemia activity. Nat Commun. 2025;16(1):989.","journal-title":"Nat Commun"},{"issue":"1","key":"1294_CR120","doi-asserted-by":"publisher","first-page":"11673","DOI":"10.1038\/s41598-025-96660-w","volume":"15","author":"S Tausch","year":"2025","unstructured":"Tausch S, et al. Inflammatory signaling pathways play a role in SYK inhibitor resistant AML. Sci Rep. 2025;15(1):11673.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR121","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1038\/s41467-025-59969-8","volume":"16","author":"S Duan","year":"2025","unstructured":"Duan S, et al. WNK1 signalling regulates amino acid transport and mTORC1 activity to sustain acute myeloid leukaemia growth. Nat Commun. 2025;16(1):4920.","journal-title":"Nat Commun"},{"issue":"2","key":"1294_CR122","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41375-024-02471-9","volume":"39","author":"M Hegde","year":"2025","unstructured":"Hegde M, et al. The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling. Leukemia. 2025;39(2):360\u201370.","journal-title":"Leukemia"},{"key":"1294_CR123","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20211248","author":"MG Posner","year":"2022","unstructured":"Posner MG. Multimerin-1 and cancer: a review. 2022. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20211248."},{"issue":"1","key":"1294_CR124","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41389-025-00553-6","volume":"14","author":"Q Zhou","year":"2025","unstructured":"Zhou Q, et al. FLT3 inhibition upregulates OCT4\/NANOG to promote maintenance and TKI resistance of FLT3-ITD+ acute myeloid leukemia. Oncogenesis. 2025;14(1):7.","journal-title":"Oncogenesis"},{"issue":"33","key":"1294_CR125","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1038\/s41388-025-03464-3","volume":"44","author":"J Liu","year":"2025","unstructured":"Liu J, et al. MARCH1, transcriptionally regulated by POU2F2, facilitates acute myeloid leukemia progression via inducing MYCT1 degradation. Oncogene. 2025;44(33):2983\u201396.","journal-title":"Oncogene"},{"issue":"1","key":"1294_CR126","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1186\/s12885-024-12667-y","volume":"24","author":"X Li","year":"2024","unstructured":"Li X, et al. MARCH1 negatively regulates TBK1-mTOR signaling pathway by ubiquitinating TBK1. BMC Cancer. 2024;24(1):902.","journal-title":"BMC Cancer"},{"issue":"10","key":"1294_CR127","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/bloodadvances.2022008405","volume":"7","author":"T Sakoda","year":"2023","unstructured":"Sakoda T, et al. TIM-3 signaling hijacks the canonical Wnt\/\u03b2-catenin pathway to maintain cancer stemness in acute myeloid leukemia. Blood Adv. 2023;7(10):2053\u201365.","journal-title":"Blood Adv"},{"issue":"12","key":"1294_CR128","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","volume":"108","author":"M Jan","year":"2011","unstructured":"Jan M, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A. 2011;108(12):5009\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1294_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101826","author":"V Rubino","year":"2024","unstructured":"Rubino V, et al. IL-21\/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy. Cell Rep Med. 2024. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101826.","journal-title":"Cell Rep Med"},{"issue":"19","key":"1294_CR130","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1038\/s41388-020-1261-0","volume":"39","author":"M Floren","year":"2020","unstructured":"Floren M, et al. Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and \u03b21 integrin activation. Oncogene. 2020;39(19):3910\u201325.","journal-title":"Oncogene"},{"issue":"11","key":"1294_CR131","doi-asserted-by":"publisher","first-page":"4058","DOI":"10.1016\/j.ymthe.2024.09.036","volume":"32","author":"Q Pan","year":"2024","unstructured":"Pan Q, et al. Anti-CLL1 liposome loaded with miR-497-5p and venetoclax as a novel therapeutic strategy in acute myeloid leukemia. Mol Ther. 2024;32(11):4058\u201374.","journal-title":"Mol Ther"},{"issue":"13","key":"1294_CR132","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey A, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18(13):3204\u201318.","journal-title":"Cell Rep"},{"key":"1294_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110197","author":"A Grenier","year":"2022","unstructured":"Grenier A, et al. AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia. Cell Rep. 2022. https:\/\/doi.org\/10.1016\/j.celrep.2021.110197.","journal-title":"Cell Rep"},{"key":"1294_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34717","author":"Y Chai","year":"2024","unstructured":"Chai Y, et al. Exploration of the mechanism of fraxetin in treating acute myeloid leukemia based on network pharmacology and experimental verification. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34717.","journal-title":"Heliyon"},{"issue":"11","key":"1294_CR135","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1084\/jem.20141898","volume":"212","author":"ME Varney","year":"2015","unstructured":"Varney ME, et al. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor\u2013TRAF6 signaling. J Exp Med. 2015;212(11):1967\u201385.","journal-title":"J Exp Med"},{"issue":"2","key":"1294_CR136","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/leu.2016.276","volume":"31","author":"ME Varney","year":"2017","unstructured":"Varney ME, et al. Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome. Leukemia. 2017;31(2):491\u20135.","journal-title":"Leukemia"},{"issue":"13","key":"1294_CR137","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1073\/pnas.94.13.6948","volume":"94","author":"N Zhao","year":"1997","unstructured":"Zhao N, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1\u20131.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997;94(13):6948\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1294_CR138","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bbrc.2004.03.030","volume":"317","author":"T Matsumura","year":"2004","unstructured":"Matsumura T, et al. TIFAB inhibits TIFA, TRAF-interacting protein with a forkhead-associated domain. Biochem Biophys Res Commun. 2004;317(1):230\u20134.","journal-title":"Biochem Biophys Res Commun"},{"issue":"14","key":"1294_CR139","doi-asserted-by":"publisher","first-page":"12144","DOI":"10.1074\/jbc.M300720200","volume":"278","author":"H Takatsuna","year":"2003","unstructured":"Takatsuna H, et al. Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling *. J Biol Chem. 2003;278(14):12144\u201350.","journal-title":"J Biol Chem"},{"issue":"5","key":"1294_CR140","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1159\/000491478","volume":"47","author":"W Men","year":"2018","unstructured":"Men W, et al. Tifa promotes cell survival and migration in lung adenocarcinoma. Cell Physiol Biochem. 2018;47(5):2097\u2013108.","journal-title":"Cell Physiol Biochem"},{"issue":"10","key":"1294_CR141","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.celrep.2017.08.039","volume":"20","author":"S Zimmermann","year":"2017","unstructured":"Zimmermann S, et al. ALPK1- and TIFA-dependent innate immune response triggered by the Helicobacter pylori type IV secretion system. Cell Rep. 2017;20(10):2384\u201395.","journal-title":"Cell Rep"},{"issue":"8","key":"1294_CR142","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1016\/j.celrep.2020.01.093","volume":"30","author":"M Niederkorn","year":"2020","unstructured":"Niederkorn M, et al. TIFAB regulates USP15-mediated p53 signaling during stressed and malignant hematopoiesis. Cell Rep. 2020;30(8):2776-2790.e6.","journal-title":"Cell Rep"},{"issue":"11","key":"1294_CR143","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1182\/blood.V89.11.3936","volume":"89","author":"Y Arai","year":"1997","unstructured":"Arai Y, et al. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10. Blood. 1997;89(11):3936\u201344.","journal-title":"Blood"},{"issue":"1","key":"1294_CR144","doi-asserted-by":"publisher","first-page":"10303","DOI":"10.1038\/s41467-024-53822-0","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, et al. DEAD-box RNA helicase 10 is required for 18S rRNA maturation by controlling the release of U3 snoRNA from pre-rRNA in embryonic stem cells. Nat Commun. 2024;15(1):10303.","journal-title":"Nat Commun"},{"issue":"5","key":"1294_CR145","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrm.2017.130","volume":"19","author":"MW Hentze","year":"2018","unstructured":"Hentze MW, et al. A brave new world of RNA-binding proteins. Nat Rev Mol Cell Biol. 2018;19(5):327\u201341.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1294_CR146","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.semcancer.2022.03.025","volume":"86","author":"W Li","year":"2022","unstructured":"Li W, Deng X, Chen J. RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer. Semin Cancer Biol. 2022;86:664\u201377.","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"1294_CR147","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1038\/onc.2009.352","volume":"27","author":"S Menon","year":"2008","unstructured":"Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene. 2008;27(2):S43\u201351.","journal-title":"Oncogene"},{"issue":"6","key":"1294_CR148","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960\u201376.","journal-title":"Cell"},{"key":"1294_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112794","author":"F Qian","year":"2023","unstructured":"Qian F, et al. Activation of GPR44 decreases severity of myeloid leukemia via specific targeting of leukemia initiating stem cells. Cell Rep. 2023. https:\/\/doi.org\/10.1016\/j.celrep.2023.112794.","journal-title":"Cell Rep"},{"issue":"1","key":"1294_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"1294_CR151","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124\u201334.","journal-title":"Nat Med"},{"issue":"7","key":"1294_CR152","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.celrep.2019.04.076","volume":"27","author":"R Evans","year":"2019","unstructured":"Evans R, et al. Integrin-Mediated Macrophage Adhesion Promotes Lymphovascular Dissemination in Breast Cancer. Cell Rep. 2019;27(7):1967-1978.e4.","journal-title":"Cell Rep"},{"issue":"6","key":"1294_CR153","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.stem.2021.01.011","volume":"28","author":"T Wang","year":"2021","unstructured":"Wang T, et al. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets. Cell Stem Cell. 2021;28(6):1074-1089.e7.","journal-title":"Cell Stem Cell"},{"issue":"4","key":"1294_CR154","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","volume":"54","author":"G Ehx","year":"2021","unstructured":"Ehx G, et al. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity. 2021;54(4):737-752.e10.","journal-title":"Immunity"},{"key":"1294_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02542-5","author":"J Huang","year":"2025","unstructured":"Huang J, et al. STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated hematopoietic stem\/progenitor cells. Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02542-5.","journal-title":"Leukemia"},{"issue":"12","key":"1294_CR156","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1038\/s41375-023-02055-z","volume":"37","author":"J Xie","year":"2023","unstructured":"Xie J, et al. STING activation in TET2-mutated hematopoietic stem\/progenitor cells contributes to the increased self-renewal and neoplastic transformation. Leukemia. 2023;37(12):2457\u201367.","journal-title":"Leukemia"},{"issue":"4","key":"1294_CR157","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41375-025-02542-5","volume":"39","author":"J Huang","year":"2025","unstructured":"Huang J, et al. STING mediates increased self-renewal and lineage skewing in DNMT3A-mutated hematopoietic stem\/progenitor cells. Leukemia. 2025;39(4):929\u201341.","journal-title":"Leukemia"},{"issue":"10","key":"1294_CR158","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/s41375-024-02383-8","volume":"38","author":"Y Sun","year":"2024","unstructured":"Sun Y, et al. STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells. Leukemia. 2024;38(10):2102\u201314.","journal-title":"Leukemia"},{"issue":"2","key":"1294_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.","journal-title":"Blood Cancer J"},{"issue":"6","key":"1294_CR160","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41375-022-01554-9","volume":"36","author":"K Clesham","year":"2022","unstructured":"Clesham K, et al. Identification of a c-MYB-directed therapeutic for acute myeloid leukemia. Leukemia. 2022;36(6):1541\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR161","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/leu.2016.177","volume":"31","author":"E Manara","year":"2017","unstructured":"Manara E, et al. Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia. 2017;31(1):18\u201325.","journal-title":"Leukemia"},{"issue":"2","key":"1294_CR162","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41419-021-03515-z","volume":"12","author":"M Li","year":"2021","unstructured":"Li M, et al. Regulation of MYB by distal enhancer elements in human myeloid leukemia. Cell Death Dis. 2021;12(2):223.","journal-title":"Cell Death Dis"},{"issue":"19","key":"1294_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194864","volume":"13","author":"A Auyez","year":"2021","unstructured":"Auyez A, et al. AXL receptor in cancer metastasis and drug resistance: when normal functions go askew. Cancers. 2021;13(19):4864.","journal-title":"Cancers"},{"issue":"12","key":"1294_CR164","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrc3847","volume":"14","author":"DK Graham","year":"2014","unstructured":"Graham DK, et al. The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14(12):769\u201385.","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"1294_CR165","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1182\/blood.2020007651","volume":"137","author":"X Niu","year":"2021","unstructured":"Niu X, et al. Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. Blood. 2021;137(26):3641\u201355.","journal-title":"Blood"},{"issue":"3","key":"1294_CR166","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.molcel.2019.05.022","volume":"75","author":"A Najafov","year":"2019","unstructured":"Najafov A, et al. TAM kinases promote necroptosis by regulating Oligomerization of MLKL. Mol Cell. 2019;75(3):457-468.e4.","journal-title":"Mol Cell"},{"issue":"12","key":"1294_CR167","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1038\/s41418-021-00811-1","volume":"28","author":"X Wang","year":"2021","unstructured":"Wang X, et al. MLKL promotes cellular differentiation in myeloid leukemia by facilitating the release of G-CSF. Cell Death Differ. 2021;28(12):3235\u201350.","journal-title":"Cell Death Differ"},{"key":"1294_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221:107753.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1294_CR169","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","volume":"13","author":"ID Ferguson","year":"2022","unstructured":"Ferguson ID, et al. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat Commun. 2022;13(1):4121.","journal-title":"Nat Commun"},{"issue":"3","key":"1294_CR170","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"1","key":"1294_CR171","doi-asserted-by":"publisher","first-page":"10419","DOI":"10.1038\/s41467-024-54650-y","volume":"15","author":"Q Li","year":"2024","unstructured":"Li Q, et al. A dendritic cell vaccine for both vaccination and neoantigen-reactive T cell preparation for cancer immunotherapy in mice. Nat Commun. 2024;15(1):10419.","journal-title":"Nat Commun"},{"issue":"7","key":"1294_CR172","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1128\/MCB.18.7.4301","volume":"18","author":"HS Radomska","year":"1998","unstructured":"Radomska HS, et al. CCAAT\/enhancer binding protein \u03b1 is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol. 1998;18(7):4301\u201314.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"1294_CR173","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1128\/MCB.16.3.1231","volume":"16","author":"D-E Zhang","year":"1996","unstructured":"Zhang D-E, et al. CCAAT enhancer-binding protein (C\/EBP) and AML1 (CBF\u03b12) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol. 1996;16(3):1231\u201340.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"1294_CR174","doi-asserted-by":"publisher","DOI":"10.1002\/bies.201900178","volume":"42","author":"L Schmidt","year":"2020","unstructured":"Schmidt L, Heyes E, Grebien F. Gain-of-function effects of N-terminal CEBPA mutations in acute myeloid leukemia. BioEssays. 2020;42(2):e1900178.","journal-title":"BioEssays"},{"issue":"8","key":"1294_CR175","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1182\/blood-2002-03-0990","volume":"100","author":"C Preudhomme","year":"2002","unstructured":"Preudhomme C, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100(8):2717\u201323.","journal-title":"Blood"},{"issue":"2","key":"1294_CR176","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/jcp.24729","volume":"230","author":"P Dhawan","year":"2015","unstructured":"Dhawan P, et al. C\/EBP\u03b1 and the vitamin D receptor cooperate in the regulation of cathelicidin in lung epithelial cells. J Cell Physiol. 2015;230(2):464\u201372.","journal-title":"J Cell Physiol"},{"issue":"15","key":"1294_CR177","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.7150\/ijbs.49785","volume":"16","author":"D Zhang","year":"2020","unstructured":"Zhang D, et al. Oleate acid-stimulated HMMR expression by CEBP\u03b1 is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma. Int J Biol Sci. 2020;16(15):2812\u201327.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"1294_CR178","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41420-024-02179-w","volume":"10","author":"Z Xia","year":"2024","unstructured":"Xia Z, et al. C\/EBP\u03b1-mediated ACSL4-dependent ferroptosis exacerbates tubular injury in diabetic kidney disease. Cell Death Discov. 2024;10(1):448.","journal-title":"Cell Death Discov"},{"key":"1294_CR179","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08257-4","author":"A Elewaut","year":"2024","unstructured":"Elewaut A, et al. Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. Nature. 2024. https:\/\/doi.org\/10.1038\/s41586-024-08257-4.","journal-title":"Nature"},{"key":"1294_CR180","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1146\/annurev-immunol-100219-020937","volume":"38","author":"PA Savage","year":"2020","unstructured":"Savage PA, Klawon DEJ, Miller CH. Regulatory t cell development. Annu Rev Immunol. 2020;38:421\u201353.","journal-title":"Annu Rev Immunol"},{"issue":"588","key":"1294_CR181","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz6804","volume":"13","author":"W Yang","year":"2021","unstructured":"Yang W, et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci Transl Med. 2021;13(588):eaaz6804.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1294_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54710-3","volume":"15","author":"Y Feng","year":"2024","unstructured":"Feng Y, et al. Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients. Nat Commun. 2024;15(1):10259.","journal-title":"Nat Commun"},{"issue":"4","key":"1294_CR183","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.apsb.2023.01.020","volume":"13","author":"Y-T Chan","year":"2023","unstructured":"Chan Y-T, et al. Pancreatic melatonin enhances anti-tumor immunity in pancreatic adenocarcinoma through regulating tumor-associated neutrophils infiltration and NETosis. Acta Pharm Sin B. 2023;13(4):1554\u201367.","journal-title":"Acta Pharm Sin B"},{"key":"1294_CR184","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","volume":"9","author":"KG De la Cruz-L\u00f3pez","year":"2019","unstructured":"De la Cruz-L\u00f3pez KG, et al. Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol. 2019;9:1143.","journal-title":"Front Oncol"},{"issue":"10","key":"1294_CR185","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","volume":"124","author":"W-L Chen","year":"2014","unstructured":"Chen W-L, et al. A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. Blood. 2014;124(10):1645\u201354.","journal-title":"Blood"},{"issue":"4","key":"1294_CR186","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11302-023-09928-z","volume":"19","author":"X Bai","year":"2023","unstructured":"Bai X, et al. P2X7 receptor promotes migration and invasion of non-small cell lung cancer A549 cells through the PI3K\/Akt pathways. Purinergic Signal. 2023;19(4):685\u201397.","journal-title":"Purinergic Signal"},{"issue":"8","key":"1294_CR187","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.trecan.2021.04.008","volume":"7","author":"AM Chiarella","year":"2021","unstructured":"Chiarella AM, et al. Extracellular ATP and adenosine in cancer pathogenesis and treatment. Trends Cancer. 2021;7(8):731\u201350.","journal-title":"Trends Cancer"},{"issue":"11","key":"1294_CR188","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115489","volume":"22","author":"P Donizy","year":"2021","unstructured":"Donizy P, et al. Prognostic role of tumoral PD-L1 and IDO1 expression, and intratumoral CD8+ and FoxP3+ lymphocyte infiltrates in 132 primary cutaneous Merkel cell carcinomas. Int J Mol Sci. 2021;22(11):5489.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1294_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76919-4","volume":"14","author":"Z-M Huang","year":"2024","unstructured":"Huang Z-M, et al. A novel risk score model of lactate metabolism for predicting outcomes and immune signatures in acute myeloid leukemia. Sci Rep. 2024;14(1):25742.","journal-title":"Sci Rep"},{"issue":"9","key":"1294_CR190","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/s43018-024-00807-z","volume":"5","author":"X Chu","year":"2024","unstructured":"Chu X, et al. Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms. Nat Cancer. 2024;5(9):1409\u201326.","journal-title":"Nat Cancer"},{"issue":"6","key":"1294_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00504-5","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, et al. Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center. Blood Cancer J. 2021;11(6):112.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1294_CR192","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1200\/JCO.2010.30.2554","volume":"29","author":"G Marcucci","year":"2011","unstructured":"Marcucci G, Haferlach T, D\u00f6hner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475\u201386.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1294_CR193","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.stem.2015.08.011","volume":"17","author":"M Ye","year":"2015","unstructured":"Ye M, et al. Hematopoietic differentiation is required for initiation of acute myeloid leukemia. Cell Stem Cell. 2015;17(5):611\u201323.","journal-title":"Cell Stem Cell"},{"issue":"5929","key":"1294_CR194","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1126\/science.1170116","volume":"324","author":"M Tahiliani","year":"2009","unstructured":"Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930\u20135.","journal-title":"Science"},{"issue":"6","key":"1294_CR195","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12185-017-2243-z","volume":"105","author":"R Itzykson","year":"2017","unstructured":"Itzykson R, et al. CMML: clinical and molecular aspects. Int J Hematol. 2017;105(6):711\u20139.","journal-title":"Int J Hematol"},{"issue":"1","key":"1294_CR196","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","volume":"20","author":"K Moran-Crusio","year":"2011","unstructured":"Moran-Crusio K, et al. <em>Tet2<\/em> loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11\u201324.","journal-title":"Cancer Cell"},{"issue":"1","key":"1294_CR197","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25\u201338.","journal-title":"Cancer Cell"},{"issue":"25","key":"1294_CR198","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"1294_CR199","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12185-013-1257-4","volume":"97","author":"T Naoe","year":"2013","unstructured":"Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol. 2013;97(2):165\u201374.","journal-title":"Int J Hematol"},{"issue":"7","key":"1294_CR200","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"Roboz GJ, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463\u201371.","journal-title":"Blood"},{"issue":"5","key":"1294_CR201","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/s41375-024-02235-5","volume":"38","author":"M Jassinskaja","year":"2024","unstructured":"Jassinskaja M, et al. A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia. Leukemia. 2024;38(5):1115\u201330.","journal-title":"Leukemia"},{"issue":"19","key":"1294_CR202","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood-2015-11-677708","volume":"127","author":"N Man","year":"2016","unstructured":"Man N, et al. Differential role of Id1 in MLL-AF9\u2013driven leukemia based on cell of origin. Blood. 2016;127(19):2322\u20136.","journal-title":"Blood"},{"issue":"3","key":"1294_CR203","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1084\/jem.20181765","volume":"216","author":"RG Rowe","year":"2019","unstructured":"Rowe RG, et al. The developmental stage of the hematopoietic niche regulates lineage in MLL-rearranged leukemia. J Exp Med. 2019;216(3):527\u201338.","journal-title":"J Exp Med"},{"issue":"14","key":"1294_CR204","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","volume":"341","author":"B Lowenberg","year":"1999","unstructured":"Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051\u201362.","journal-title":"N Engl J Med"},{"issue":"7","key":"1294_CR205","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser S, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7):2137\u201345.","journal-title":"Blood"},{"issue":"3","key":"1294_CR206","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.23908","volume":"90","author":"E Huleg\u00e5rdh","year":"2015","unstructured":"Huleg\u00e5rdh E, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208\u201314.","journal-title":"Am J Hematol"},{"issue":"22","key":"1294_CR207","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1182\/blood.V128.22.4013.4013","volume":"128","author":"L Renaud","year":"2016","unstructured":"Renaud L, et al. De novo and secondary acute myeloid leukemia, real world data on outcomes from the French Nord-Pas-De-Calais Picardie acute myeloid leukemia observatory. Blood. 2016;128(22):4013\u20134013.","journal-title":"Blood"},{"issue":"5","key":"1294_CR208","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/febs.13198","volume":"282","author":"S Ozgur","year":"2015","unstructured":"Ozgur S, et al. The conformational plasticity of eukaryotic RNA-dependent ATPases. FEBS J. 2015;282(5):850\u201363.","journal-title":"FEBS J"},{"issue":"1","key":"1294_CR209","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41467-020-14829-5","volume":"11","author":"A Rio-Machin","year":"2020","unstructured":"Rio-Machin A, et al. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. Nat Commun. 2020;11(1):1044.","journal-title":"Nat Commun"},{"key":"1294_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2025.04.012","author":"M Sirenko","year":"2025","unstructured":"Sirenko M, et al. Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia. Cell Stem Cell. 2025. https:\/\/doi.org\/10.1016\/j.stem.2025.04.012.","journal-title":"Cell Stem Cell"},{"key":"1294_CR211","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02695-3","author":"EJ Vick","year":"2025","unstructured":"Vick EJ, et al. Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization. Leukemia. 2025. https:\/\/doi.org\/10.1038\/s41375-025-02695-3.","journal-title":"Leukemia"},{"issue":"4","key":"1294_CR212","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/gm40","volume":"1","author":"ER Mardis","year":"2009","unstructured":"Mardis ER. New strategies and emerging technologies for massively parallel sequencing: applications in medical research. Genome Med. 2009;1(4):40.","journal-title":"Genome Med"},{"issue":"1","key":"1294_CR213","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/leu.2010.241","volume":"25","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, et al. A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia. 2011;25(1):184\u20136.","journal-title":"Leukemia"},{"issue":"25","key":"1294_CR214","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","volume":"363","author":"TJ Ley","year":"2010","unstructured":"Ley TJ, et al. DNMT3AMutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"1294_CR215","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst T, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722\u20136.","journal-title":"Nat Genet"},{"issue":"8","key":"1294_CR216","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ng.620","volume":"42","author":"G Nikoloski","year":"2010","unstructured":"Nikoloski G, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010;42(8):665\u20137.","journal-title":"Nat Genet"},{"issue":"2","key":"1294_CR217","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241\u20137.","journal-title":"Leukemia"},{"issue":"7367","key":"1294_CR218","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64\u20139.","journal-title":"Nature"},{"issue":"15","key":"1294_CR219","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384\u201395.","journal-title":"N Engl J Med"},{"issue":"1","key":"1294_CR220","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ng.1031","volume":"44","author":"TA Graubert","year":"2012","unstructured":"Graubert TA, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2012;44(1):53\u20137.","journal-title":"Nat Genet"},{"issue":"9","key":"1294_CR221","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1038\/s41375-024-02347-y","volume":"38","author":"J-C Jann","year":"2024","unstructured":"Jann J-C, et al. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia. 2024;38(9):1992\u20132002.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR222","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00790-1","volume":"13","author":"J-N Eckardt","year":"2023","unstructured":"Eckardt J-N, et al. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome. Blood Cancer J. 2023;13(1):18.","journal-title":"Blood Cancer J"},{"issue":"23","key":"1294_CR223","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","volume":"130","author":"J Nangalia","year":"2017","unstructured":"Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130(23):2475\u201383.","journal-title":"Blood"},{"issue":"6","key":"1294_CR224","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000578","volume":"5","author":"SN Constantinescu","year":"2021","unstructured":"Constantinescu SN, et al. Functional consequences of mutations in myeloproliferative neoplasms. Hemasphere. 2021;5(6):e578.","journal-title":"Hemasphere"},{"issue":"9","key":"1294_CR225","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR226","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2019000943","volume":"136","author":"AJ Dunbar","year":"2020","unstructured":"Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136(1):61\u201370.","journal-title":"Blood"},{"issue":"1","key":"1294_CR227","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma DP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9\u201316.","journal-title":"Blood"},{"issue":"1","key":"1294_CR228","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1053\/j.seminhematol.2016.10.002","volume":"54","author":"M Jan","year":"2017","unstructured":"Jan M, Ebert BL, Jaiswal S. Clonal hematopoiesis. Semin Hematol. 2017;54(1):43\u201350.","journal-title":"Semin Hematol"},{"issue":"10","key":"1294_CR229","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/s41588-022-01179-9","volume":"54","author":"AS Nam","year":"2022","unstructured":"Nam AS, et al. Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation. Nat Genet. 2022;54(10):1514\u201326.","journal-title":"Nat Genet"},{"issue":"14","key":"1294_CR230","first-page":"1590","volume":"136","author":"GA Challen","year":"2020","unstructured":"Challen GA, Goodell MA. Clonal hematopoiesis: mechanisms driving dominance of stem cell clones. Blood. 2020;136(14):1590\u20138.","journal-title":"Blood"},{"issue":"2","key":"1294_CR231","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.stem.2021.12.007","volume":"29","author":"T Muto","year":"2022","unstructured":"Muto T, et al. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022;29(2):298-314.e9.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1294_CR232","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108579","volume":"34","author":"K Murakami","year":"2021","unstructured":"Murakami K, et al. Ogt regulates hematopoietic stem cell maintenance via PINK1-dependent mitophagy. Cell Rep. 2021;34(1):108579.","journal-title":"Cell Rep"},{"issue":"5","key":"1294_CR233","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41375-024-02245-3","volume":"38","author":"S Matsui","year":"2024","unstructured":"Matsui S, et al. Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression. Leukemia. 2024;38(5):1032\u201345.","journal-title":"Leukemia"},{"issue":"2","key":"1294_CR234","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"1294_CR235","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","volume":"22","author":"RL Bowman","year":"2018","unstructured":"Bowman RL, Busque L, Levine RL. Clonal hematopoiesis and evolution to hematopoietic malignancies. Cell Stem Cell. 2018;22(2):157\u201370.","journal-title":"Cell Stem Cell"},{"issue":"3","key":"1294_CR236","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","volume":"99","author":"M Okano","year":"1999","unstructured":"Okano M, et al. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247\u201357.","journal-title":"Cell"},{"issue":"8","key":"1294_CR237","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/s41588-024-01851-2","volume":"56","author":"OA Stefansson","year":"2024","unstructured":"Stefansson OA, et al. The correlation between CpG methylation and gene expression is driven by sequence variants. Nat Genet. 2024;56(8):1624\u201331.","journal-title":"Nat Genet"},{"issue":"8","key":"1294_CR238","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.mayocp.2018.04.002","volume":"93","author":"DP Steensma","year":"2018","unstructured":"Steensma DP. Clinical implications of clonal hematopoiesis. Mayo Clin Proc. 2018;93(8):1122\u201330.","journal-title":"Mayo Clin Proc"},{"issue":"7853","key":"1294_CR239","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41586-021-03341-5","volume":"592","author":"TP Fidler","year":"2021","unstructured":"Fidler TP, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021;592(7853):296\u2013301.","journal-title":"Nature"},{"issue":"14","key":"1294_CR240","first-page":"1606","volume":"136","author":"S Jaiswal","year":"2020","unstructured":"Jaiswal S. Clonal hematopoiesis and nonhematologic disorders. Blood. 2020;136(14):1606\u201314.","journal-title":"Blood"},{"issue":"5","key":"1294_CR241","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41375-023-01857-5","volume":"37","author":"M Sakuma","year":"2023","unstructured":"Sakuma M, et al. Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies. Leukemia. 2023;37(5):1080\u201391.","journal-title":"Leukemia"},{"issue":"6","key":"1294_CR242","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","volume":"130","author":"F Zink","year":"2017","unstructured":"Zink F, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742\u201352.","journal-title":"Blood"},{"issue":"1","key":"1294_CR243","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1038\/s41467-022-31878-0","volume":"13","author":"O Pich","year":"2022","unstructured":"Pich O, et al. Discovering the drivers of clonal hematopoiesis. Nat Commun. 2022;13(1):4267.","journal-title":"Nat Commun"},{"issue":"26","key":"1294_CR244","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488\u201398.","journal-title":"N Engl J Med"},{"issue":"26","key":"1294_CR245","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","volume":"371","author":"G Genovese","year":"2014","unstructured":"Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477\u201387.","journal-title":"N Engl J Med"},{"issue":"12","key":"1294_CR246","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","volume":"20","author":"M Xie","year":"2014","unstructured":"Xie M, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472\u20138.","journal-title":"Nat Med"},{"issue":"7714","key":"1294_CR247","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41586-018-0321-x","volume":"559","author":"P-R Loh","year":"2018","unstructured":"Loh P-R, et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature. 2018;559(7714):350\u20135.","journal-title":"Nature"},{"issue":"7819","key":"1294_CR248","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41586-020-2430-6","volume":"584","author":"P-R Loh","year":"2020","unstructured":"Loh P-R, Genovese G, McCarroll SA. Monogenic and polygenic inheritance become instruments for clonal selection. Nature. 2020;584(7819):136\u201341.","journal-title":"Nature"},{"issue":"8","key":"1294_CR249","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/bloodadvances.2024015149","volume":"9","author":"RD Chow","year":"2025","unstructured":"Chow RD, et al. Persistent post-remission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia. Blood Adv. 2025;9(8):1888\u201399.","journal-title":"Blood Adv"},{"issue":"1","key":"1294_CR250","doi-asserted-by":"publisher","first-page":"12484","DOI":"10.1038\/ncomms12484","volume":"7","author":"AL Young","year":"2016","unstructured":"Young AL, et al. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016;7(1):12484.","journal-title":"Nat Commun"},{"issue":"7913","key":"1294_CR251","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","volume":"606","author":"E Mitchell","year":"2022","unstructured":"Mitchell E, et al. Clonal dynamics of haematopoiesis across the human lifespan. Nature. 2022;606(7913):343\u201350.","journal-title":"Nature"},{"issue":"7913","key":"1294_CR252","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","volume":"606","author":"MA Fabre","year":"2022","unstructured":"Fabre MA, et al. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022;606(7913):335\u201342.","journal-title":"Nature"},{"issue":"11","key":"1294_CR253","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41588-021-00957-1","volume":"53","author":"GYP Poon","year":"2021","unstructured":"Poon GYP, et al. Synonymous mutations reveal genome-wide levels of positive selection in healthy tissues. Nat Genet. 2021;53(11):1597\u2013605.","journal-title":"Nat Genet"},{"issue":"12","key":"1294_CR254","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1038\/s41588-023-01555-z","volume":"55","author":"SN Stacey","year":"2023","unstructured":"Stacey SN, et al. Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis. Nat Genet. 2023;55(12):2149\u201359.","journal-title":"Nat Genet"},{"issue":"1","key":"1294_CR255","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1038\/s41467-023-41315-5","volume":"14","author":"DW Brown","year":"2023","unstructured":"Brown DW, et al. Shared and distinct genetic etiologies for different types of clonal hematopoiesis. Nat Commun. 2023;14(1):5536.","journal-title":"Nat Commun"},{"issue":"1","key":"1294_CR256","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nm.3751","volume":"21","author":"A Yoda","year":"2015","unstructured":"Yoda A, et al. Mutations in G protein \u03b2 subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015;21(1):71\u20135.","journal-title":"Nat Med"},{"issue":"5","key":"1294_CR257","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/s41375-018-0340-5","volume":"33","author":"A Chase","year":"2019","unstructured":"Chase A, et al. PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia. Leukemia. 2019;33(5):1184\u201394.","journal-title":"Leukemia"},{"issue":"3","key":"1294_CR258","doi-asserted-by":"publisher","first-page":"eabl4644","DOI":"10.1126\/sciadv.abl4644","volume":"8","author":"S Rodriguez","year":"2022","unstructured":"Rodriguez S, et al. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma. Sci Adv. 2022;8(3):eabl4644.","journal-title":"Sci Adv"},{"issue":"8","key":"1294_CR259","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41408-020-00351-w","volume":"10","author":"W Shuai","year":"2020","unstructured":"Shuai W, et al. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020;10(8):86.","journal-title":"Blood Cancer J"},{"issue":"3","key":"1294_CR260","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","volume":"17","author":"S Jaiswal","year":"2020","unstructured":"Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Rev Cardiol. 2020;17(3):137\u201344.","journal-title":"Nat Rev Cardiol"},{"key":"1294_CR261","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-med-042921-112347","volume":"74","author":"H Ahmad","year":"2023","unstructured":"Ahmad H, Jahn N, Jaiswal S. Clonal hematopoiesis and its impact on human health. Annu Rev Med. 2023;74:249\u201360.","journal-title":"Annu Rev Med"},{"issue":"6","key":"1294_CR262","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1182\/blood-2017-04-777029","volume":"130","author":"M Buscarlet","year":"2017","unstructured":"Buscarlet M, et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130(6):753\u201362.","journal-title":"Blood"},{"issue":"16","key":"1294_CR263","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1182\/bloodadvances.2018024729","volume":"3","author":"EK Cook","year":"2019","unstructured":"Cook EK, et al. Comorbid and inflammatory characteristics of genetic subtypes of clonal hematopoiesis. Blood Adv. 2019;3(16):2482\u20136.","journal-title":"Blood Adv"},{"issue":"10","key":"1294_CR264","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1038\/s41375-020-0896-8","volume":"34","author":"AAZ Dawoud","year":"2020","unstructured":"Dawoud AAZ, Tapper WJ, Cross NCP. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia. 2020;34(10):2660\u201372.","journal-title":"Leukemia"},{"issue":"10","key":"1294_CR265","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","volume":"133","author":"S Ogawa","year":"2019","unstructured":"Ogawa S. Genetics of MDS. Blood. 2019;133(10):1049\u201359.","journal-title":"Blood"},{"issue":"7958","key":"1294_CR266","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41586-023-05806-1","volume":"616","author":"JS Weinstock","year":"2023","unstructured":"Weinstock JS, et al. Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. Nature. 2023;616(7958):755\u201363.","journal-title":"Nature"},{"issue":"5","key":"1294_CR267","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.cell.2017.09.042","volume":"171","author":"I Martincorena","year":"2017","unstructured":"Martincorena I, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171(5):1029-1041.e21.","journal-title":"Cell"},{"issue":"6","key":"1294_CR268","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41588-024-01755-1","volume":"56","author":"N Bernstein","year":"2024","unstructured":"Bernstein N, et al. Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis. Nat Genet. 2024;56(6):1147\u201355.","journal-title":"Nat Genet"},{"issue":"7714","key":"1294_CR269","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559(7714):400\u20134.","journal-title":"Nature"},{"issue":"9","key":"1294_CR270","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/stem.2845","volume":"36","author":"L Busque","year":"2018","unstructured":"Busque L, et al. Concise review: age-related clonal hematopoiesis: stem cells tempting the devil. Stem Cells. 2018;36(9):1287\u201394.","journal-title":"Stem Cells"},{"issue":"6465","key":"1294_CR271","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1126\/science.aan4673","volume":"366","author":"S Jaiswal","year":"2019","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):4673.","journal-title":"Science"},{"issue":"8","key":"1294_CR272","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","volume":"28","author":"D Hormaechea-Agulla","year":"2021","unstructured":"Hormaechea-Agulla D, et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN\u03b3 signaling. Cell Stem Cell. 2021;28(8):1428-1442.e6.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"1294_CR273","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/2159-8290.CD-22-0086","volume":"12","author":"JM SanMiguel","year":"2022","unstructured":"SanMiguel JM, et al. Distinct tumor necrosis factor alpha receptors dictate stem cell fitness versus lineage output in Dnmt3a-mutant clonal hematopoiesis. Cancer Discov. 2022;12(12):2763\u201373.","journal-title":"Cancer Discov"},{"issue":"1","key":"1294_CR274","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41556-022-01053-0","volume":"25","author":"CA Mitchell","year":"2023","unstructured":"Mitchell CA, et al. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat Cell Biol. 2023;25(1):30\u201341.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"1294_CR275","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1182\/blood.2022016835","volume":"141","author":"F Caiado","year":"2023","unstructured":"Caiado F, et al. Aging drives Tet2+\/\u2212 clonal hematopoiesis via IL-1 signaling. Blood. 2023;141(8):886\u2013903.","journal-title":"Blood"},{"issue":"7706","key":"1294_CR276","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41586-018-0125-z","volume":"557","author":"M Meisel","year":"2018","unstructured":"Meisel M, et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 2018;557(7706):580\u20134.","journal-title":"Nature"},{"issue":"11","key":"1294_CR277","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","volume":"27","author":"A Niroula","year":"2021","unstructured":"Niroula A, et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021;27(11):1921\u20137.","journal-title":"Nat Med"},{"issue":"12","key":"1294_CR278","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1038\/s41591-023-02620-0","volume":"29","author":"B de Basea","year":"2023","unstructured":"de Basea B, Gomez M, et al. Risk of hematological malignancies from CT radiation exposure in children, adolescents and young adults. Nat Med. 2023;29(12):3111\u20139.","journal-title":"Nat Med"},{"issue":"9","key":"1294_CR279","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41409-020-0863-z","volume":"55","author":"S Cesaro","year":"2020","unstructured":"Cesaro S, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a retrospective analysis and a review of the literature by the severe aplastic Anemia working party of the European society for blood and marrow transplantation (SAAWP-EBMT). Bone Marrow Transplant. 2020;55(9):1796\u2013809.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"1294_CR280","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/S2352-3026(19)30206-6","volume":"7","author":"KC Myers","year":"2020","unstructured":"Myers KC, et al. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol. 2020;7(3):e238\u201346.","journal-title":"Lancet Haematol"},{"issue":"10","key":"1294_CR281","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1038\/s41375-024-02367-8","volume":"38","author":"S Ketharnathan","year":"2024","unstructured":"Ketharnathan S, et al. Loss of Dnajc21 leads to cytopenia and altered nucleotide metabolism in zebrafish. Leukemia. 2024;38(10):2115\u201326.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR282","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41467-021-21588-4","volume":"12","author":"AL Kennedy","year":"2021","unstructured":"Kennedy AL, et al. Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nat Commun. 2021;12(1):1334.","journal-title":"Nat Commun"},{"issue":"4","key":"1294_CR283","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1182\/blood-2017-08-801985","volume":"131","author":"J Xia","year":"2018","unstructured":"Xia J, et al. Somatic mutations and clonal hematopoiesis in congenital neutropenia. Blood. 2018;131(4):408\u201316.","journal-title":"Blood"},{"issue":"2","key":"1294_CR284","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1053\/j.seminhematol.2017.05.002","volume":"54","author":"MW Wlodarski","year":"2017","unstructured":"Wlodarski MW, Collin M, Horwitz MS. GATA2 deficiency and related myeloid neoplasms. Semin Hematol. 2017;54(2):81\u20136.","journal-title":"Semin Hematol"},{"issue":"23","key":"1294_CR285","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1182\/blood.2021012781","volume":"138","author":"EJ Kozyra","year":"2021","unstructured":"Kozyra EJ, et al. Association of unbalanced translocation der(1;7) with germline GATA2 mutations. Blood. 2021;138(23):2441\u20135.","journal-title":"Blood"},{"issue":"5","key":"1294_CR286","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.1111\/ajco.13685","volume":"18","author":"N He","year":"2022","unstructured":"He N, et al. Upregulation of O-GlcNAc transferase is involved in the pathogenesis of acute myeloid leukemia. Asia Pac J Clin Oncol. 2022;18(5):e318\u201328.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"1294_CR287","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41419-025-07721-x","volume":"16","author":"N He","year":"2025","unstructured":"He N, et al. Adipocytes regulate monocyte development through the OGT-NEFA-CD36\/FABP4 pathway in high-fat diet-induced obesity. Cell Death Dis. 2025;16(1):401.","journal-title":"Cell Death Dis"},{"issue":"7","key":"1294_CR288","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1200\/JCO.2004.08.060","volume":"22","author":"MS Tallman","year":"2004","unstructured":"Tallman MS, et al. Acute Monocytic Leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute Myeloid Leukemia: a report from the eastern cooperative oncology group. J Clin Oncol. 2004;22(7):1276\u201386.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1294_CR289","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41375-024-02151-8","volume":"38","author":"C-C Chen","year":"2024","unstructured":"Chen C-C, et al. Inherent genome instability underlies trisomy 21-associated myeloid malignancies. Leukemia. 2024;38(3):521\u20139.","journal-title":"Leukemia"},{"issue":"3","key":"1294_CR290","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrc.2017.116","volume":"18","author":"G Nalepa","year":"2018","unstructured":"Nalepa G, Clapp DW. Fanconi anaemia and cancer: an intricate relationship. Nat Rev Cancer. 2018;18(3):168\u201385.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1294_CR291","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"269","key":"1294_CR292","doi-asserted-by":"publisher","first-page":"l1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1\u2013l1.","journal-title":"Sci Signal"},{"issue":"9","key":"1294_CR293","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1172\/JCI67364","volume":"123","author":"G Nalepa","year":"2013","unstructured":"Nalepa G, et al. Fanconi anemia signaling network regulates the spindle assembly checkpoint. J Clin Invest. 2013;123(9):3839\u201347.","journal-title":"J Clin Invest"},{"issue":"11","key":"1294_CR294","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/ncb2855","volume":"15","author":"P Collin","year":"2013","unstructured":"Collin P, et al. The spindle assembly checkpoint works like a rheostat rather than a toggle switch. Nat Cell Biol. 2013;15(11):1378\u201385.","journal-title":"Nat Cell Biol"},{"key":"1294_CR295","doi-asserted-by":"publisher","first-page":"752933","DOI":"10.3389\/fonc.2021.752933","volume":"11","author":"DM Edwards","year":"2021","unstructured":"Edwards DM, et al. Mitotic errors promote genomic instability and leukemia in a novel mouse model of fanconi anemia. Front Oncol. 2021;11:752933.","journal-title":"Front Oncol"},{"issue":"18","key":"1294_CR296","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1182\/blood-2014-04-526301","volume":"124","author":"D Ruggero","year":"2014","unstructured":"Ruggero D, Shimamura A. Marrow failure: a window into ribosome biology. Blood. 2014;124(18):2784\u201392.","journal-title":"Blood"},{"issue":"10","key":"1294_CR297","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-17-0550","volume":"7","author":"SO Sulima","year":"2017","unstructured":"Sulima SO, et al. How ribosomes translate cancer. Cancer Discov. 2017;7(10):1069\u201387.","journal-title":"Cancer Discov"},{"issue":"4","key":"1294_CR298","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/ng1040","volume":"32","author":"KM Lower","year":"2002","unstructured":"Lower KM, et al. Mutations in PHF6 are associated with B\u00f6rjeson-Forssman \u2013Lehmann syndrome. Nat Genet. 2002;32(4):661\u20135.","journal-title":"Nat Genet"},{"issue":"11","key":"1294_CR299","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1038\/leu.2016.212","volume":"30","author":"T Mori","year":"2016","unstructured":"Mori T, et al. Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms. Leukemia. 2016;30(11):2270\u20133.","journal-title":"Leukemia"},{"issue":"4","key":"1294_CR300","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/ng.542","volume":"42","author":"P Van Vlierberghe","year":"2010","unstructured":"Van Vlierberghe P, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42(4):338\u201342.","journal-title":"Nat Genet"},{"issue":"1","key":"1294_CR301","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41467-021-22750-8","volume":"12","author":"E Supper","year":"2021","unstructured":"Supper E, et al. Cut-like homeobox 1 (CUX1) tumor suppressor gene haploinsufficiency induces apoptosis evasion to sustain myeloid leukemia. Nat Commun. 2021;12(1):2482.","journal-title":"Nat Commun"},{"issue":"4","key":"1294_CR302","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/bjh.12964","volume":"166","author":"ME McNerney","year":"2014","unstructured":"McNerney ME, et al. The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7\/del(7q). Br J Haematol. 2014;166(4):550\u20136.","journal-title":"Br J Haematol"},{"issue":"22","key":"1294_CR303","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1101\/gad.1619407","volume":"21","author":"B Argiropoulos","year":"2007","unstructured":"Argiropoulos B, Yung E, Humphries RK. Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. Genes Dev. 2007;21(22):2845\u20139.","journal-title":"Genes Dev"},{"issue":"8","key":"1294_CR304","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1038\/s41375-022-01602-4","volume":"36","author":"P Xiang","year":"2022","unstructured":"Xiang P, et al. Elucidating the importance and regulation of key enhancers for human MEIS1 expression. Leukemia. 2022;36(8):1980\u20139.","journal-title":"Leukemia"},{"issue":"5","key":"1294_CR305","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nm1567","volume":"13","author":"J Bernhagen","year":"2007","unstructured":"Bernhagen J, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med. 2007;13(5):587\u201396.","journal-title":"Nat Med"},{"issue":"20","key":"1294_CR306","doi-asserted-by":"publisher","first-page":"15566","DOI":"10.1074\/jbc.M110.103408","volume":"285","author":"V Saini","year":"2010","unstructured":"Saini V, Marchese A, Majetschak M. CXC chemokine receptor 4 Is a cell surface receptor for extracellular ubiquitin*. J Biol Chem. 2010;285(20):15566\u201376.","journal-title":"J Biol Chem"},{"key":"1294_CR307","doi-asserted-by":"crossref","unstructured":"Ramakrishnan, R., et al., 2020 CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine <em>MLL-AF9<\/em>-Driven Acute Myeloid Leukemia. Cell Reports,. 31(8).","DOI":"10.1016\/j.celrep.2020.107684"},{"issue":"2","key":"1294_CR308","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, et al. CD47 Is an adverse prognostic factor and therapeutic antibody target on human acute myeloid Leukemia Stem cells. Cell. 2009;138(2):286\u201399.","journal-title":"Cell"},{"key":"1294_CR309","doi-asserted-by":"publisher","first-page":"996746","DOI":"10.3389\/fimmu.2022.996746","volume":"13","author":"Q Haas","year":"2022","unstructured":"Haas Q, et al. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities. Front Immunol. 2022;13:996746.","journal-title":"Front Immunol"},{"issue":"8","key":"1294_CR310","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101130","volume":"4","author":"MM Xie","year":"2023","unstructured":"Xie MM, et al. An agonistic anti-signal regulatory protein \u03b1 antibody for chronic inflammatory diseases. Cell Rep Med. 2023;4(8):101130.","journal-title":"Cell Rep Med"},{"issue":"1","key":"1294_CR311","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41392-025-02303-x","volume":"10","author":"DA Pereira-Martins","year":"2025","unstructured":"Pereira-Martins DA, et al. High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability. Signal Transduct Target Ther. 2025;10(1):222.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1294_CR312","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41375-024-02454-w","volume":"39","author":"V Krishnamoorthy","year":"2024","unstructured":"Krishnamoorthy V, et al. The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9. Leukemia. 2024;39(2):346\u201359.","journal-title":"Leukemia"},{"issue":"12","key":"1294_CR313","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1038\/s41375-024-02430-4","volume":"38","author":"Y Sunami","year":"2024","unstructured":"Sunami Y, et al. Rapid increase of C\/EBP\u03b1 p42 induces growth arrest of acute myeloid leukemia (AML) cells by Cop1 deletion in Trib1-expressing AML. Leukemia. 2024;38(12):2585\u201397.","journal-title":"Leukemia"},{"issue":"2","key":"1294_CR314","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/cr.2018.1","volume":"28","author":"J Yan","year":"2018","unstructured":"Yan J, et al. Histone H3 lysine 4 monomethylation modulates long-range chromatin interactions at enhancers. Cell Res. 2018;28(2):204\u201320.","journal-title":"Cell Res"},{"issue":"2","key":"1294_CR315","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cell.2017.09.026","volume":"171","author":"SSP Rao","year":"2017","unstructured":"Rao SSP, et al. Cohesin loss eliminates all loop domains. Cell. 2017;171(2):305-320.e24.","journal-title":"Cell"},{"issue":"5","key":"1294_CR316","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.stem.2019.08.003","volume":"25","author":"AD Viny","year":"2019","unstructured":"Viny AD, et al. Cohesin members stag1 and stag2 display distinct roles in chromatin accessibility and topological control of hsc self-renewal and differentiation. Cell Stem Cell. 2019;25(5):682-696.e8.","journal-title":"Cell Stem Cell"},{"issue":"7935","key":"1294_CR317","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-022-05365-x","volume":"611","author":"J Xu","year":"2022","unstructured":"Xu J, et al. Subtype-specific 3D genome alteration in acute myeloid leukaemia. Nature. 2022;611(7935):387\u201398.","journal-title":"Nature"},{"issue":"1","key":"1294_CR318","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41588-018-0270-1","volume":"51","author":"SA Assi","year":"2019","unstructured":"Assi SA, et al. Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nat Genet. 2019;51(1):151\u201362.","journal-title":"Nat Genet"},{"issue":"10","key":"1294_CR319","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/2159-8290.CD-17-0399","volume":"7","author":"MR McKeown","year":"2017","unstructured":"McKeown MR, et al. Superenhancer analysis defines novel epigenomic subtypes of Non-APL AML, including an RAR\u03b1 dependency targetable by SY-1425, a potent and selective RAR\u03b1 agonist. Cancer Discov. 2017;7(10):1136\u201353.","journal-title":"Cancer Discov"},{"issue":"4","key":"1294_CR320","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccr.2012.03.014","volume":"21","author":"WJ Harris","year":"2012","unstructured":"Harris WJ, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21(4):473\u201387.","journal-title":"Cancer Cell"},{"issue":"8","key":"1294_CR321","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2017-11-814319","volume":"132","author":"H Luo","year":"2018","unstructured":"Luo H, et al. CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia. Blood. 2018;132(8):837\u201348.","journal-title":"Blood"},{"issue":"2","key":"1294_CR322","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41375-020-0856-3","volume":"35","author":"R Ghasemi","year":"2021","unstructured":"Ghasemi R, et al. Contribution of CTCF binding to transcriptional activity at the HOXA locus in NPM1-mutant AML cells. Leukemia. 2021;35(2):404\u201316.","journal-title":"Leukemia"},{"issue":"9\u201310","key":"1294_CR323","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1101\/gad.319590.118","volume":"33","author":"M Palangat","year":"2019","unstructured":"Palangat M, et al. The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation. Genes Dev. 2019;33(9\u201310):482\u201397.","journal-title":"Genes Dev"},{"issue":"3","key":"1294_CR324","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nsmb1209","volume":"14","author":"R Karni","year":"2007","unstructured":"Karni R, et al. The gene encoding the splicing factor SF2\/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007;14(3):185\u201393.","journal-title":"Nat Struct Mol Biol"},{"issue":"8","key":"1294_CR325","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41588-023-01460-5","volume":"55","author":"P Bland","year":"2023","unstructured":"Bland P, et al. SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response. Nat Genet. 2023;55(8):1311\u201323.","journal-title":"Nat Genet"},{"issue":"7","key":"1294_CR326","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrc.2016.51","volume":"16","author":"H Dvinge","year":"2016","unstructured":"Dvinge H, et al. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016;16(7):413\u201330.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"1294_CR327","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1158\/2159-8290.CD-20-0358","volume":"10","author":"CM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor CM, Narla G. Splice of life for cancer: missplicing of PPP2R5A by mutant SF3B1 leads to MYC stabilization and tumorigenesis. Cancer Discov. 2020;10(6):765\u20137.","journal-title":"Cancer Discov"},{"issue":"7","key":"1294_CR328","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3324\/haematol.2021.279500","volume":"107","author":"MM Patnaik","year":"2022","unstructured":"Patnaik MM. How I diagnose and treat chronic myelomonocytic leukemia. Haematologica. 2022;107(7):1503\u201317.","journal-title":"Haematologica"},{"key":"1294_CR329","first-page":"1","volume":"20","author":"Y Shi","year":"2025","unstructured":"Shi Y, et al. Pan-cancer oncogenic properties and therapeutic potential of SF3B4. Cancer Gene Therap. 2025;20:1\u20135.","journal-title":"Cancer Gene Therap"},{"issue":"1","key":"1294_CR330","doi-asserted-by":"publisher","first-page":"16235","DOI":"10.1038\/s41598-025-99865-1","volume":"15","author":"S Khan","year":"2025","unstructured":"Khan S, et al. Revealing the role of U2AF1 in splicing regulation and chimeric RNA dynamics. Sci Rep. 2025;15(1):16235.","journal-title":"Sci Rep"},{"issue":"3","key":"1294_CR331","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.stem.2025.01.010","volume":"32","author":"J Hong","year":"2025","unstructured":"Hong J, et al. PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. Cell Stem Cell. 2025;32(3):463\u201378.","journal-title":"Cell Stem Cell"},{"key":"1294_CR332","doi-asserted-by":"crossref","unstructured":"Melo Garcia, L., et al., 2025 Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell Reports,. 44(1):","DOI":"10.1016\/j.celrep.2024.115122"},{"issue":"17","key":"1294_CR333","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2024026040","volume":"145","author":"L He","year":"2025","unstructured":"He L, et al. PSTK inhibition activates cGAS\u2013STING precipitating ferroptotic cell death in leukemic stem cells. Blood. 2025;145(17):1903\u201314.","journal-title":"Blood"},{"issue":"11","key":"1294_CR334","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1038\/s41401-023-01112-8","volume":"44","author":"H-L Wang","year":"2023","unstructured":"Wang H-L, et al. Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway. Acta Pharmacol Sin. 2023;44(11):2296\u2013306.","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"1294_CR335","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41397-025-00361-6","volume":"25","author":"T Xu","year":"2025","unstructured":"Xu T, et al. Systematic identification of cancer pathways and potential drugs for intervention through multi-omics analysis. Pharmacogenomics J. 2025;25(2):2.","journal-title":"Pharmacogenomics J"},{"key":"1294_CR336","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cytogfr.2018.08.004","volume":"43","author":"S Binder","year":"2018","unstructured":"Binder S, Luciano M, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia (AML): a focus on pro- and anti-inflammatory mediators. Cytokine Growth Factor Rev. 2018;43:8\u201315.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"1294_CR337","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/sj.leu.2403145","volume":"18","author":"KU Birkenkamp","year":"2004","unstructured":"Birkenkamp KU, et al. Constitutive NF-\u03baB DNA-binding activity in AML is frequently mediated by a Ras\/PI3-K\/PKB-dependent pathway. Leukemia. 2004;18(1):103\u201312.","journal-title":"Leukemia"},{"issue":"2","key":"1294_CR338","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/0008-5472.CAN-16-1004","volume":"77","author":"TW Wei","year":"2017","unstructured":"Wei TW, et al. Aurora A and NF-\u03baB Survival pathway drive Chemoresistance in acute myeloid leukemia via the TRAF-interacting protein TIFA. Cancer Res. 2017;77(2):494\u2013508.","journal-title":"Cancer Res"},{"issue":"5","key":"1294_CR339","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/cdd.2017.40","volume":"24","author":"A Haimovici","year":"2017","unstructured":"Haimovici A, et al. PU.1 supports TRAIL-induced cell death by inhibiting NF-\u03baB-mediated cell survival and inducing DR5 expression. Cell Death Different. 2017;24(5):866\u201377.","journal-title":"Cell Death Different"},{"issue":"9","key":"1294_CR340","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/s41590-024-01920-y","volume":"25","author":"A Abraham","year":"2024","unstructured":"Abraham A, et al. Arid1a-dependent canonical BAF complex suppresses inflammatory programs to drive efficient germinal center B cell responses. Nat Immunol. 2024;25(9):1704\u201317.","journal-title":"Nat Immunol"},{"issue":"13","key":"1294_CR341","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.febslet.2011.03.068","volume":"585","author":"N Cheung","year":"2011","unstructured":"Cheung N, So CWE. Transcriptional and epigenetic networks in haematological malignancy. FEBS Lett. 2011;585(13):2100\u201311.","journal-title":"FEBS Lett"},{"issue":"8","key":"1294_CR342","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.celrep.2016.08.082","volume":"17","author":"A Mandoli","year":"2016","unstructured":"Mandoli A, et al. The Hematopoietic transcription factors RUNX1 and ERG prevent AML1-ETO oncogene overexpression and onset of the apoptosis program in t(8;21) AMLs. Cell Rep. 2016;17(8):2087\u2013100.","journal-title":"Cell Rep"},{"issue":"10","key":"1294_CR343","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41417-019-0159-x","volume":"27","author":"T Wang","year":"2020","unstructured":"Wang T, et al. Ectopia associated MN1 fusions and aberrant activation in myeloid neoplasms with t(12;22)(p13;q12). Cancer Gene Ther. 2020;27(10):810\u20138.","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"1294_CR344","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00277-017-3208-2","volume":"97","author":"H Shao","year":"2018","unstructured":"Shao H, et al. Myeloid neoplasms with t(12;22)(p13;q12)\/MN1-EVT6: a systematic review of 12 cases. Ann Hematol. 2018;97(3):417\u201324.","journal-title":"Ann Hematol"},{"issue":"8","key":"1294_CR345","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/sj.leu.2404778","volume":"21","author":"C Carella","year":"2007","unstructured":"Carella C, et al. MN1 overexpression is an important step in the development of inv(16) AML. Leukemia. 2007;21(8):1679\u201390.","journal-title":"Leukemia"},{"issue":"21","key":"1294_CR346","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1182\/blood-2016-11-709881","volume":"129","author":"N Songdej","year":"2017","unstructured":"Songdej N, Rao AK. Hematopoietic transcription factor mutations: important players in inherited platelet defects. Blood. 2017;129(21):2873\u201381.","journal-title":"Blood"},{"issue":"2","key":"1294_CR347","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1053\/j.seminhematol.2017.04.005","volume":"54","author":"H Hock","year":"2017","unstructured":"Hock H, Shimamura A. ETV6 in hematopoiesis and leukemia predisposition. Semin Hematol. 2017;54(2):98\u2013104.","journal-title":"Semin Hematol"},{"key":"1294_CR348","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.critrevonc.2017.05.011","volume":"116","author":"P Rasighaemi","year":"2017","unstructured":"Rasighaemi P, Ward AC. ETV6 and ETV7: Siblings in hematopoiesis and its disruption in disease. Crit Rev Oncol Hematol. 2017;116:106\u201315.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"1294_CR349","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1182\/blood.V85.9.2289.bloodjournal8592289","volume":"85","author":"PP Liu","year":"1995","unstructured":"Liu PP, et al. Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia. Blood. 1995;85(9):2289\u2013302.","journal-title":"Blood"},{"issue":"3","key":"1294_CR350","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.2741\/3977","volume":"17","author":"K Lam","year":"2012","unstructured":"Lam K, Zhang DE. RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis. Front Biosci (Landmark Ed). 2012;17(3):1120\u201339.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"7460","key":"1294_CR351","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature12287","volume":"500","author":"X-J Sun","year":"2013","unstructured":"Sun X-J, et al. A stable transcription factor complex nucleated by oligomeric AML1\u2013ETO controls leukaemogenesis. Nature. 2013;500(7460):93\u20137.","journal-title":"Nature"},{"issue":"6","key":"1294_CR352","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.celrep.2014.08.024","volume":"8","author":"A Ptasinska","year":"2014","unstructured":"Ptasinska A, et al. Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal. Cell Rep. 2014;8(6):1974\u201388.","journal-title":"Cell Rep"},{"issue":"4","key":"1294_CR353","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.ccell.2018.08.015","volume":"34","author":"N Martinez-Soria","year":"2018","unstructured":"Martinez-Soria N, et al. The oncogenic transcription factor RUNX1\/ETO corrupts cell cycle regulation to drive leukemic transformation. Cancer Cell. 2018;34(4):626-642.e8.","journal-title":"Cancer Cell"},{"issue":"4","key":"1294_CR354","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/86515","volume":"7","author":"T Pabst","year":"2001","unstructured":"Pabst T, et al. AML1\u2013ETO downregulates the granulocytic differentiation factor C\/EBP\u03b1 in t(8;21) myeloid leukemia. Nat Med. 2001;7(4):444\u201351.","journal-title":"Nat Med"},{"issue":"1","key":"1294_CR355","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/blood-2002-04-1288","volume":"101","author":"RK Vangala","year":"2003","unstructured":"Vangala RK, et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood. 2003;101(1):270\u20137.","journal-title":"Blood"},{"issue":"19","key":"1294_CR356","doi-asserted-by":"publisher","first-page":"6470","DOI":"10.1128\/MCB.21.19.6470-6483.2001","volume":"21","author":"JM Amann","year":"2001","unstructured":"Amann JM, et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through Its oligomerization domain. Mol Cell Biol. 2001;21(19):6470\u201383.","journal-title":"Mol Cell Biol"},{"issue":"10","key":"1294_CR357","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00018-018-2756-5","volume":"75","author":"H Iwasa","year":"2018","unstructured":"Iwasa H, Hossain S, Hata Y. Tumor suppressor C-RASSF proteins. Cell Mol Life Sci. 2018;75(10):1773\u201387.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"1294_CR358","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41408-020-0282-9","volume":"10","author":"SA Stoner","year":"2020","unstructured":"Stoner SA, et al. The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling. Blood Cancer J. 2020;10(2):16.","journal-title":"Blood Cancer J"},{"issue":"10","key":"1294_CR359","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa2024534","volume":"384","author":"EJ Duncavage","year":"2021","unstructured":"Duncavage EJ, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med. 2021;384(10):924\u201335.","journal-title":"N Engl J Med"},{"issue":"13","key":"1294_CR360","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1182\/bloodadvances.2022008364","volume":"7","author":"HH Zhu","year":"2023","unstructured":"Zhu HH, et al. A global study for acute myeloid leukemia with RARG rearrangement. Blood Adv. 2023;7(13):2972\u201382.","journal-title":"Blood Adv"},{"issue":"18","key":"1294_CR361","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1182\/blood.2021011677","volume":"138","author":"A Astolfi","year":"2021","unstructured":"Astolfi A, et al. Torque teno mini virus as a cause of childhood acute promyelocytic leukemia lacking PML\/RARA fusion. Blood. 2021;138(18):1773\u20137.","journal-title":"Blood"},{"key":"1294_CR362","doi-asserted-by":"publisher","first-page":"1074913","DOI":"10.3389\/fonc.2022.1074913","volume":"12","author":"X Chen","year":"2022","unstructured":"Chen X, et al. Torque teno mini virus driven childhood acute promyelocytic leukemia: The third case report and sequence analysis. Front Oncol. 2022;12:1074913.","journal-title":"Front Oncol"},{"issue":"1","key":"1294_CR363","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ijlh.14189","volume":"46","author":"J Chen","year":"2024","unstructured":"Chen J, et al. TTMV: RARA-driven myeloid sarcoma in pediatrics with germline SAMD9 mutation and relapsed with refractory acute promyelocytic leukemia. Int J Lab Hematol. 2024;46(1):190\u20134.","journal-title":"Int J Lab Hematol"},{"issue":"7","key":"1294_CR364","doi-asserted-by":"publisher","first-page":"100509","DOI":"10.1016\/j.modpat.2024.100509","volume":"37","author":"HK Tsai","year":"2024","unstructured":"Tsai HK, et al. Acute promyelocytic leukemia with torque teno mini virus::rara fusion: an approach to screening and diagnosis. Mod Pathol. 2024;37(7):100509.","journal-title":"Mod Pathol"},{"key":"1294_CR365","doi-asserted-by":"crossref","unstructured":"Wang, L., et al., Case report of pediatric TTMV-related acute promyelocytic leukemia with central nervous system infiltration and rapid accumulation of RARA-LBD mutations. Heliyon, 2024. 10(5):","DOI":"10.1016\/j.heliyon.2024.e27107"},{"issue":"2","key":"1294_CR366","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41375-024-02481-7","volume":"39","author":"J Lou","year":"2024","unstructured":"Lou J, et al. Infection-related pathway activation and vulnerability to arsenic trioxide in acute promyelocytic leukemia with TTMV:RARA. Leukemia. 2024;39(2):490\u20134.","journal-title":"Leukemia"},{"key":"1294_CR367","doi-asserted-by":"crossref","unstructured":"Charles Cano, F., et al., 2025 XPO1-dependency of DEK::NUP214 leukemia. Leukemia,.","DOI":"10.1038\/s41375-025-02570-1"},{"issue":"1","key":"1294_CR368","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41467-024-55047-7","volume":"16","author":"F Wang","year":"2025","unstructured":"Wang F, et al. Oncogenic role of RARG rearrangements in acute myeloid leukemia resembling acute promyelocytic leukemia. Nat Commun. 2025;16(1):617.","journal-title":"Nat Commun"},{"issue":"1","key":"1294_CR369","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41467-024-54860-4","volume":"16","author":"T Liu","year":"2025","unstructured":"Liu T, et al. CPSF6-RAR\u03b3 interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia. Nat Commun. 2025;16(1):616.","journal-title":"Nat Commun"},{"issue":"1","key":"1294_CR370","doi-asserted-by":"publisher","first-page":"9341","DOI":"10.1038\/s41467-024-53399-8","volume":"15","author":"DH Janssens","year":"2024","unstructured":"Janssens DH, et al. MLL oncoprotein levels influence leukemia lineage identities. Nat Commun. 2024;15(1):9341.","journal-title":"Nat Commun"},{"issue":"5","key":"1294_CR371","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/s41375-024-02205-x","volume":"38","author":"JC Wong","year":"2024","unstructured":"Wong JC, et al. 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies. Leukemia. 2024;38(5):1182\u20136.","journal-title":"Leukemia"},{"issue":"4","key":"1294_CR372","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/ncb3124","volume":"17","author":"LK Boroughs","year":"2015","unstructured":"Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17(4):351\u20139.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"1294_CR373","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Robert A. Weinberg, Hallmarks of Cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"6","key":"1294_CR374","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","volume":"13","author":"G Kroemer","year":"2008","unstructured":"Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer\u2019s Achilles\u2019 Heel. Cancer Cell. 2008;13(6):472\u201382.","journal-title":"Cancer Cell"},{"issue":"1","key":"1294_CR375","doi-asserted-by":"publisher","first-page":"28576","DOI":"10.1038\/s41598-025-99845-5","volume":"15","author":"S Hussain","year":"2025","unstructured":"Hussain S, et al. Role of metabolomic changes in diagnosis and assessment of treatment response in acute myeloid leukemia. Sci Rep. 2025;15(1):28576.","journal-title":"Sci Rep"},{"issue":"10","key":"1294_CR376","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1161\/ATVBAHA.107.148429","volume":"27","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, et al. Transcriptional activation of hepatic ACSL3 and ACSL5 by oncostatin m reduces hypertriglyceridemia through enhanced beta-oxidation. Arterioscler Thromb Vasc Biol. 2007;27(10):2198\u2013205.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1294_CR377","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/nrneph.2017.59","volume":"13","author":"HI Wettersten","year":"2017","unstructured":"Wettersten HI, et al. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol. 2017;13(7):410\u20139.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"1294_CR378","doi-asserted-by":"publisher","first-page":"20191920","DOI":"10.1084\/jem.20191920","volume":"217","author":"T Manzo","year":"2020","unstructured":"Manzo T, et al. Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J Exp Med. 2020;217(8):20191920.","journal-title":"J Exp Med"},{"issue":"10","key":"1294_CR379","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1038\/s41418-021-00859-z","volume":"28","author":"X Chen","year":"2021","unstructured":"Chen X, et al. Organelle-specific regulation of ferroptosis. Cell Death Differ. 2021;28(10):2843\u201356.","journal-title":"Cell Death Differ"},{"issue":"8","key":"1294_CR380","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1038\/s41418-021-00769-0","volume":"28","author":"W Cui","year":"2021","unstructured":"Cui W, et al. Peroxisome-driven ether-linked phospholipids biosynthesis is essential for ferroptosis. Cell Death Differ. 2021;28(8):2536\u201351.","journal-title":"Cell Death Differ"},{"issue":"11","key":"1294_CR381","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nrc3340","volume":"12","author":"A Chiarugi","year":"2012","unstructured":"Chiarugi A, et al. The NAD metabolome \u2014 a key determinant of cancer cell biology. Nat Rev Cancer. 2012;12(11):741\u201352.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1294_CR382","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","volume":"27","author":"CL Jones","year":"2020","unstructured":"Jones CL, et al. Nicotinamide metabolism mediates resistance to Venetoclax in relapsed acute myeloid Leukemia stem cells. Cell Stem Cell. 2020;27(5):748-764.e4.","journal-title":"Cell Stem Cell"},{"key":"1294_CR383","doi-asserted-by":"crossref","unstructured":"Wang, M., et al., 2025 SIRT5 inhibition impairs mitochondrial metabolism and enhances venetoclax-induced elimination of acute myeloid leukemia cells. Leukemia","DOI":"10.1038\/s41375-025-02673-9"},{"issue":"11","key":"1294_CR384","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc.2016.114","volume":"16","author":"BJ Altman","year":"2016","unstructured":"Altman BJ, Stine ZE, Dang CV. Erratum: from Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(11):749\u2013749.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1294_CR385","doi-asserted-by":"publisher","first-page":"16387","DOI":"10.1038\/s41598-025-93169-0","volume":"15","author":"B Murato\u011flu","year":"2025","unstructured":"Murato\u011flu B, et al. Circadian rhythm and aryl hydrocarbon receptor crosstalk in bone marrow adipose tissue and implications in leukemia. Sci Rep. 2025;15(1):16387.","journal-title":"Sci Rep"},{"issue":"6","key":"1294_CR386","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/s41375-024-02222-w","volume":"38","author":"J Guo","year":"2024","unstructured":"Guo J, et al. 8-Cl-Ado and 8-NH2-Ado synergize with venetoclax to target the methionine-MAT2A-SAM axis in acute myeloid leukemia. Leukemia. 2024;38(6):1236\u201345.","journal-title":"Leukemia"},{"issue":"11","key":"1294_CR387","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41375-024-02390-9","volume":"38","author":"V Dembitz","year":"2024","unstructured":"Dembitz V, et al. Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation. Leukemia. 2024;38(11):2395\u2013409.","journal-title":"Leukemia"},{"issue":"13","key":"1294_CR388","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood.2024025245","volume":"145","author":"SE Millman","year":"2024","unstructured":"Millman SE, et al. Alpha-ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia. Blood. 2024;145(13):1422\u201336.","journal-title":"Blood"},{"key":"1294_CR389","doi-asserted-by":"crossref","unstructured":"Hlavaty, S.I., et al., 2024 ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. Cell Reports, 43(12).","DOI":"10.1016\/j.celrep.2024.114988"},{"issue":"12","key":"1294_CR390","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41419-024-07308-y","volume":"15","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. SLC25A21 correlates with the prognosis of adult acute myeloid leukemia through inhibiting the growth of leukemia cells via downregulating CXCL8. Cell Death Dis. 2024;15(12):921.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1294_CR391","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-021-01416-w","volume":"36","author":"L de Beauchamp","year":"2022","unstructured":"de Beauchamp L, Himonas E, Helgason GV. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. Leukemia. 2022;36(1):1\u201312.","journal-title":"Leukemia"},{"issue":"4","key":"1294_CR392","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molmed.2020.10.001","volume":"27","author":"R Culp-Hill","year":"2021","unstructured":"Culp-Hill R, D\u2019Alessandro A, Pietras EM. Extinguishing the embers: targeting AML metabolism. Trends Mol Med. 2021;27(4):332\u201344.","journal-title":"Trends Mol Med"},{"issue":"7","key":"1294_CR393","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019;9(7):890\u2013909.","journal-title":"Cancer Discov"},{"issue":"23","key":"1294_CR394","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.1111\/febs.16142","volume":"289","author":"B L\u00fcscher","year":"2022","unstructured":"L\u00fcscher B, et al. ADP-ribosyltransferases, an update on function and nomenclature. Febs j. 2022;289(23):7399\u2013410.","journal-title":"Febs j"},{"issue":"3","key":"1294_CR395","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1021\/acs.chemrev.7b00122","volume":"118","author":"B L\u00fcscher","year":"2018","unstructured":"L\u00fcscher B, et al. ADP-Ribosylation, a multifaceted posttranslational modification involved in the control of cell physiology in health and disease. Chem Rev. 2018;118(3):1092\u2013136.","journal-title":"Chem Rev"},{"issue":"3","key":"1294_CR396","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41375-022-01796-7","volume":"37","author":"S Stratmann","year":"2023","unstructured":"Stratmann S, et al. Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children. Leukemia. 2023;37(3):550\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR397","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40170-025-00392-4","volume":"13","author":"A Erdem","year":"2025","unstructured":"Erdem A, et al. Lactate dehydrogenase a-coupled NAD+ regeneration is critical for acute myeloid leukemia cell survival. Cancer Metabol. 2025;13(1):22.","journal-title":"Cancer Metabol"},{"issue":"1","key":"1294_CR398","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13578-025-01386-x","volume":"15","author":"X Ma","year":"2025","unstructured":"Ma X, et al. The HNRNPC\/CELF2 signaling pathway drives glycolytic reprogramming and mitochondrial dysfunction in drug-resistant acute myeloid leukemia. Cell Biosci. 2025;15(1):61.","journal-title":"Cell Biosci"},{"key":"1294_CR399","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2025.111735","volume":"131","author":"Y Liao","year":"2025","unstructured":"Liao Y, et al. OTUB1 promotes the progression of acute myeloid leukemia by regulating glycolysis via deubiquitinating c-Myc. Cell Signal. 2025;131:111735.","journal-title":"Cell Signal"},{"issue":"1","key":"1294_CR400","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/1471-2407-14-396","volume":"14","author":"A L\u2019Abbate","year":"2014","unstructured":"L\u2019Abbate A, et al. FOXP1 and TP63 involvement in the progression of myelodysplastic syndrome with 5q- and additional cytogenetic abnormalities. BMC Cancer. 2014;14(1):396.","journal-title":"BMC Cancer"},{"issue":"1","key":"1294_CR401","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12885-015-1282-1","volume":"15","author":"Y Jin","year":"2015","unstructured":"Jin Y, et al. Tenovin-6-mediated inhibition of SIRT1\/2 induces apoptosis in acute lymphoblastic leukemia (ALL) cells and eliminates ALL stem\/progenitor cells. BMC Cancer. 2015;15(1):226.","journal-title":"BMC Cancer"},{"key":"1294_CR402","doi-asserted-by":"publisher","first-page":"1569641","DOI":"10.3389\/fimmu.2025.1569641","volume":"16","author":"X-M Wen","year":"2025","unstructured":"Wen X-M, et al. FOXP1 is associated with oncogenesis and clinical outcomes in hematologic malignancies. Front Immunol. 2025;16:1569641.","journal-title":"Front Immunol"},{"issue":"19","key":"1294_CR403","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/blood.2024025761","volume":"145","author":"F Alikarami","year":"2025","unstructured":"Alikarami F, et al. GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia. Blood. 2025;145(19):2179\u201395.","journal-title":"Blood"},{"issue":"5","key":"1294_CR404","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41419-022-04891-w","volume":"13","author":"K Seiler","year":"2022","unstructured":"Seiler K, et al. Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions. Cell Death Dis. 2022;13(5):448.","journal-title":"Cell Death Dis"},{"issue":"14","key":"1294_CR405","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1182\/blood-2017-03-772939","volume":"130","author":"CR Marlein","year":"2017","unstructured":"Marlein CR, et al. NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. Blood. 2017;130(14):1649\u201360.","journal-title":"Blood"},{"issue":"5","key":"1294_CR406","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cmet.2020.09.001","volume":"32","author":"D Forte","year":"2020","unstructured":"Forte D, et al. Bone marrow mesenchymal stem cells support acute myeloid Leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy. Cell Metab. 2020;32(5):829-843.e9.","journal-title":"Cell Metab"},{"key":"1294_CR407","doi-asserted-by":"crossref","unstructured":"Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New England Journal of Medicine, 2015. 372(26): p. 2481\u20132498.","DOI":"10.1056\/NEJMoa1402121"},{"issue":"2","key":"1294_CR408","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/leu.2016.275","volume":"31","author":"BC Medeiros","year":"2017","unstructured":"Medeiros BC, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272\u201381.","journal-title":"Leukemia"},{"issue":"8","key":"1294_CR409","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u201373.","journal-title":"N Engl J Med"},{"issue":"7274","key":"1294_CR410","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739\u201344.","journal-title":"Nature"},{"issue":"5","key":"1294_CR411","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.molcel.2020.12.026","volume":"81","author":"Y Qing","year":"2021","unstructured":"Qing Y, et al. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO\/m6A\/<em>PFKP<\/em>\/<em>LDHB<\/em> axis. Mol Cell. 2021;81(5):922-939.e9.","journal-title":"Mol Cell"},{"issue":"3","key":"1294_CR412","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","volume":"17","author":"PS Ward","year":"2010","unstructured":"Ward PS, et al. The common feature of Leukemia-associated IDH1 and IDH2 mutations Is a neomorphic enzyme activity converting & #x3b1;-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell. 2010;17(3):225\u201334.","journal-title":"Cancer Cell"},{"issue":"1","key":"1294_CR413","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, et al. Oncometabolite 2-Hydroxyglutarate Is a competitive inhibitor of & #x3b1;-Ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17\u201330.","journal-title":"Cancer Cell"},{"issue":"4","key":"1294_CR414","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ccell.2019.03.006","volume":"35","author":"Y Huang","year":"2019","unstructured":"Huang Y, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35(4):677-691.e10.","journal-title":"Cancer Cell"},{"issue":"83","key":"1294_CR415","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.1126\/sciimmunol.abn6173","volume":"8","author":"M van Gulijk","year":"2023","unstructured":"van Gulijk M, et al. PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance. Sci Immunol. 2023;8(83):6173.","journal-title":"Sci Immunol"},{"issue":"1","key":"1294_CR416","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41698-025-00933-6","volume":"9","author":"Y-Y Zhang","year":"2025","unstructured":"Zhang Y-Y, et al. Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy. npj Precis Oncol. 2025;9(1):142.","journal-title":"npj Precis Oncol."},{"issue":"1","key":"1294_CR417","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte T, et al. CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat Commun. 2024;15(1):8439.","journal-title":"Nat Commun"},{"issue":"21","key":"1294_CR418","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309\u201337.","journal-title":"Cell"},{"issue":"1","key":"1294_CR419","doi-asserted-by":"publisher","first-page":"13635","DOI":"10.1038\/s41598-025-95607-5","volume":"15","author":"P Xu","year":"2025","unstructured":"Xu P, et al. Disulfidptosis-related LncRNAs forecast the prognosis of acute myeloid leukemia. Sci Rep. 2025;15(1):13635.","journal-title":"Sci Rep"},{"key":"1294_CR420","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","volume":"11","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, et al. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020;11:784.","journal-title":"Front Immunol"},{"key":"1294_CR421","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"1294_CR422","doi-asserted-by":"publisher","first-page":"15856","DOI":"10.1038\/s41598-022-19972-1","volume":"12","author":"M Marconato","year":"2022","unstructured":"Marconato M, et al. Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia. Sci Rep. 2022;12(1):15856.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR423","doi-asserted-by":"publisher","first-page":"18356","DOI":"10.1038\/s41598-024-68069-4","volume":"14","author":"A Afgar","year":"2024","unstructured":"Afgar A, et al. 6-Gingerol modulates miRNAs and PODXL gene expression via methyltransferase enzymes in NB4 cells: an in silico and in vitro study. Sci Rep. 2024;14(1):18356.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR424","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1038\/s41467-025-61647-8","volume":"16","author":"H Jiang","year":"2025","unstructured":"Jiang H, et al. ST2\/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche. Nat Commun. 2025;16(1):6580.","journal-title":"Nat Commun"},{"issue":"11","key":"1294_CR425","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/s43018-021-00262-0","volume":"2","author":"G Wu","year":"2021","unstructured":"Wu G, et al. LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2\u2013cFLIP\u2013NF-\u03baB signaling axis. Nature Cancer. 2021;2(11):1170\u201384.","journal-title":"Nature Cancer"},{"key":"1294_CR426","doi-asserted-by":"crossref","unstructured":"Pan, Y., et al., 2024 Immunotherapy-relevance of a candidate prognostic score for Acute Myeloid Leukemia. Heliyon,. 10(11).","DOI":"10.1016\/j.heliyon.2024.e32154"},{"issue":"4","key":"1294_CR427","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41435-024-00285-4","volume":"25","author":"U Schnetzke","year":"2024","unstructured":"Schnetzke U, et al. Validating genetic variants in innate immunity linked to infectious events in acute myeloid leukemia post-induction chemotherapy. Genes Immun. 2024;25(4):317\u201323.","journal-title":"Genes Immun"},{"issue":"1","key":"1294_CR428","doi-asserted-by":"publisher","first-page":"17874","DOI":"10.1038\/s41598-024-68755-3","volume":"14","author":"Y Qin","year":"2024","unstructured":"Qin Y, et al. Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns. Sci Rep. 2024;14(1):17874.","journal-title":"Sci Rep"},{"issue":"4","key":"1294_CR429","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2017.03.001","volume":"31","author":"S Mohr","year":"2017","unstructured":"Mohr S, et al. Hoxa9 and Meis1 cooperatively induce addiction to syk signaling by suppressing miR-146a in acute myeloid leukemia. Cancer Cell. 2017;31(4):549-562.e11.","journal-title":"Cancer Cell"},{"issue":"1","key":"1294_CR430","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/cdd.2015.136","volume":"23","author":"N Lalaoui","year":"2016","unstructured":"Lalaoui N, Johnstone R, Ekert PG. Autophagy and AML\u2014food for thought. Cell Death Differ. 2016;23(1):5\u20136.","journal-title":"Cell Death Differ"},{"issue":"4","key":"1294_CR431","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1152\/physrev.00041.2015","volume":"96","author":"J Beermann","year":"2016","unstructured":"Beermann J, et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297\u2013325.","journal-title":"Physiol Rev"},{"issue":"7414","key":"1294_CR432","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"I Dunham","year":"2012","unstructured":"Dunham I, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489(7414):57\u201374.","journal-title":"Nature"},{"issue":"4","key":"1294_CR433","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.01.019","volume":"35","author":"R Esposito","year":"2019","unstructured":"Esposito R, et al. Hacking the Cancer genome: profiling therapeutically actionable long non-coding rnas using crispr-cas9 screening. Cancer Cell. 2019;35(4):545\u201357.","journal-title":"Cancer Cell"},{"issue":"4","key":"1294_CR434","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1628","volume":"14","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, et al. m(6)A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clin Transl Med. 2024;14(4):e1628.","journal-title":"Clin Transl Med"},{"issue":"3","key":"1294_CR435","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41556-023-01091-2","volume":"25","author":"X Liu","year":"2023","unstructured":"Liu X, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol. 2023;25(3):404\u201314.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1294_CR436","doi-asserted-by":"publisher","first-page":"16995","DOI":"10.1038\/s41598-025-01730-8","volume":"15","author":"Y Wei","year":"2025","unstructured":"Wei Y, et al. A novel LncRNA risk model for disulfidptosis-related prognosis prediction and response to chemotherapy in acute myeloid leukemia. Sci Rep. 2025;15(1):16995.","journal-title":"Sci Rep"},{"issue":"3","key":"1294_CR437","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/leu.2014.231","volume":"29","author":"D Gerloff","year":"2015","unstructured":"Gerloff D, et al. NF-\u03baB\/STAT5\/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia. 2015;29(3):535\u201347.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR438","doi-asserted-by":"publisher","first-page":"8890","DOI":"10.1038\/s41598-025-92827-7","volume":"15","author":"W Wang","year":"2025","unstructured":"Wang W, et al. Overexpression of miR-99a promoted expansion and suppressed differentiation of hematopoietic stem\/progenitor cells. Sci Rep. 2025;15(1):8890.","journal-title":"Sci Rep"},{"issue":"8","key":"1294_CR439","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.celrep.2019.04.081","volume":"27","author":"H Wang","year":"2019","unstructured":"Wang H, et al. ZEB1 represses neural differentiation and cooperates with CTBP2 to dynamically regulate cell migration during neocortex development. Cell Rep. 2019;27(8):2335-2353.e6.","journal-title":"Cell Rep"},{"key":"1294_CR440","doi-asserted-by":"crossref","unstructured":"Zhang, Y., et al., 2025 miR-128\u20133p Reduces Proliferation and Immune Escape in Acute Myeloid Leukemia Through Targeted Regulation of ZEB1. Applied Biochemistry and Biotechnology,","DOI":"10.1007\/s12010-025-05255-8"},{"issue":"25","key":"1294_CR441","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1182\/blood-2008-07-170589","volume":"113","author":"R Garzon","year":"2009","unstructured":"Garzon R, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411\u20138.","journal-title":"Blood"},{"issue":"7","key":"1294_CR442","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/s41417-021-00378-6","volume":"29","author":"C Zhao","year":"2022","unstructured":"Zhao C, et al. Acute myeloid leukemia cell-derived extracellular vesicles carrying microRNA-548ac regulate hematopoietic function via the TRIM28\/STAT3 pathway. Cancer Gene Ther. 2022;29(7):918\u201329.","journal-title":"Cancer Gene Ther"},{"key":"1294_CR443","doi-asserted-by":"crossref","unstructured":"Hollensen, A.K., et al., circZNF827 nucleates a transcription inhibitory complex to balance neuronal differentiation. Elife, 2020. 9.","DOI":"10.7554\/eLife.58478"},{"issue":"1","key":"1294_CR444","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.molcel.2014.08.019","volume":"56","author":"R Ashwal-Fluss","year":"2014","unstructured":"Ashwal-Fluss R, et al. circRNA biogenesis competes with Pre-mRNA splicing. Mol Cell. 2014;56(1):55\u201366.","journal-title":"Mol Cell"},{"issue":"1","key":"1294_CR445","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1038\/s41467-025-58070-4","volume":"16","author":"D Kelly","year":"2025","unstructured":"Kelly D, et al. A functional screen uncovers circular RNAs regulating excitatory synaptogenesis in hippocampal neurons. Nat Commun. 2025;16(1):3040.","journal-title":"Nat Commun"},{"issue":"1","key":"1294_CR446","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2017.02.021","volume":"66","author":"NR Pamudurti","year":"2017","unstructured":"Pamudurti NR, et al. Translation of CircRNAs. Mol Cell. 2017;66(1):9-21.e7.","journal-title":"Mol Cell"},{"issue":"7441","key":"1294_CR447","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen TB, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384\u20138.","journal-title":"Nature"},{"issue":"1","key":"1294_CR448","doi-asserted-by":"publisher","first-page":"14704","DOI":"10.1038\/s41598-023-41974-w","volume":"13","author":"J Fu","year":"2023","unstructured":"Fu J, et al. Distinct N7-methylguanosine profiles of circular RNAs in drug-resistant acute myeloid leukemia. Sci Rep. 2023;13(1):14704.","journal-title":"Sci Rep"},{"key":"1294_CR449","doi-asserted-by":"crossref","unstructured":"Yao, L., et al., circAFF2 promotes the development of AML by binding to PML mRNA. Oncogene, 2025.","DOI":"10.1038\/s41388-025-03299-y"},{"issue":"1","key":"1294_CR450","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12915-025-02233-8","volume":"23","author":"M Wang","year":"2025","unstructured":"Wang M, et al. Transcriptome analysis reveals PTBP1 as a key regulator of circRNA biogenesis. BMC Biol. 2025;23(1):127.","journal-title":"BMC Biol"},{"issue":"2","key":"1294_CR451","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7150\/ijms.28047","volume":"16","author":"B Lei","year":"2019","unstructured":"Lei B, et al. Circular RNA: a novel biomarker and therapeutic target for human cancers. Int J Med Sci. 2019;16(2):292\u2013301.","journal-title":"Int J Med Sci"},{"issue":"1","key":"1294_CR452","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-021-01481-w","volume":"21","author":"CH Wong","year":"2022","unstructured":"Wong CH, et al. CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial\u2013mesenchymal transition protein. Mol Cancer. 2022;21(1):10.","journal-title":"Mol Cancer"},{"issue":"13","key":"1294_CR453","doi-asserted-by":"publisher","first-page":"2003376","DOI":"10.1002\/advs.202003376","volume":"8","author":"L Jia","year":"2021","unstructured":"Jia L, Wang Y, Wang CY. circFAT1 promotes cancer stemness and immune evasion by promoting STAT3 activation. Adv Sci (Weinh). 2021;8(13):2003376.","journal-title":"Adv Sci (Weinh)"},{"key":"1294_CR454","doi-asserted-by":"crossref","unstructured":"Bridges, M.C., A.C. Daulagala, and A. Kourtidis, LNCcation: lncRNA localization and function. Journal of Cell Biology, 2021. 220(2).","DOI":"10.1083\/jcb.202009045"},{"issue":"6","key":"1294_CR455","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.it.2022.04.002","volume":"43","author":"DC Peltier","year":"2022","unstructured":"Peltier DC, Roberts A, Reddy P. LNCing RNA to immunity. Trends Immunol. 2022;43(6):478\u201395.","journal-title":"Trends Immunol"},{"issue":"11","key":"1294_CR456","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/leu.2013.114","volume":"27","author":"M Mallardo","year":"2013","unstructured":"Mallardo M, et al. NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model. Leukemia. 2013;27(11):2248\u201351.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR457","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41467-021-22095-2","volume":"12","author":"G Zhu","year":"2021","unstructured":"Zhu G, et al. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. Nat Commun. 2021;12(1):1956.","journal-title":"Nat Commun"},{"issue":"1","key":"1294_CR458","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","volume":"173","author":"DP Bartel","year":"2018","unstructured":"Bartel DP. Metazoan MicroRNAs. Cell. 2018;173(1):20\u201351.","journal-title":"Cell"},{"issue":"4","key":"1294_CR459","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1701","volume":"13","author":"PM Fr\u00e9d\u00e9rick","year":"2022","unstructured":"Fr\u00e9d\u00e9rick PM, Simard MJ. Regulation and different functions of the animal microRNA-induced silencing complex. Wiley Interdiscip Rev RNA. 2022;13(4):e1701.","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"7","key":"1294_CR460","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrg3965","volume":"16","author":"S Jonas","year":"2015","unstructured":"Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 2015;16(7):421\u201333.","journal-title":"Nat Rev Genet"},{"key":"1294_CR461","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2025.156883","volume":"188","author":"L Xiang","year":"2025","unstructured":"Xiang L, Lin X, Wu Y. LINC-PINT suppresses the progression of acute myeloid leukemia via miR-767-5p\/SUZ12-mediated JAK\/STAT signaling pathway. Cytokine. 2025;188:156883.","journal-title":"Cytokine"},{"issue":"9","key":"1294_CR462","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/onc.2015.174","volume":"35","author":"CT Collins","year":"2016","unstructured":"Collins CT, Hess JL. Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Oncogene. 2016;35(9):1090\u20138.","journal-title":"Oncogene"},{"issue":"5439","key":"1294_CR463","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1126\/science.286.5439.531","volume":"286","author":"TR Golub","year":"1999","unstructured":"Golub TR, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286(5439):531\u20137.","journal-title":"Science"},{"issue":"11","key":"1294_CR464","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/leu.2008.198","volume":"22","author":"M Andreeff","year":"2008","unstructured":"Andreeff M, et al. HOX expression patterns identify a common signature for favorable AML. Leukemia. 2008;22(11):2041\u20137.","journal-title":"Leukemia"},{"issue":"5","key":"1294_CR465","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1600-0609.2009.01309.x","volume":"83","author":"M Zangenberg","year":"2009","unstructured":"Zangenberg M, et al. The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML. Eur J Haematol. 2009;83(5):439\u201348.","journal-title":"Eur J Haematol"},{"issue":"25","key":"1294_CR466","doi-asserted-by":"publisher","first-page":"12223","DOI":"10.1073\/pnas.91.25.12223","volume":"91","author":"G Sauvageau","year":"1994","unstructured":"Sauvageau G, et al. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells. Proc Natl Acad Sci. 1994;91(25):12223\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"1294_CR467","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/leu.2015.6","volume":"29","author":"DH Spencer","year":"2015","unstructured":"Spencer DH, et al. Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells. Leukemia. 2015;29(6):1279\u201389.","journal-title":"Leukemia"},{"issue":"6","key":"1294_CR468","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.ccell.2019.10.011","volume":"36","author":"H Luo","year":"2019","unstructured":"Luo H, et al. <em>HOTTIP<\/em> lncRNA promotes hematopoietic stem cell self-renewal leading to AML-like disease in mice. Cancer Cell. 2019;36(6):645-659.e8.","journal-title":"Cancer Cell"},{"issue":"7619","key":"1294_CR469","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature19346","volume":"537","author":"JJ Kotzin","year":"2016","unstructured":"Kotzin JJ, et al. The long non-coding RNA Morrbid regulates Bim and short-lived myeloid cell lifespan. Nature. 2016;537(7619):239\u201343.","journal-title":"Nature"},{"key":"1294_CR470","doi-asserted-by":"crossref","unstructured":"Cai, Z., et al., Targeting Bim via a lncRNA <em>Morrbid<\/em> Regulates the Survival of Preleukemic and Leukemic Cells. Cell Reports, 2020. 31(12).","DOI":"10.1016\/j.celrep.2020.107816"},{"issue":"10","key":"1294_CR471","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1038\/s41375-021-01307-0","volume":"35","author":"M Gourvest","year":"2021","unstructured":"Gourvest M, et al. A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA. Leukemia. 2021;35(10):2784\u201398.","journal-title":"Leukemia"},{"key":"1294_CR472","doi-asserted-by":"crossref","unstructured":"Selkirk, E., et al., SGOL1-AS1 enhances cell survival in acute myeloid leukemia by maintaining pro-inflammatory signaling. Heliyon, 2022. 8(11).","DOI":"10.1016\/j.heliyon.2022.e11362"},{"key":"1294_CR473","doi-asserted-by":"crossref","unstructured":"Bai, D., et al., Single-cell parallel analysis of DNA damage and transcriptome reveals selective genome vulnerability. Nature Methods, 2025.","DOI":"10.1038\/s41592-025-02632-3"},{"issue":"1","key":"1294_CR474","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41420-025-02512-x","volume":"11","author":"K Zhao","year":"2025","unstructured":"Zhao K, et al. METTL13 is essential for the survival of acute myeloid leukemia cells by regulating MYC. Cell Death Discovery. 2025;11(1):240.","journal-title":"Cell Death Discovery"},{"issue":"5","key":"1294_CR475","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41375-021-01225-1","volume":"35","author":"L Yao","year":"2021","unstructured":"Yao L, et al. RNA methylation in hematological malignancies and its interactions with other epigenetic modifications. Leukemia. 2021;35(5):1243\u201357.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR476","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-023-00386-2","volume":"12","author":"W-W Liu","year":"2023","unstructured":"Liu W-W, et al. Emerging roles of m6A RNA modification in cancer therapeutic resistance. Exp Hematol Oncol. 2023;12(1):21.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1294_CR477","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.stem.2022.12.006","volume":"30","author":"L Han","year":"2023","unstructured":"Han L, et al. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell. 2023;30(1):52-68.e13.","journal-title":"Cell Stem Cell"},{"issue":"2","key":"1294_CR478","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.bbrc.2003.09.235","volume":"311","author":"J Lv","year":"2003","unstructured":"Lv J, et al. Molecular cloning of a novel human gene encoding histone acetyltransferase-like protein involved in transcriptional activation of hTERT. Biochem Biophys Res Commun. 2003;311(2):506\u201313.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"1294_CR479","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.cell.2018.10.030","volume":"175","author":"D Arango","year":"2018","unstructured":"Arango D, et al. Acetylation of cytidine in mRNA promotes translation efficiency. Cell. 2018;175(7):1872-1886.e24.","journal-title":"Cell"},{"issue":"38","key":"1294_CR480","doi-asserted-by":"publisher","first-page":"26201","DOI":"10.1074\/jbc.M114.593996","volume":"289","author":"S Ito","year":"2014","unstructured":"Ito S, et al. A single acetylation of 18 S rRNA Is essential for biogenesis of the small ribosomal subunit in <em>Saccharomyces cerevisiae<\/em>*. J Biol Chem. 2014;289(38):26201\u201312.","journal-title":"J Biol Chem"},{"issue":"52","key":"1294_CR481","doi-asserted-by":"publisher","first-page":"35724","DOI":"10.1074\/jbc.C114.602698","volume":"289","author":"S Ito","year":"2014","unstructured":"Ito S, et al. Human NAT10 Is an ATP-dependent RNA acetyltransferase responsible for <em>N<\/em>4-acetylcytidine formation in 18 S Ribosomal RNA (rRNA) *. J Biol Chem. 2014;289(52):35724\u201330.","journal-title":"J Biol Chem"},{"key":"1294_CR482","doi-asserted-by":"crossref","unstructured":"Zhang, S., et al., NAT10-mediated mRNA N4-acetylcytidine reprograms serine metabolism to drive leukaemogenesis and stemness in acute myeloid leukaemia. Nature Cell Biology, 2024.","DOI":"10.1038\/s41556-024-01548-y"},{"issue":"5","key":"1294_CR483","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41590-020-0650-4","volume":"21","author":"Z Shulman","year":"2020","unstructured":"Shulman Z, Stern-Ginossar N. The RNA modification N6-methyladenosine as a novel regulator of the immune system. Nat Immunol. 2020;21(5):501\u201312.","journal-title":"Nat Immunol"},{"key":"1294_CR484","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-immunol-101921-045401","volume":"41","author":"D Han","year":"2023","unstructured":"Han D, Xu MM. RNA modification in the immune system. Annu Rev Immunol. 2023;41:73\u201398.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"1294_CR485","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.cmet.2021.04.001","volume":"33","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metab. 2021;33(6):1221-1233.e11.","journal-title":"Cell Metab"},{"issue":"44","key":"1294_CR486","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1038\/s41388-022-02471-y","volume":"41","author":"A Maiques-Diaz","year":"2022","unstructured":"Maiques-Diaz A, et al. HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block. Oncogene. 2022;41(44):4841\u201354.","journal-title":"Oncogene"},{"issue":"4","key":"1294_CR487","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.stem.2020.12.005","volume":"28","author":"E Wang","year":"2021","unstructured":"Wang E, et al. Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation. Cell Stem Cell. 2021;28(4):718-731.e6.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"1294_CR488","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941\u201353.","journal-title":"Cell"},{"issue":"38","key":"1294_CR489","doi-asserted-by":"publisher","first-page":"13956","DOI":"10.1073\/pnas.0606381103","volume":"103","author":"Y Chen","year":"2006","unstructured":"Chen Y, et al. Crystal structure of human histone lysine-specific demethylase 1 (LSD1). Proc Natl Acad Sci. 2006;103(38):13956\u201361.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"1294_CR490","doi-asserted-by":"publisher","first-page":"4214","DOI":"10.1038\/s41467-025-58966-1","volume":"16","author":"F Huang","year":"2025","unstructured":"Huang F, et al. m6A\/IGF2BP3-driven serine biosynthesis fuels AML stemness and metabolic vulnerability. Nat Commun. 2025;16(1):4214.","journal-title":"Nat Commun"},{"issue":"2","key":"1294_CR491","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/cgt.2013.87","volume":"21","author":"H Wang","year":"2014","unstructured":"Wang H, et al. Methylation of SFRP5 is related to multidrug resistance in leukemia cells. Cancer Gene Ther. 2014;21(2):83\u20139.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"1294_CR492","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41392-023-01605-2","volume":"8","author":"Z-W Huang","year":"2023","unstructured":"Huang Z-W, et al. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct Target Ther. 2023;8(1):391.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1294_CR493","doi-asserted-by":"publisher","first-page":"15456","DOI":"10.1038\/ncomms15456","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, et al. Loss of Asxl2 leads to myeloid malignancies in mice. Nat Commun. 2017;8(1):15456.","journal-title":"Nat Commun"},{"issue":"7457","key":"1294_CR494","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214\u20138.","journal-title":"Nature"},{"issue":"1","key":"1294_CR495","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","volume":"19","author":"W Xu","year":"2011","unstructured":"Xu W, et al. Oncometabolite 2-Hydroxyglutarate Is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17\u201330.","journal-title":"Cancer Cell"},{"issue":"14","key":"1294_CR496","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2011-02-339747","volume":"118","author":"W-C Chou","year":"2011","unstructured":"Chou W-C, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood. 2011;118(14):3803\u201310.","journal-title":"Blood"},{"issue":"1","key":"1294_CR497","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1038\/s41598-020-59365-w","volume":"10","author":"J Wang","year":"2020","unstructured":"Wang J, et al. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia. Sci Rep. 2020;10(1):2706.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR498","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.stemcr.2020.05.002","volume":"15","author":"B Ramdas","year":"2020","unstructured":"Ramdas B, et al. Driver mutations in Leukemia promote disease pathogenesis through a combination of cell-autonomous and niche modulation. Stem Cell Reports. 2020;15(1):95\u2013109.","journal-title":"Stem Cell Reports"},{"issue":"5595","key":"1294_CR499","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"R Cao","year":"2002","unstructured":"Cao R, et al. Role of histone H3 Lysine 27 methylation in polycomb-group silencing. Science. 2002;298(5595):1039\u201343.","journal-title":"Science"},{"issue":"11","key":"1294_CR500","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41419-024-07109-3","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI\/SNF loss-of-function tumors. Cell Death Dis. 2024;15(11):794.","journal-title":"Cell Death Dis"},{"key":"1294_CR501","doi-asserted-by":"crossref","unstructured":"Han, M., et al., Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors. Frontiers in Oncology, 2019. 9.","DOI":"10.3389\/fonc.2019.00194"},{"issue":"8","key":"1294_CR502","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/2159-8290.CD-16-1032","volume":"7","author":"JL Glass","year":"2017","unstructured":"Glass JL, et al. Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers. Cancer Discov. 2017;7(8):868\u201383.","journal-title":"Cancer Discov"},{"issue":"1","key":"1294_CR503","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","volume":"127","author":"BJ Wouters","year":"2016","unstructured":"Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2016;127(1):42\u201352.","journal-title":"Blood"},{"issue":"5","key":"1294_CR504","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bjh.12957","volume":"166","author":"GM Bravo","year":"2014","unstructured":"Bravo GM, et al. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. Br J Haematol. 2014;166(5):646\u201359.","journal-title":"Br J Haematol"},{"issue":"10","key":"1294_CR505","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1038\/s41375-022-01659-1","volume":"36","author":"T-J Zhang","year":"2022","unstructured":"Zhang T-J, et al. SLIT2 promoter hypermethylation-mediated SLIT2-IT1\/miR-218 repression drives leukemogenesis and predicts adverse prognosis in myelodysplastic neoplasm. Leukemia. 2022;36(10):2488\u201398.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR506","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/biom8010011","volume":"8","author":"K Wood","year":"2018","unstructured":"Wood K, Tellier M, Murphy S. DOT1L and H3K79 Methylation in Transcription and genomic stability. Biomolecules. 2018;8(1):11.","journal-title":"Biomolecules"},{"issue":"1","key":"1294_CR507","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1038\/s41467-025-59930-9","volume":"16","author":"S Troester","year":"2025","unstructured":"Troester S, et al. Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12. Nat Commun. 2025;16(1):4656.","journal-title":"Nat Commun"},{"issue":"5","key":"1294_CR508","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"Z-Y Wang","year":"2008","unstructured":"Wang Z-Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505\u201315.","journal-title":"Blood"},{"issue":"4","key":"1294_CR509","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41419-021-03604-z","volume":"12","author":"DA Pereira-Martins","year":"2021","unstructured":"Pereira-Martins DA, et al. MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model. Cell Death Dis. 2021;12(4):371.","journal-title":"Cell Death Dis"},{"issue":"8","key":"1294_CR510","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.bbadis.2010.10.007","volume":"182","author":"V Duong","year":"2011","unstructured":"Duong V, Rochette-Egly C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim et Biophys Acta (BBA) Mol Basis Disease. 2011;182(8):1023\u201331.","journal-title":"Biochim et Biophys Acta (BBA) Mol Basis Disease"},{"issue":"4976","key":"1294_CR511","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1126\/science.2218500","volume":"249","author":"J Borrow","year":"1990","unstructured":"Borrow J, et al. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science. 1990;249(4976):1577\u201380.","journal-title":"Science"},{"issue":"1","key":"1294_CR512","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s42003-024-06972-2","volume":"7","author":"AP Privitera","year":"2024","unstructured":"Privitera AP, et al. Super-resolved analysis of colocalization between replication and transcription along the cell cycle in a model of oncogene activation. Commun Biol. 2024;7(1):1260.","journal-title":"Commun Biol"},{"issue":"6","key":"1294_CR513","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","volume":"122","author":"MT Epping","year":"2005","unstructured":"Epping MT, et al. The human tumor antigen PRAME Is a dominant repressor of retinoic acid receptor signaling. Cell. 2005;122(6):835\u201347.","journal-title":"Cell"},{"issue":"9","key":"1294_CR514","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1158\/1078-0432.CCR-11-2524","volume":"19","author":"L Bullinger","year":"2013","unstructured":"Bullinger L, et al. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation\u2013a possible target for ATRA response in AML without t(15;17). Clin Cancer Res. 2013;19(9):2562\u201371.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1294_CR515","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ajhg.2014.12.017","volume":"96","author":"S Newman","year":"2015","unstructured":"Newman S, et al. Next-generation sequencing of duplication CNVs reveals that most are tandem and some create fusion genes at breakpoints. Am J Human Gene. 2015;96(2):208\u201320.","journal-title":"Am J Human Gene"},{"issue":"4","key":"1294_CR516","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrc2091","volume":"7","author":"F Mitelman","year":"2007","unstructured":"Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233\u201345.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1294_CR517","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/ng1335","volume":"36","author":"F Mitelman","year":"2004","unstructured":"Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet. 2004;36(4):331\u20134.","journal-title":"Nat Genet"},{"issue":"9","key":"1294_CR518","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1182\/blood.V92.9.3152","volume":"92","author":"MHH Kramer","year":"1998","unstructured":"Kramer MHH, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92(9):3152\u201362.","journal-title":"Blood"},{"issue":"suppl 6","key":"1294_CR519","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1289\/ehp.961041239","volume":"104","author":"RD Irons","year":"1996","unstructured":"Irons RD, Stillman WS. The process of leukemogenesis. Environ Health Perspect. 1996;104(suppl 6):1239\u201346.","journal-title":"Environ Health Perspect"},{"key":"1294_CR520","doi-asserted-by":"publisher","first-page":"204062072097698","DOI":"10.1177\/2040620720976984","volume":"12","author":"X Han","year":"2021","unstructured":"Han X, et al. Acute myeloid leukemia with CPSF6-RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration. Ther Adv Hematol. 2021;12:2040620720976984.","journal-title":"Ther Adv Hematol"},{"issue":"40","key":"1294_CR521","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022488","volume":"99","author":"W Wei","year":"2020","unstructured":"Wei W, et al. Alkaloid-based regimen is beneficial for acute myeloid leukemia resembling acute promyelocytic leukemia with NUP98\/RARG fusion and RUNX1 mutation: a case report. Medicine (Baltimore). 2020;99(40):e22488.","journal-title":"Medicine (Baltimore)"},{"key":"1294_CR522","doi-asserted-by":"publisher","first-page":"10559","DOI":"10.2147\/OTT.S273172","volume":"13","author":"S Tao","year":"2020","unstructured":"Tao S, et al. Acute myeloid leukemia with NUP98-RARG gene fusion similar to acute promyelocytic leukemia: case report and literature review. Onco Targets Ther. 2020;13:10559\u201366.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"1294_CR523","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.3324\/haematol.2019.244715","volume":"105","author":"Z Su","year":"2020","unstructured":"Su Z, et al. Novel reciprocal fusion genes involving HNRNPC and RARG in acute promyelocytic leukemia lacking RARA rearrangement. Haematologica. 2020;105(7):e376\u20138.","journal-title":"Haematologica"},{"issue":"6","key":"1294_CR524","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/s41375-018-0338-z","volume":"33","author":"J Zhao","year":"2019","unstructured":"Zhao J, et al. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia. Leukemia. 2019;33(6):1387\u201399.","journal-title":"Leukemia"},{"issue":"7","key":"1294_CR525","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1080\/10428194.2018.1553302","volume":"60","author":"X Zhang","year":"2019","unstructured":"Zhang X, et al. RAR\u03b3-rearrangements resemble acute promyelocytic leukemia and benefit from 3 + 7 regimen. Leuk Lymphoma. 2019;60(7):1831\u20134.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"1294_CR526","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41416-019-0456-z","volume":"120","author":"X Chen","year":"2019","unstructured":"Chen X, et al. A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide. Br J Cancer. 2019;120(11):1023\u20135.","journal-title":"Br J Cancer"},{"issue":"10","key":"1294_CR527","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/s41417-024-00818-z","volume":"31","author":"S Xie","year":"2024","unstructured":"Xie S, et al. Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAK\u03b1\u2013JNK pathway. Cancer Gene Ther. 2024;31(10):1486\u201397.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"1294_CR528","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41698-021-00179-y","volume":"5","author":"J-W Sidhom","year":"2021","unstructured":"Sidhom J-W, et al. Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features. npj Precis Oncol. 2021;5(1):38.","journal-title":"npj Precis Oncol"},{"issue":"11","key":"1294_CR529","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.1990.8.11.1913","volume":"8","author":"RM Stone","year":"1990","unstructured":"Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990;8(11):1913\u201321.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1294_CR530","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1073\/pnas.1222863110","volume":"110","author":"B Jiao","year":"2013","unstructured":"Jiao B, et al. 8-CPT-cAMP\/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF\/RAR\u03b1 degradation. Proc Natl Acad Sci. 2013;110(9):3495\u2013500.","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"1294_CR531","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrc2943","volume":"10","author":"H de Th\u00e9","year":"2010","unstructured":"de Th\u00e9 H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010;10(11):775\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"33","key":"1294_CR532","doi-asserted-by":"publisher","first-page":"13522","DOI":"10.1073\/pnas.1310067110","volume":"110","author":"N Girard","year":"2013","unstructured":"Girard N, et al. RAR\u03b1-PLZF oncogene inhibits C\/EBP\u03b1 function in myeloid cells. Proc Natl Acad Sci. 2013;110(33):13522\u20137.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"1294_CR533","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41419-021-03889-0","volume":"12","author":"S Li","year":"2021","unstructured":"Li S, et al. A novel fusion protein TBLR1-RAR\u03b1 acts as an oncogene to induce murine promyelocytic leukemia: identification and treatment strategies. Cell Death Dis. 2021;12(6):607.","journal-title":"Cell Death Dis"},{"issue":"6","key":"1294_CR534","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.3324\/haematol.2016.162206","volume":"102","author":"A Fasan","year":"2017","unstructured":"Fasan A, et al. Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse. Haematologica. 2017;102(6):e222\u20134.","journal-title":"Haematologica"},{"issue":"9","key":"1294_CR535","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/leu.2011.114","volume":"25","author":"PA Greif","year":"2011","unstructured":"Greif PA, et al. Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing. Leukemia. 2011;25(9):1519\u201322.","journal-title":"Leukemia"},{"issue":"2","key":"1294_CR536","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148346","volume":"11","author":"M Ib\u00e1\u00f1ez","year":"2016","unstructured":"Ib\u00e1\u00f1ez M, et al. The mutational landscape of acute promyelocytic leukemia reveals an interacting network of co-occurrences and recurrent mutations. PLoS ONE. 2016;11(2):e0148346.","journal-title":"PLoS ONE"},{"issue":"13","key":"1294_CR537","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1084\/jem.20131121","volume":"210","author":"GA dos Santos","year":"2013","unstructured":"dos Santos GA, Kats L, Pandolfi PP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013;210(13):2793\u2013802.","journal-title":"J Exp Med"},{"issue":"2","key":"1294_CR538","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41401-024-01371-z","volume":"46","author":"X-J Shao","year":"2025","unstructured":"Shao X-J, et al. Palmitoyltransferase ZDHHC3 is essential for the oncogenic activity of PML\/RAR\u03b1 in acute promyelocytic leukemia. Acta Pharmacol Sin. 2025;46(2):462\u201373.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"1294_CR539","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood.V83.1.10.10","volume":"83","author":"F Grignani","year":"1994","unstructured":"Grignani F, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood. 1994;83(1):10\u201325.","journal-title":"Blood"},{"issue":"33","key":"1294_CR540","doi-asserted-by":"publisher","first-page":"12133","DOI":"10.1073\/pnas.1412944111","volume":"111","author":"K Korf","year":"2014","unstructured":"Korf K, et al. The PML domain of PML\u2013RAR\u03b1 blocks senescence to promote leukemia. Proc Natl Acad Sci. 2014;111(33):12133\u20138.","journal-title":"Proc Natl Acad Sci"},{"key":"1294_CR541","doi-asserted-by":"crossref","unstructured":"Minami, M., et al., Distinct leukemogenic mechanism of acute promyelocytic leukemia based on genomic structure of PML::RAR\u03b1. Leukemia, 2025.","DOI":"10.1038\/s41375-025-02530-9"},{"issue":"9","key":"1294_CR542","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41419-021-04080-1","volume":"12","author":"D Tang","year":"2021","unstructured":"Tang D, et al. LncRNA KCNQ1OT1 activated by c-Myc promotes cell proliferation via interacting with FUS to stabilize MAP3K1 in acute promyelocytic leukemia. Cell Death Dis. 2021;12(9):795.","journal-title":"Cell Death Dis"},{"key":"1294_CR543","doi-asserted-by":"crossref","unstructured":"Ozturk, K., et al., Interface-guided phenotyping of coding variants in the transcription factor RUNX1. Cell Reports, 2024. 43(7).","DOI":"10.1016\/j.celrep.2024.114436"},{"key":"1294_CR544","doi-asserted-by":"crossref","unstructured":"Cumbo, C., et al., RUNX1A isoform is overexpressed in acute myeloid leukemia and is associated with FLT3 internal tandem duplications. Cancer Gene Therapy, 2025.","DOI":"10.21203\/rs.3.rs-5733882\/v1"},{"key":"1294_CR545","doi-asserted-by":"crossref","unstructured":"Zhang, X., et al., 2025 Deubiquitinase USP6 stabilizes oncogenic RUNX1 fusion proteins to promote the leukemic potential and malignant progression. Leukemia,.","DOI":"10.1038\/s41375-025-02698-0"},{"key":"1294_CR546","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fonc.2015.00083","volume":"5","author":"E Curran","year":"2015","unstructured":"Curran E, Corrales L, Kline J. Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol. 2015;5:83.","journal-title":"Front Oncol"},{"issue":"8","key":"1294_CR547","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00262-017-1966-2","volume":"66","author":"M Kortylewski","year":"2017","unstructured":"Kortylewski M, Moreira D. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother. 2017;66(8):979\u201388.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"1294_CR548","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4161\/jkst.20006","volume":"1","author":"M Bar-Natan","year":"2012","unstructured":"Bar-Natan M, et al. STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAK-STAT. 2012;1(2):55\u201364.","journal-title":"JAK-STAT"},{"issue":"26","key":"1294_CR549","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1200\/JCO.2008.21.3264","volume":"27","author":"M Benekli","year":"2009","unstructured":"Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009;27(26):4422\u201332.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1294_CR550","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/blood.2022016033","volume":"140","author":"MH Kramer","year":"2022","unstructured":"Kramer MH, et al. Proteomic and phosphoproteomic landscapes of acute myeloid leukemia. Blood. 2022;140(13):1533\u201348.","journal-title":"Blood"},{"issue":"2","key":"1294_CR551","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","volume":"123","author":"A Yokoyama","year":"2005","unstructured":"Yokoyama A, et al. The menin tumor suppressor protein is an essential oncogenic cofactor for mll-associated leukemogenesis. Cell. 2005;123(2):207\u201318.","journal-title":"Cell"},{"issue":"1","key":"1294_CR552","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","volume":"14","author":"A Yokoyama","year":"2008","unstructured":"Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell. 2008;14(1):36\u201346.","journal-title":"Cancer Cell"},{"issue":"10","key":"1294_CR553","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","volume":"6","author":"MW K\u00fchn","year":"2016","unstructured":"K\u00fchn MW, et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 2016;6(10):1166\u201381.","journal-title":"Cancer Discov"},{"issue":"7954","key":"1294_CR554","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615(7954):913\u20139.","journal-title":"Nature"},{"key":"1294_CR555","doi-asserted-by":"crossref","unstructured":"Zhu, X., et al., Menin orchestrates macrophage reprogramming to maintain the pulmonary immune homeostasis. Cell Reports, 2025. 44(1).","DOI":"10.1016\/j.celrep.2024.115219"},{"issue":"1","key":"1294_CR556","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/17474086.2016.1107471","volume":"9","author":"C Lai","year":"2016","unstructured":"Lai C, Karp JE, Hourigan CS. Precision medicine for acute myeloid leukemia. Expert Rev Hematol. 2016;9(1):1\u20133.","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"1294_CR557","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"AACR Project GENIE","year":"2017","unstructured":"AACR Project GENIE. Powering precision medicine through an international consortium. Cancer Discov. 2017;7(8):818\u201331.","journal-title":"Cancer Discov"},{"key":"1294_CR558","doi-asserted-by":"publisher","first-page":"612880","DOI":"10.3389\/fonc.2020.612880","volume":"10","author":"VE Kennedy","year":"2020","unstructured":"Kennedy VE, Smith CC. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. Front Oncol. 2020;10:612880.","journal-title":"Front Oncol"},{"issue":"11","key":"1294_CR559","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.ccell.2024.10.009","volume":"42","author":"RL Bowman","year":"2024","unstructured":"Bowman RL, et al. <em>In\u00a0vivo<\/em> models of subclonal oncogenesis and dependency in hematopoietic malignancy. Cancer Cell. 2024;42(11):1955-1969.e7.","journal-title":"Cancer Cell"},{"issue":"9","key":"1294_CR560","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e10610","volume":"8","author":"D Rong","year":"2022","unstructured":"Rong D, et al. Histone methylation modification patterns and relevant M-RiskScore in acute myeloid leukemia. Heliyon. 2022;8(9):e10610.","journal-title":"Heliyon"},{"issue":"1","key":"1294_CR561","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12916-021-02047-9","volume":"19","author":"T Zeng","year":"2021","unstructured":"Zeng T, et al. The establishment of a prognostic scoring model based on the new tumor immune microenvironment classification in acute myeloid leukemia. BMC Med. 2021;19(1):176.","journal-title":"BMC Med"},{"issue":"3","key":"1294_CR562","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/21681163.2022.2073912","volume":"11","author":"VJ Ramya","year":"2023","unstructured":"Ramya VJ, Lakshmi S. An efficient hybrid model for acute myeloid leukaemia detection using convolutional bi-lstm based recurrent neural network. Comput Methods Biomech Biomed Eng Imaging Visual. 2023;11(3):413\u201324.","journal-title":"Comput Methods Biomech Biomed Eng Imaging Visual"},{"issue":"9","key":"1294_CR563","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJM van Dongen","year":"2012","unstructured":"van Dongen JJM, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908\u201375.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR564","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41375-020-0762-8","volume":"35","author":"W Arindrarto","year":"2021","unstructured":"Arindrarto W, et al. Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing. Leukemia. 2021;35(1):47\u201361.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR565","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41467-018-08023-x","volume":"10","author":"X Wang","year":"2019","unstructured":"Wang X, et al. Bulk tissue cell type deconvolution with multi-subject single-cell expression reference. Nat Commun. 2019;10(1):380.","journal-title":"Nat Commun"},{"key":"1294_CR566","doi-asserted-by":"publisher","first-page":"762260","DOI":"10.3389\/fcell.2021.762260","volume":"9","author":"C Dai","year":"2021","unstructured":"Dai C, et al. Deconvolution of bulk gene expression profiles with single-cell transcriptomics to develop a cell type composition-based prognostic model for acute myeloid leukemia. Front Cell Dev Biol. 2021;9:762260.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1294_CR567","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1186\/s12864-020-06888-1","volume":"21","author":"H Li","year":"2020","unstructured":"Li H, et al. A deconvolution method and its application in analyzing the cellular fractions in acute myeloid leukemia samples. BMC Genomics. 2020;21(1):652.","journal-title":"BMC Genomics"},{"issue":"6","key":"1294_CR568","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng AGX, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28(6):1212\u201323.","journal-title":"Nat Med"},{"issue":"1","key":"1294_CR569","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.1038\/s41467-018-07170-5","volume":"9","author":"O Poirion","year":"2018","unstructured":"Poirion O, et al. Using single nucleotide variations in single-cell RNA-seq to identify subpopulations and genotype-phenotype linkage. Nat Commun. 2018;9(1):4892.","journal-title":"Nat Commun"},{"key":"1294_CR570","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fgene.2019.00008","volume":"10","author":"SL Goldman","year":"2019","unstructured":"Goldman SL, et al. The impact of heterogeneity on single-cell sequencing. Front Genet. 2019;10:8.","journal-title":"Front Genet"},{"issue":"1","key":"1294_CR571","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41698-024-00596-9","volume":"8","author":"EO Karakaslar","year":"2024","unstructured":"Karakaslar EO, et al. A transcriptomic based deconvolution framework for assessing differentiation stages and drug responses of AML. npj Precis Oncol. 2024;8(1):105.","journal-title":"npj Precis Oncol"},{"key":"1294_CR572","doi-asserted-by":"publisher","first-page":"968340","DOI":"10.3389\/fonc.2022.968340","volume":"12","author":"A Mosquera Orgueira","year":"2022","unstructured":"Mosquera Orgueira A, et al. Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia. Front Oncol. 2022;12:968340.","journal-title":"Front Oncol"},{"issue":"1","key":"1294_CR573","doi-asserted-by":"publisher","first-page":"11064","DOI":"10.1038\/s41598-024-61022-5","volume":"14","author":"Y-H Wang","year":"2024","unstructured":"Wang Y-H, et al. Stellae-123 gene expression signature improved risk stratification in Taiwanese acute myeloid leukemia patients. Sci Rep. 2024;14(1):11064.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR574","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41408-024-01078-8","volume":"14","author":"P Hirsch","year":"2024","unstructured":"Hirsch P, et al. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: an ALFA study. Blood Cancer J. 2024;14(1):97.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1294_CR575","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422\u201333.","journal-title":"N Engl J Med"},{"issue":"2","key":"1294_CR576","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","volume":"35","author":"M Balsat","year":"2017","unstructured":"Balsat M, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 Mutation: a study by the acute leukemia french association group. J Clin Oncol. 2017;35(2):185\u201393.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1294_CR577","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1182\/blood.2020005524","volume":"137","author":"L Fenwarth","year":"2021","unstructured":"Fenwarth L, et al. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood. 2021;137(4):524\u201332.","journal-title":"Blood"},{"issue":"14","key":"1294_CR578","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","volume":"120","author":"JAL Yin","year":"2012","unstructured":"Yin JAL, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120(14):2826\u201335.","journal-title":"Blood"},{"issue":"12","key":"1294_CR579","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","volume":"121","author":"E Jourdan","year":"2013","unstructured":"Jourdan E, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213\u201323.","journal-title":"Blood"},{"issue":"1","key":"1294_CR580","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41698-024-00643-5","volume":"8","author":"H Elsayed","year":"2024","unstructured":"Elsayed H, et al. Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials. Npj Precis Oncol. 2024;8(1):168.","journal-title":"Npj Precis Oncol"},{"issue":"1","key":"1294_CR581","doi-asserted-by":"publisher","first-page":"12410","DOI":"10.1038\/s41598-022-16685-3","volume":"12","author":"J Shao","year":"2022","unstructured":"Shao J, et al. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia. Sci Rep. 2022;12(1):12410.","journal-title":"Sci Rep"},{"issue":"10","key":"1294_CR582","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1038\/s41375-022-01677-z","volume":"36","author":"C Desprez","year":"2022","unstructured":"Desprez C, et al. Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia\u2014a Grand Ouest Against Leukemia (GOAL) study. Leukemia. 2022;36(10):2408\u201317.","journal-title":"Leukemia"},{"issue":"23","key":"1294_CR583","doi-asserted-by":"publisher","first-page":"12684","DOI":"10.3390\/ijms222312684","volume":"22","author":"I Kase-Kato","year":"2021","unstructured":"Kase-Kato I, et al. Molecular pathogenesis of the coronin family: CORO2A facilitates migration and invasion abilities in oral squamous cell carcinoma. Int J Mol Sci. 2021;22(23):12684.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1294_CR584","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1186\/s12885-015-1645-7","volume":"15","author":"RH Rastetter","year":"2015","unstructured":"Rastetter RH, et al. Coronin 2A (CRN5) expression is associated with colorectal adenoma-adenocarcinoma sequence and oncogenic signalling. BMC Cancer. 2015;15(1):638.","journal-title":"BMC Cancer"},{"issue":"1","key":"1294_CR585","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41419-025-07928-y","volume":"16","author":"Q Li","year":"2025","unstructured":"Li Q, et al. Chidamide and cytarabine synergistically treat acute myeloid leukemia: inhibiting ribosome biogenesis via the MYC-RRP9 pathway. Cell Death Dis. 2025;16(1):601.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1294_CR586","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","volume":"167","author":"DB Sykes","year":"2016","unstructured":"Sykes DB, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167(1):171-186.e15.","journal-title":"Cell"},{"issue":"5","key":"1294_CR587","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1182\/bloodadvances.2019001245","volume":"4","author":"D Pan","year":"2020","unstructured":"Pan D, Rampal R, Mascarenhas J. Clinical developments in epigenetic-directed therapies in acute myeloid leukemia. Blood Adv. 2020;4(5):970\u201382.","journal-title":"Blood Adv"},{"issue":"1","key":"1294_CR588","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41419-025-07831-6","volume":"16","author":"Z Li","year":"2025","unstructured":"Li Z, et al. Targeting PRDX1 impairs acute myeloid leukemic blasts and stem cells by disrupting redox homeostasis. Cell Death Dis. 2025;16(1):627.","journal-title":"Cell Death Dis"},{"issue":"10393","key":"1294_CR589","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, et al. Acute myeloid leukaemia. The Lancet. 2023;401(10393):2073\u201386.","journal-title":"The Lancet"},{"issue":"3","key":"1294_CR590","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102268","volume":"35","author":"D Wang","year":"2024","unstructured":"Wang D, et al. Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice. Mol Therap Nucleic Acids. 2024;35(3):102268.","journal-title":"Mol Therap Nucleic Acids"},{"issue":"1","key":"1294_CR591","doi-asserted-by":"publisher","first-page":"16775","DOI":"10.1038\/s41598-025-01675-y","volume":"15","author":"S Aakko","year":"2025","unstructured":"Aakko S, et al. CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies. Sci Rep. 2025;15(1):16775.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR592","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41698-025-01013-5","volume":"9","author":"J Watts","year":"2025","unstructured":"Watts J, et al. Functional cure with single agent olutasidenib in relapsed IDH1\/NPM1 co-mutated AML. npj Precis Oncol. 2025;9(1):211.","journal-title":"npj Precis Oncol"},{"issue":"13","key":"1294_CR593","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","volume":"7","author":"S de Botton","year":"2023","unstructured":"de Botton S, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023;7(13):3117\u201327.","journal-title":"Blood Adv"},{"issue":"6","key":"1294_CR594","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12032-025-02769-3","volume":"42","author":"SS Akhkand","year":"2025","unstructured":"Akhkand SS, et al. Genetically engineered K562 cells augment NK cell cytotoxicity against acute myeloid leukemia and reduce dependency on IL-15. Med Oncol. 2025;42(6):211.","journal-title":"Med Oncol"},{"issue":"11","key":"1294_CR595","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41389-021-00366-3","volume":"10","author":"K Zhou","year":"2021","unstructured":"Zhou K, et al. Loss of MBD2 attenuates MLL-AF9-driven leukemogenesis by suppressing the leukemic cell cycle via CDKN1C. Oncogenesis. 2021;10(11):79.","journal-title":"Oncogenesis"},{"issue":"Supplement 1","key":"1294_CR596","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood-2020-136566","volume":"136","author":"S Loges","year":"2020","unstructured":"Loges S, et al. The combination of AXL Inhibitor bemcentinib and low dose cytarabine is well tolerated and efficacious in elderly relapsed aml patients: update from the ongoing BGBC003 phase II trial (NCT02488408). Blood. 2020;136(Supplement 1):14\u201314.","journal-title":"Blood"},{"issue":"11","key":"1294_CR597","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1158\/2159-8290.CD-20-1378","volume":"11","author":"I Tirado-Gonzalez","year":"2021","unstructured":"Tirado-Gonzalez I, et al. AXL inhibition in macrophages stimulates host-versus-leukemia immunity and eradicates na\u00efve and treatment-resistant leukemia. Cancer Discov. 2021;11(11):2924\u201343.","journal-title":"Cancer Discov"},{"issue":"1","key":"1294_CR598","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18(1):153.","journal-title":"Mol Cancer"},{"issue":"3","key":"1294_CR599","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/cancers14030466","volume":"14","author":"M-A Goyette","year":"2022","unstructured":"Goyette M-A, C\u00f4t\u00e9 J-F. AXL receptor tyrosine kinase as a promising therapeutic target directing multiple aspects of cancer progression and metastasis. Cancers. 2022;14(3):466.","journal-title":"Cancers"},{"issue":"1","key":"1294_CR600","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1038\/s41467-024-47689-4","volume":"15","author":"H Itonaga","year":"2024","unstructured":"Itonaga H, et al. Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity. Nat Commun. 2024;15(1):3415.","journal-title":"Nat Commun"},{"issue":"15","key":"1294_CR601","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","volume":"133","author":"MA Sanz","year":"2019","unstructured":"Sanz MA, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630\u201343.","journal-title":"Blood"},{"issue":"1","key":"1294_CR602","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s12185-021-03224-5","volume":"115","author":"V Dembitz","year":"2022","unstructured":"Dembitz V, et al. All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16. Int J Hematol. 2022;115(1):43\u201353.","journal-title":"Int J Hematol"},{"issue":"6","key":"1294_CR603","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722\u201331.","journal-title":"Blood"},{"issue":"6","key":"1294_CR604","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","volume":"130","author":"MD Amatangelo","year":"2017","unstructured":"Amatangelo MD, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130(6):732\u201341.","journal-title":"Blood"},{"issue":"11","key":"1294_CR605","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","volume":"33","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33(11):2575\u201384.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR606","doi-asserted-by":"publisher","first-page":"11344","DOI":"10.1038\/s41598-022-15520-z","volume":"12","author":"B Tomic","year":"2022","unstructured":"Tomic B, et al. Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis. Sci Rep. 2022;12(1):11344.","journal-title":"Sci Rep"},{"issue":"4","key":"1294_CR607","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Gui\u00e8ze","year":"2019","unstructured":"Gui\u00e8ze R, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36(4):369-384.e13.","journal-title":"Cancer Cell"},{"issue":"4","key":"1294_CR608","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"1294_CR609","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.bbmt.2018.01.016","volume":"24","author":"SS Patel","year":"2018","unstructured":"Patel SS, et al. Prognostic Factors for mortality among day +100 survivors after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24(5):1029\u201334.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1294_CR610","doi-asserted-by":"publisher","first-page":"104746","DOI":"10.1016\/j.exphem.2025.104746","volume":"144","author":"T Tachibana","year":"2025","unstructured":"Tachibana T, et al. Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. Exp Hematol. 2025;144:104746.","journal-title":"Exp Hematol"},{"key":"1294_CR611","unstructured":"Mitchell, E., et al., The long-term effects of chemotherapy on normal blood cells. Nature Genetics, 2025."},{"key":"1294_CR612","unstructured":"DiNardo, C.D., et al., Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia, 2025."},{"issue":"1","key":"1294_CR613","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1038\/s41467-021-26849-w","volume":"12","author":"S Ngo","year":"2021","unstructured":"Ngo S, et al. Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy. Nat Commun. 2021;12(1):6546.","journal-title":"Nat Commun"},{"issue":"4","key":"1294_CR614","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short NJ, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506\u201325.","journal-title":"Cancer Discov"},{"issue":"12","key":"1294_CR615","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nature Cancer. 2020;1(12):1176\u201387.","journal-title":"Nature Cancer"},{"issue":"7","key":"1294_CR616","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7(7):716\u201335.","journal-title":"Cancer Discov"},{"key":"1294_CR617","doi-asserted-by":"crossref","unstructured":"Xu, Y., et al., Role of Main RNA Methylation in Hepatocellular Carcinoma: N6-Methyladenosine, 5-Methylcytosine, and N1-Methyladenosine. Frontiers in Cell and Developmental Biology, 2021. 9.","DOI":"10.3389\/fcell.2021.767668"},{"issue":"1","key":"1294_CR618","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1186\/s12935-020-01679-w","volume":"20","author":"S Xie","year":"2020","unstructured":"Xie S, et al. Emerging roles of RNA methylation in gastrointestinal cancers. Cancer Cell Int. 2020;20(1):585.","journal-title":"Cancer Cell Int"},{"key":"1294_CR619","doi-asserted-by":"crossref","unstructured":"Zhang, C., et al., 2024 Identification and validation of a prognostic risk-scoring model for AML based on m7G-associated gene clustering. Frontiers in Oncology,13.","DOI":"10.3389\/fonc.2023.1301236"},{"issue":"1","key":"1294_CR620","doi-asserted-by":"publisher","first-page":"25940","DOI":"10.1038\/s41598-024-77314-9","volume":"14","author":"AY Ge","year":"2024","unstructured":"Ge AY, et al. A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation. Sci Rep. 2024;14(1):25940.","journal-title":"Sci Rep"},{"issue":"12","key":"1294_CR621","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41430-024-01488-8","volume":"78","author":"R van Lieshout","year":"2024","unstructured":"van Lieshout R, et al. Changes in nutritional status and associations with physical and clinical outcomes in acute myeloid leukemia patients during intensive chemotherapy. Eur J Clin Nutr. 2024;78(12):1082\u201394.","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"1294_CR622","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.1038\/s41598-025-89703-9","volume":"15","author":"W Xu","year":"2025","unstructured":"Xu W, et al. Changes in physical fitness in acute leukemia patients during chemotherapy. Sci Rep. 2025;15(1):5632.","journal-title":"Sci Rep"},{"issue":"4","key":"1294_CR623","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/sj.onc.1202414","volume":"18","author":"MHM Koken","year":"1999","unstructured":"Koken MHM, et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF\/RAR\u03b1 fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene. 1999;18(4):1113\u20138.","journal-title":"Oncogene"},{"issue":"5975","key":"1294_CR624","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1126\/science.1183424","volume":"328","author":"X-W Zhang","year":"2010","unstructured":"Zhang X-W, et al. Arsenic trioxide controls the fate of the PML-RAR\u03b1 oncoprotein by directly binding PML. Science. 2010;328(5975):240\u20133.","journal-title":"Science"},{"issue":"4","key":"1294_CR625","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1046\/j.1365-2141.2000.01933.x","volume":"108","author":"K Kitamura","year":"2000","unstructured":"Kitamura K, et al. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. Br J Haematol. 2000;108(4):696\u2013702.","journal-title":"Br J Haematol"},{"issue":"6669","key":"1294_CR626","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/35901","volume":"391","author":"F Grignani","year":"1998","unstructured":"Grignani F, et al. Fusion proteins of the retinoic acid receptor-\u03b1 recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998;391(6669):815\u20138.","journal-title":"Nature"},{"key":"1294_CR627","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41389-025-00544-7","volume":"14","author":"E Valima","year":"2025","unstructured":"Valima E, et al. SUMOylation inhibition potentiates the glucocorticoid receptor to program growth arrest of acute lymphoblastic leukemia cells. Oncogene. 2025;14:1\u20133.","journal-title":"Oncogene"},{"issue":"5","key":"1294_CR628","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/ncb1717","volume":"10","author":"V Lallemand-Breitenbach","year":"2008","unstructured":"Lallemand-Breitenbach V, et al. Arsenic degrades PML or PML\u2013RAR\u03b1 through a SUMO-triggered RNF4\/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10(5):547\u201355.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1294_CR629","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.bbrc.2019.04.079","volume":"513","author":"P Zhou","year":"2019","unstructured":"Zhou P, et al. 2\u2013D08 as a SUMOylation inhibitor induced ROS accumulation mediates apoptosis of acute myeloid leukemia cells possibly through the deSUMOylation of NOX2. Biochem Biophys Res Commun. 2019;513(4):1063\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"1294_CR630","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1158\/0008-5472.CAN-17-3361","volume":"78","author":"H Baik","year":"2018","unstructured":"Baik H, et al. Targeting the SUMO pathway primes all-trans retinoic acid-induced differentiation of nonpromyelocytic acute myeloid leukemias. Cancer Res. 2018;78(10):2601\u201313.","journal-title":"Cancer Res"},{"issue":"5","key":"1294_CR631","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.stem.2018.10.001","volume":"23","author":"J-C Cossec","year":"2018","unstructured":"Cossec J-C, et al. SUMO safeguards somatic and pluripotent cell identities by enforcing distinct chromatin states. Cell Stem Cell. 2018;23(5):742-757.e8.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"1294_CR632","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41408-021-00584-3","volume":"11","author":"RJ Stubbins","year":"2021","unstructured":"Stubbins RJ, Karsan A. Differentiation therapy for myeloid malignancies: beyond cytotoxicity. Blood Cancer J. 2021;11(12):193.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1294_CR633","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrd2180","volume":"5","author":"SD Gore","year":"2006","unstructured":"Gore SD, Jones C, Kirkpatrick P. Decitabine. Nat Rev Drug Discovery. 2006;5(11):891\u20132.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"1294_CR634","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd1698","volume":"4","author":"J-PJ Issa","year":"2005","unstructured":"Issa J-PJ, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discovery. 2005;4(4):275\u20136.","journal-title":"Nat Rev Drug Discovery"},{"issue":"2","key":"1294_CR635","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","volume":"129","author":"LY Lee","year":"2017","unstructured":"Lee LY, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017;129(2):257\u201360.","journal-title":"Blood"},{"issue":"3","key":"1294_CR636","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40265-019-1062-3","volume":"79","author":"S Dhillon","year":"2019","unstructured":"Dhillon S. Gilteritinib: first global approval. Drugs. 2019;79(3):331\u20139.","journal-title":"Drugs"},{"issue":"26","key":"1294_CR637","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1200\/JCO.22.02721","volume":"41","author":"KW Pratz","year":"2023","unstructured":"Pratz KW, et al. Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: a phase IB study in patients with newly diagnosed AML. J Clin Oncol. 2023;41(26):4236\u201346.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1294_CR638","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nature Cancer. 2020;1(8):826\u201339.","journal-title":"Nature Cancer"},{"issue":"2","key":"1294_CR639","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216\u201328.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1294_CR640","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s43018-024-00814-0","volume":"5","author":"U Rauh","year":"2024","unstructured":"Rauh U, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature Cancer. 2024;5(10):1479\u201393.","journal-title":"Nature Cancer"},{"issue":"4","key":"1294_CR641","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao W, et al. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019;35(4):559-572.e7.","journal-title":"Cancer Cell"},{"issue":"29","key":"1294_CR642","doi-asserted-by":"publisher","first-page":"8780","DOI":"10.1126\/sciadv.abm8780","volume":"8","author":"E Mugarza","year":"2022","unstructured":"Mugarza E, et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci Adv. 2022;8(29):8780.","journal-title":"Sci Adv"},{"key":"1294_CR643","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3389\/fonc.2019.00953","volume":"9","author":"H Yang","year":"2019","unstructured":"Yang H, et al. New Horizons in KRAS-Mutant lung cancer: dawn after darkness. Front Oncol. 2019;9:953.","journal-title":"Front Oncol"},{"issue":"7781","key":"1294_CR644","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217\u201323.","journal-title":"Nature"},{"issue":"19","key":"1294_CR645","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1158\/0008-5472.CAN-22-0325","volume":"82","author":"J Boumelha","year":"2022","unstructured":"Boumelha J, et al. An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations. Can Res. 2022;82(19):3435\u201348.","journal-title":"Can Res"},{"key":"1294_CR646","doi-asserted-by":"publisher","first-page":"1584376","DOI":"10.3389\/fphar.2025.1584376","volume":"16","author":"X Hu","year":"2025","unstructured":"Hu X, et al. FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis. Front Pharmacol. 2025;16:1584376.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1294_CR647","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/blood.V86.5.1661.bloodjournal8651661","volume":"86","author":"M Gabbianelli","year":"1995","unstructured":"Gabbianelli M, et al. Multi-level effects of flt3 Ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors\/monocytic precursors. Blood. 1995;86(5):1661\u201370.","journal-title":"Blood"},{"issue":"1","key":"1294_CR648","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/stem.140146","volume":"14","author":"MZ Ratajczak","year":"2009","unstructured":"Ratajczak MZ, et al. FLT3\/FLK-2 (STK-1) Ligand does not stimulate human megakaryopoiesis in vitro. Stem Cells. 2009;14(1):146\u201350.","journal-title":"Stem Cells"},{"issue":"3","key":"1294_CR649","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","volume":"87","author":"CE Carow","year":"1996","unstructured":"Carow CE, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias. Blood. 1996;87(3):1089\u201396.","journal-title":"Blood"},{"issue":"9","key":"1294_CR650","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/blood-2003-07-2441","volume":"103","author":"SA Armstrong","year":"2004","unstructured":"Armstrong SA, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103(9):3544\u20136.","journal-title":"Blood"},{"issue":"2","key":"1294_CR651","first-page":"238","volume":"10","author":"O Rosnet","year":"1996","unstructured":"Rosnet O, et al. Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996;10(2):238\u201348.","journal-title":"Leukemia"},{"issue":"3","key":"1294_CR652","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ymthe.2019.12.014","volume":"28","author":"YA Yeung","year":"2020","unstructured":"Yeung YA, et al. An optimized full-length FLT3\/CD3 bispecific antibody demonstrates potent anti-leukemia activity and reversible hematological toxicity. Mol Ther. 2020;28(3):889\u2013900.","journal-title":"Mol Ther"},{"issue":"1","key":"1294_CR653","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ccell.2018.05.014","volume":"34","author":"H Zeng","year":"2018","unstructured":"Zeng H, et al. Bi-allelic loss of CDKN2A initiates melanoma invasion via BRN2 activation. Cancer Cell. 2018;34(1):56-68.e9.","journal-title":"Cancer Cell"},{"key":"1294_CR654","doi-asserted-by":"crossref","unstructured":"Chen, W., et al., Investigating POU3F4 in cancer: Expression patterns, prognostic implications, and functional roles in tumor immunity. Heliyon, 2025. 11(1).","DOI":"10.1016\/j.heliyon.2024.e41587"},{"issue":"3","key":"1294_CR655","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ymgme.2014.11.017","volume":"114","author":"KM Sakamoto","year":"2015","unstructured":"Sakamoto KM, et al. Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab. 2015;114(3):397\u2013402.","journal-title":"Mol Genet Metab"},{"key":"1294_CR656","doi-asserted-by":"crossref","unstructured":"Wang, D., et al., Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice. Molecular Therapy Nucleic Acids, 2024. 35(3).","DOI":"10.1016\/j.omtn.2024.102268"},{"issue":"10","key":"1294_CR657","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1038\/s41590-024-01962-2","volume":"25","author":"K Saeki","year":"2024","unstructured":"Saeki K, et al. IRF8 defines the epigenetic landscape in postnatal microglia, thereby directing their transcriptome programs. Nat Immunol. 2024;25(10):1928\u201342.","journal-title":"Nat Immunol"},{"issue":"1","key":"1294_CR658","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1038\/ncomms7379","volume":"6","author":"M Gupta","year":"2015","unstructured":"Gupta M, et al. IRF8 directs stress-induced autophagy in macrophages and promotes clearance of Listeria monocytogenes. Nat Commun. 2015;6(1):6379.","journal-title":"Nat Commun"},{"issue":"4","key":"1294_CR659","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1101\/gad.257592.114","volume":"29","author":"A Mancino","year":"2015","unstructured":"Mancino A, et al. A dual cis-regulatory code links IRF8 to constitutive and inducible gene expression in macrophages. Genes Dev. 2015;29(4):394\u2013408.","journal-title":"Genes Dev"},{"issue":"2","key":"1294_CR660","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/jha2.128","volume":"2","author":"S Gali\u00e8gue-Zouitina","year":"2021","unstructured":"Gali\u00e8gue-Zouitina S, et al. Bimodal expression of RHOH during myelomonocytic differentiation: implications for the expansion of AML differentiation therapy. EJHaem. 2021;2(2):196\u2013210.","journal-title":"EJHaem"},{"issue":"1","key":"1294_CR661","doi-asserted-by":"publisher","first-page":"28297","DOI":"10.1038\/s41598-024-79307-0","volume":"14","author":"F Lepr\u00eatre","year":"2024","unstructured":"Lepr\u00eatre F, et al. Full-length RNA-Seq of the RHOH gene in human B cells reveals new exons and splicing patterns. Sci Rep. 2024;14(1):28297.","journal-title":"Sci Rep"},{"issue":"14","key":"1294_CR662","doi-asserted-by":"publisher","first-page":"1294555","DOI":"10.3389\/fimmu.2023.1294555","volume":"14","author":"GM Branella","year":"2023","unstructured":"Branella GM, et al. Ligand-based targeting of c-kit using engineered \u03b3\u03b4 T cells as a strategy for treating acute myeloid leukemia. Front Immunol. 2023;14(14):1294555.","journal-title":"Front Immunol"},{"key":"1294_CR663","doi-asserted-by":"publisher","first-page":"1017347","DOI":"10.3389\/fnut.2022.1017347","volume":"9","author":"I Elisia","year":"2022","unstructured":"Elisia I, et al. A low carbohydrate diet high in fish oil and soy protein delays inflammation, hematopoietic stem cell depletion, and mortality in miR-146a knock-out mice. Front Nutri. 2022;9:1017347.","journal-title":"Front Nutri"},{"issue":"1","key":"1294_CR664","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","volume":"13","author":"CL Batlevi","year":"2016","unstructured":"Batlevi CL, et al. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016;13(1):25\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"1294_CR665","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","volume":"25","author":"SA Weiss","year":"2019","unstructured":"Weiss SA, Wolchok JD, Sznol M. Immunotherapy of Melanoma: facts and hopes. Clin Cancer Res. 2019;25(17):5191\u2013201.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1294_CR666","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/bjh.16358","volume":"188","author":"A Ghosh","year":"2020","unstructured":"Ghosh A, Barba P, Perales M-A. Checkpoint inhibitors in AML: are we there yet? Br J Haematol. 2020;188(1):159\u201367.","journal-title":"Br J Haematol"},{"issue":"11","key":"1294_CR667","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/biomedicines9111631","volume":"9","author":"S Small","year":"2021","unstructured":"Small S, Numan Y, Platanias LC. Innate immune mechanisms and immunotherapy of myeloid malignancies. Biomedicines. 2021;9(11):1631.","journal-title":"Biomedicines"},{"issue":"1","key":"1294_CR668","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-025-01293-x","volume":"15","author":"R Zhang","year":"2025","unstructured":"Zhang R, et al. Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group. Blood Cancer J. 2025;15(1):84.","journal-title":"Blood Cancer J"},{"issue":"12","key":"1294_CR669","doi-asserted-by":"publisher","first-page":"e919","DOI":"10.1016\/S2352-3026(22)00293-9","volume":"9","author":"Y-J Chang","year":"2022","unstructured":"Chang Y-J, Pei X-Y, Huang X-J. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions. Lancet Haematol. 2022;9(12):e919\u201329.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1294_CR670","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1749-6632.1999.tb08452.x","volume":"872","author":"SM Lanzkron","year":"1999","unstructured":"Lanzkron SM, Collector MI, Sharkis SJ. Homing of long-term and short-term engrafting cells in vivo. Annal New York Acad Sci. 1999;872(1):48\u201356.","journal-title":"Annal New York Acad Sci"},{"issue":"1","key":"1294_CR671","doi-asserted-by":"publisher","first-page":"24089","DOI":"10.1038\/s41598-025-10061-7","volume":"15","author":"C Auepisit","year":"2025","unstructured":"Auepisit C, et al. Advancing the pathway to allogeneic hematopoietic stem cell transplantation through a physician\u2013nurse coordinator system in patients with acute leukemia. Sci Rep. 2025;15(1):24089.","journal-title":"Sci Rep"},{"issue":"16","key":"1294_CR672","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487\u201396.","journal-title":"N Engl J Med"},{"issue":"3","key":"1294_CR673","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41409-023-02162-6","volume":"59","author":"J Sugita","year":"2024","unstructured":"Sugita J, et al. Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor. Bone Marrow Transplant. 2024;59(3):344\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1294_CR674","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41409-020-0985-3","volume":"56","author":"S Shiratori","year":"2021","unstructured":"Shiratori S, et al. Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2021;56(1):129\u201336.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1294_CR675","doi-asserted-by":"publisher","first-page":"27982","DOI":"10.1038\/s41598-025-12373-0","volume":"15","author":"S Nono","year":"2025","unstructured":"Nono S, et al. Significance of kidney and spleen volumes analyzed via three-dimensional computed tomography prior to allogeneic stem cell transplantation. Sci Rep. 2025;15(1):27982.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR676","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1038\/s41467-025-58662-0","volume":"16","author":"JJ Rodriguez-Sevilla","year":"2025","unstructured":"Rodriguez-Sevilla JJ, et al. Natural killer cells\u2019 functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes. Nat Commun. 2025;16(1):3450.","journal-title":"Nat Commun"},{"key":"1294_CR677","doi-asserted-by":"publisher","first-page":"1521939","DOI":"10.3389\/fimmu.2025.1521939","volume":"16","author":"Y Ye","year":"2025","unstructured":"Ye Y, et al. Aclacinomycin enhances the killing effect of allogeneic NK cells on acute myeloid leukemia cells by inducing immunogenic cell death. Front Immunol. 2025;16:1521939.","journal-title":"Front Immunol"},{"issue":"16","key":"1294_CR678","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1080\/14656566.2017.1391216","volume":"18","author":"T Murphy","year":"2017","unstructured":"Murphy T, Yee KWL. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opin Pharmacother. 2017;18(16):1765\u201380.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"1294_CR679","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41.","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"1294_CR680","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood-2022-157126","volume":"140","author":"C R\u00f6llig","year":"2022","unstructured":"R\u00f6llig C, et al. Single Versus double induction with \u201c7+3\u201d containing 60 versus 90 Mg daunorubicin for newly diagnosed AML: results from the randomized controlled sal dauno-double trial. Blood. 2022;140(Supplement 1):523\u20135.","journal-title":"Blood"},{"issue":"1","key":"1294_CR681","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024;14(1):163.","journal-title":"Blood Cancer J"},{"key":"1294_CR682","doi-asserted-by":"publisher","first-page":"1530270","DOI":"10.3389\/fphar.2025.1530270","volume":"16","author":"M Xu","year":"2025","unstructured":"Xu M, et al. 20(S)-protopanaxadiol inhibits proliferation and induces apoptosis of acute myeloid leukemia cells via targeting Bcl-XL and MCL-1. Front Pharmacol. 2025;16:1530270.","journal-title":"Front Pharmacol"},{"key":"1294_CR683","doi-asserted-by":"publisher","first-page":"1538888","DOI":"10.3389\/fphar.2025.1538888","volume":"16","author":"M-H He","year":"2025","unstructured":"He M-H, et al. 2025 Evaluating the role of astragalus polysaccharide in modulating immune infiltration and enhancing prognostic biomarkers in pediatric acute myeloid leukemia. Front Pharmacol. 2025;16:1538888.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1294_CR684","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41409-025-02527-z","volume":"60","author":"J Sanz","year":"2025","unstructured":"Sanz J, et al. Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leukemia working party of the EBMT. Bone Marrow Transplant. 2025;60(4):529\u201334.","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"1294_CR685","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2020006921","volume":"137","author":"S Willier","year":"2021","unstructured":"Willier S, et al. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood. 2021;137(8):1037\u201349.","journal-title":"Blood"},{"key":"1294_CR686","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1146\/annurev-immunol-102419-035900","volume":"38","author":"S Duan","year":"2020","unstructured":"Duan S, Paulson JC. Siglecs as Immune Cell Checkpoints in Disease. Annu Rev Immunol. 2020;38:365\u201395.","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"1294_CR687","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64\u201374.","journal-title":"Leukemia"},{"issue":"4","key":"1294_CR688","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"3ff2","author":"F Perna","year":"2017","unstructured":"Perna F, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell. 2017;3ff2(4):506-519.e5.","journal-title":"Cancer Cell"},{"key":"1294_CR689","doi-asserted-by":"crossref","unstructured":"Fiorenza, S., et al., Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T&#xa0;cell therapy. Molecular Therapy Oncology, 2024. 32(3).","DOI":"10.1016\/j.omton.2024.200854"},{"issue":"1","key":"1294_CR690","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/s41467-024-50498-4","volume":"15","author":"S Kaito","year":"2024","unstructured":"Kaito S, et al. Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization. Nat Commun. 2024;15(1):7359.","journal-title":"Nat Commun"},{"issue":"2","key":"1294_CR691","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12185-019-02651-9","volume":"110","author":"M Duchmann","year":"2019","unstructured":"Duchmann M, Itzykson R. Clinical update on hypomethylating agents. Int J Hematol. 2019;110(2):161\u20139.","journal-title":"Int J Hematol"},{"issue":"15","key":"1294_CR692","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M L\u00fcbbert","year":"2011","unstructured":"L\u00fcbbert M, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase iii study of the european organisation for research and treatment of cancer leukemia group and the german mds study group. J Clin Oncol. 2011;29(15):1987\u201396.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1294_CR693","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429\u201340.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1294_CR694","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1294_CR695","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, et al. Multicenter, randomized, open-label, phase iii trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1294_CR696","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1182\/blood-2007-11-126227","volume":"112","author":"H Kroeger","year":"2008","unstructured":"Kroeger H, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008;112(4):1366\u201373.","journal-title":"Blood"},{"issue":"7","key":"1294_CR697","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"1294_CR698","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100805","volume":"61","author":"K \u0160imoni\u010dov\u00e1","year":"2022","unstructured":"\u0160imoni\u010dov\u00e1 K, et al. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Drug Resist Updates. 2022;61:100805.","journal-title":"Drug Resist Updates"},{"issue":"12","key":"1294_CR699","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"key":"1294_CR700","doi-asserted-by":"publisher","first-page":"100121","DOI":"10.1016\/j.bneo.2025.100121","volume":"19","author":"K Yamatani","year":"2025","unstructured":"Yamatani K, et al. PPAR\u03b3-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML. Blood Neoplas. 2025;19:100121.","journal-title":"Blood Neoplas"},{"issue":"11","key":"1294_CR701","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41587-019-0289-6","volume":"37","author":"J Racle","year":"2019","unstructured":"Racle J, et al. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nat Biotechnol. 2019;37(11):1283\u20136.","journal-title":"Nat Biotechnol"},{"key":"1294_CR702","doi-asserted-by":"publisher","first-page":"852147","DOI":"10.3389\/fimmu.2022.852147","volume":"13","author":"JJ Barchi","year":"2022","unstructured":"Barchi JJ. Glycoconjugate nanoparticle-based systems in cancer immunotherapy: novel designs and recent updates. Front Immunol. 2022;13:852147.","journal-title":"Front Immunol"},{"issue":"6230","key":"1294_CR703","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374.","journal-title":"Science"},{"issue":"1","key":"1294_CR704","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/s41597-024-03660-y","volume":"11","author":"Y Cai","year":"2024","unstructured":"Cai Y, et al. MHC-I-presented non-canonical antigens expand the cancer immunotherapy targets in acute myeloid leukemia. Scientific Data. 2024;11(1):831.","journal-title":"Scientific Data"},{"key":"1294_CR705","doi-asserted-by":"publisher","first-page":"1556121","DOI":"10.3389\/fimmu.2025.1556121","volume":"16","author":"DI van der Lee","year":"2025","unstructured":"van der Lee DI, et al. Mutated DNMT3A creates a public HLADQ- binding neoantigen on acute myeloid leukemia. Front Immunol. 2025;16:1556121.","journal-title":"Front Immunol"},{"key":"1294_CR706","doi-asserted-by":"crossref","unstructured":"Tirtakusuma, R., et al., Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias. Leukemia, 2025.","DOI":"10.1038\/s41375-025-02710-7"},{"issue":"2","key":"1294_CR707","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","volume":"16","author":"MA Morse","year":"2021","unstructured":"Morse MA, Gwin WR, Mitchell DA. Vaccine therapies for cancer: then and now. Target Oncol. 2021;16(2):121\u201352.","journal-title":"Target Oncol"},{"key":"1294_CR708","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana S, Gill S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;10:697.","journal-title":"Front Oncol"},{"issue":"4","key":"1294_CR709","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/ph14040288","volume":"14","author":"L Jimbu","year":"2021","unstructured":"Jimbu L, et al. Is there a place for PD-1-PD-L blockade in acute myeloid leukemia? Pharmaceuticals. 2021;14(4):288.","journal-title":"Pharmaceuticals"},{"issue":"3","key":"1294_CR710","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s12276-023-00951-z","volume":"55","author":"J Hong","year":"2023","unstructured":"Hong J, et al. Senescent cancer cell-derived nanovesicle as a personalized therapeutic cancer vaccine. Exp Mol Med. 2023;55(3):541\u201354.","journal-title":"Exp Mol Med"},{"key":"1294_CR711","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.actbio.2020.07.063","volume":"114","author":"A Banstola","year":"2020","unstructured":"Banstola A, Jeong J-H, Yook S. Immunoadjuvants for cancer immunotherapy: a review of recent developments. Acta Biomater. 2020;114:16\u201330.","journal-title":"Acta Biomater"},{"key":"1294_CR712","doi-asserted-by":"publisher","first-page":"615240","DOI":"10.3389\/fimmu.2020.615240","volume":"11","author":"S Cuzzubbo","year":"2021","unstructured":"Cuzzubbo S, et al. Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments. Front Immunol. 2021;11:615240.","journal-title":"Front Immunol"},{"issue":"9","key":"1294_CR713","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/s41375-023-01980-3","volume":"37","author":"Y Fl\u00f8isand","year":"2023","unstructured":"Fl\u00f8isand Y, et al. WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. Leukemia. 2023;37(9):1842\u20139.","journal-title":"Leukemia"},{"key":"1294_CR714","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.3389\/fimmu.2018.02503","volume":"9","author":"D Campillo-Davo","year":"2018","unstructured":"Campillo-Davo D, et al. Efficient and non-genotoxic RNA-based engineering of human T Cells using tumor-specific T Cell receptors with minimal TCR mispairing. Front Immunol. 2018;9:2503.","journal-title":"Front Immunol"},{"issue":"5","key":"1294_CR715","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/s41375-024-02250-6","volume":"38","author":"N Noronha","year":"2024","unstructured":"Noronha N, et al. Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia. Leukemia. 2024;38(5):1019\u201331.","journal-title":"Leukemia"},{"issue":"3","key":"1294_CR716","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"1294_CR717","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2011.40.6652","volume":"30","author":"JH Mendler","year":"2012","unstructured":"Mendler JH, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012;30(25):3109\u201318.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1294_CR718","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41541-025-01107-y","volume":"10","author":"C Garde","year":"2025","unstructured":"Garde C, et al. Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines. npj Vaccines. 2025;10(1):54.","journal-title":"npj Vaccines"},{"key":"1294_CR719","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.exphem.2022.04.002","volume":"111","author":"P Upadhyay","year":"2022","unstructured":"Upadhyay P, et al. Recurrent transcriptional responses in AML and MDS patients treated with decitabine. Exp Hematol. 2022;111:50\u201365.","journal-title":"Exp Hematol"},{"issue":"6","key":"1294_CR720","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s10238-023-01020-5","volume":"23","author":"Y Mei","year":"2023","unstructured":"Mei Y, Wang X. RNA modification in mRNA cancer vaccines. Clin Exp Med. 2023;23(6):1917\u201331.","journal-title":"Clin Exp Med"},{"key":"1294_CR721","doi-asserted-by":"publisher","first-page":"1301236","DOI":"10.3389\/fonc.2023.1301236","volume":"13","author":"C Zhang","year":"2024","unstructured":"Zhang C, et al. Identification and validation of a prognostic risk-scoring model for AML based on m7G-associated gene clustering. Front Oncol. 2024;13:1301236.","journal-title":"Front Oncol"},{"key":"1294_CR722","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104424","volume":"201","author":"M Ruglioni","year":"2024","unstructured":"Ruglioni M, et al. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. Crit Rev Oncol Hematol. 2024;201:104424.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1294_CR723","doi-asserted-by":"crossref","unstructured":"Li, R., et al., 2025 CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia. Leukemia","DOI":"10.1038\/s41375-025-02589-4"},{"key":"1294_CR724","doi-asserted-by":"crossref","unstructured":"Poon, G., et al., 2025 Single-cell DNA sequencing reveals pervasive positive selection throughout preleukemic evolution. Cell Genomics,.5(2).","DOI":"10.1016\/j.xgen.2024.100744"},{"key":"1294_CR725","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","volume":"348","author":"X Liu","year":"2022","unstructured":"Liu X, et al. Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84\u201394.","journal-title":"J Control Release"},{"issue":"3","key":"1294_CR726","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41571-021-00585-y","volume":"19","author":"LS Kristensen","year":"2022","unstructured":"Kristensen LS, et al. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19(3):188\u2013206.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1294_CR727","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-021-01446-z","volume":"20","author":"V Singh","year":"2021","unstructured":"Singh V, et al. Circular RNAs in acute myeloid leukemia. Mol Cancer. 2021;20(1):149.","journal-title":"Mol Cancer"},{"issue":"4","key":"1294_CR728","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41375-021-01432-w","volume":"36","author":"DT Johnson","year":"2022","unstructured":"Johnson DT, et al. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia. 2022;36(4):994\u20131005.","journal-title":"Leukemia"},{"issue":"D1","key":"1294_CR729","doi-asserted-by":"publisher","first-page":"D409","DOI":"10.1093\/nar\/gkac776","volume":"51","author":"Y Cai","year":"2022","unstructured":"Cai Y, et al. IEAtlas: an atlas of HLA-presented immune epitopes derived from non-coding regions. Nucleic Acids Res. 2022;51(D1):D409\u201317.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1294_CR730","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/s41467-020-14968-9","volume":"11","author":"C Chong","year":"2020","unstructured":"Chong C, et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat Commun. 2020;11(1):1293.","journal-title":"Nat Commun"},{"issue":"2","key":"1294_CR731","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41587-021-01021-3","volume":"40","author":"T Ouspenskaia","year":"2022","unstructured":"Ouspenskaia T, et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol. 2022;40(2):209\u201317.","journal-title":"Nat Biotechnol"},{"key":"1294_CR732","doi-asserted-by":"publisher","first-page":"104748","DOI":"10.1016\/j.exphem.2025.104748","volume":"145","author":"S Cisa-Wieczorek","year":"2025","unstructured":"Cisa-Wieczorek S, et al. D816V KIT mutation induces mitochondrial morphologic and functional changes through BNIP3 downregulation in human myeloid cell lines ROSA and TF-1. Exp Hematol. 2025;145:104748.","journal-title":"Exp Hematol"},{"issue":"1","key":"1294_CR733","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1038\/s41598-025-85929-9","volume":"15","author":"J Zhang","year":"2025","unstructured":"Zhang J, et al. Multi-omics analysis reveals the panoramic picture of TOP2A in pan-cancer. Sci Rep. 2025;15(1):6046.","journal-title":"Sci Rep"},{"issue":"3","key":"1294_CR734","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/genes13030514","volume":"13","author":"S Castiglioni","year":"2022","unstructured":"Castiglioni S, et al. KMT2A: umbrella gene for multiple diseases. Genes. 2022;13(3):514.","journal-title":"Genes"},{"issue":"1","key":"1294_CR735","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41397-025-00361-6","volume":"25","author":"T Xu","year":"2025","unstructured":"Xu T, et al. Systematic identification of cancer pathways and potential drugs for intervention through multi-omics analysis. Pharmacogenomics J. 2025;25(1):2.","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"1294_CR736","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s11033-024-09744-7","volume":"51","author":"Y Pouriafar","year":"2024","unstructured":"Pouriafar Y, et al. CDC27 gene expression patterns as a potential biomarker in Acute Leukemia. Mol Biol Rep. 2024;51(1):865.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1294_CR737","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-022-01603-y","volume":"21","author":"N Del Gaudio","year":"2022","unstructured":"Del Gaudio N, et al. CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway. Mol Cancer. 2022;21(1):125.","journal-title":"Mol Cancer"},{"issue":"6","key":"1294_CR738","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1172\/JCI62279","volume":"122","author":"T Hoshii","year":"2012","unstructured":"Hoshii T, et al. mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest. 2012;122(6):2114\u201329.","journal-title":"J Clin Invest"},{"issue":"1","key":"1294_CR739","doi-asserted-by":"publisher","first-page":"34504","DOI":"10.1038\/srep34504","volume":"6","author":"A Flores-P\u00e9rez","year":"2016","unstructured":"Flores-P\u00e9rez A, et al. Dual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer. Sci Rep. 2016;6(1):34504.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR740","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/s41467-025-56913-8","volume":"16","author":"NK Leclair","year":"2025","unstructured":"Leclair NK, et al. Antisense oligonucleotide-mediated TRA2\u03b2 poison exon inclusion induces the expression of a lncRNA with anti-tumor effects. Nat Commun. 2025;16(1):1670.","journal-title":"Nat Commun"},{"key":"1294_CR741","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106700","volume":"189","author":"Y Han","year":"2023","unstructured":"Han Y, et al. Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia. Pharmacol Res. 2023;189:106700.","journal-title":"Pharmacol Res"},{"issue":"10","key":"1294_CR742","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","volume":"19","author":"CA Bradbury","year":"2005","unstructured":"Bradbury CA, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19(10):1751\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR743","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1038\/s41467-023-41994-0","volume":"14","author":"H Mumme","year":"2023","unstructured":"Mumme H, et al. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia. Nat Commun. 2023;14(1):6209.","journal-title":"Nat Commun"},{"issue":"1","key":"1294_CR744","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12967-019-2114-x","volume":"17","author":"A Rzepiel","year":"2019","unstructured":"Rzepiel A, et al. Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia. J Transl Med. 2019;17(1):372.","journal-title":"J Transl Med"},{"issue":"12","key":"1294_CR745","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong Y, et al. T-Cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res. 2016;22(12):3057\u201366.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1294_CR746","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/leu.2016.332","volume":"31","author":"AK Eisfeld","year":"2017","unstructured":"Eisfeld AK, et al. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia. 2017;31(6):1278\u201385.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR747","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41467-025-56577-4","volume":"16","author":"CJ Kenny","year":"2025","unstructured":"Kenny CJ, et al. LUC7 proteins define two major classes of 5\u2032 splice sites in animals and plants. Nat Commun. 2025;16(1):1574.","journal-title":"Nat Commun"},{"issue":"10","key":"1294_CR748","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1158\/2159-8290.CD-23-1452","volume":"14","author":"S Kimura","year":"2024","unstructured":"Kimura S, et al. Biologic and clinical analysis of childhood gamma delta T-ALL identifies LMO2\/STAG2 rearrangements as extremely high risk. Cancer Discov. 2024;14(10):1838\u201359.","journal-title":"Cancer Discov"},{"issue":"3","key":"1294_CR749","doi-asserted-by":"publisher","first-page":"e142149","DOI":"10.1172\/jci.insight.142149","volume":"6","author":"Z Tothova","year":"2021","unstructured":"Tothova Z, et al. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS\/AML. JCI Insight. 2021;6(3):e142149.","journal-title":"JCI Insight"},{"issue":"6","key":"1294_CR750","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1038\/bcj.2016.36","volume":"6","author":"A Maiga","year":"2016","unstructured":"Maiga A, et al. Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets. Blood Cancer J. 2016;6(6):e431\u2013e431.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1294_CR751","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/2159-8290.CD-20-1849","volume":"12","author":"Y Wei","year":"2022","unstructured":"Wei Y, et al. SLC5A3-Dependent Myo-inositol auxotrophy in acute myeloid leukemia. Cancer Discov. 2022;12(2):450\u201367.","journal-title":"Cancer Discov"},{"key":"1294_CR752","doi-asserted-by":"crossref","unstructured":"Richards, C.J., et al., 2025 Elastic properties of leukemic cells linked to maturation stage and integrin activation. iScience, 112150.","DOI":"10.1016\/j.isci.2025.112150"},{"issue":"12","key":"1294_CR753","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/s43018-023-00656-2","volume":"4","author":"K Knorr","year":"2023","unstructured":"Knorr K, et al. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nature Cancer. 2023;4(12):1675\u201392.","journal-title":"Nature Cancer"},{"issue":"1","key":"1294_CR754","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41419-025-07529-9","volume":"16","author":"B Barik","year":"2025","unstructured":"Barik B, et al. PTBP2 promotes cell survival and autophagy in chronic myeloid leukemia by stabilizing BNIP3. Cell Death Dis. 2025;16(1):195.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1294_CR755","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1038\/s41598-025-91524-9","volume":"15","author":"L Fei","year":"2025","unstructured":"Fei L, et al. Identification of a novel unfolded protein response related signature for predicting the prognosis of acute myeloid leukemia. Sci Rep. 2025;15(1):6705.","journal-title":"Sci Rep"},{"issue":"3","key":"1294_CR756","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41375-021-01435-7","volume":"36","author":"M Duchmann","year":"2022","unstructured":"Duchmann M, et al. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML. Leukemia. 2022;36(3):656\u201363.","journal-title":"Leukemia"},{"issue":"12","key":"1294_CR757","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1038\/s41409-021-01450-3","volume":"56","author":"AM Jimenez Jimenez","year":"2021","unstructured":"Jimenez Jimenez AM, et al. An adapted european leukemianet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR Anal Bone Marrow Transplant. 2021;56(12):3068\u201377.","journal-title":"A CIBMTR Anal Bone Marrow Transplant"},{"issue":"1","key":"1294_CR758","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41375-021-01408-w","volume":"36","author":"J-N Eckardt","year":"2022","unstructured":"Eckardt J-N, et al. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. Leukemia. 2022;36(1):111\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR759","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/s41467-021-22625-y","volume":"12","author":"TR Docking","year":"2021","unstructured":"Docking TR, et al. A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia. Nat Commun. 2021;12(1):2474.","journal-title":"Nat Commun"},{"key":"1294_CR760","doi-asserted-by":"crossref","unstructured":"Pino, J.C., et al., Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia. Cell Reports Medicine, 2024. 5(1).","DOI":"10.1016\/j.xcrm.2023.101359"},{"key":"1294_CR761","doi-asserted-by":"crossref","unstructured":"Wang, T., et al., Molecular precision medicine: Multi-omics-based stratification model for acute myeloid leukemia. Heliyon, 2024. 10(17).","DOI":"10.1016\/j.heliyon.2024.e36155"},{"key":"1294_CR762","doi-asserted-by":"crossref","unstructured":"Jing, L., et al., Prognostic insights and immune microenvironment delineation in acute myeloid leukemia by ferroptosis-derived signature. Heliyon, 2024. 10(6).","DOI":"10.1016\/j.heliyon.2024.e28237"},{"issue":"1","key":"1294_CR763","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1038\/s41467-025-59362-5","volume":"16","author":"HL Mumme","year":"2025","unstructured":"Mumme HL, et al. Identification of leukemia-enriched signature through the development of a comprehensive pediatric single-cell atlas. Nat Commun. 2025;16(1):4114.","journal-title":"Nat Commun"},{"key":"1294_CR764","doi-asserted-by":"publisher","first-page":"1513040","DOI":"10.3389\/fimmu.2025.1513040","volume":"16","author":"H Gong","year":"2025","unstructured":"Gong H, et al. Development and validation of a disulfidptosis-related genes signature for predicting outcomes and immunotherapy in acute myeloid leukemia. Front Immunol. 2025;16:1513040.","journal-title":"Front Immunol"},{"key":"1294_CR765","doi-asserted-by":"crossref","unstructured":"Krakow, E.F., et al., 2025 A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Bone Marrow Transplantation","DOI":"10.1038\/s41409-025-02602-5"},{"issue":"1","key":"1294_CR766","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41392-024-02065-y","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, et al. A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia. Signal Transduct Target Ther. 2024;9(1):358.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1294_CR767","doi-asserted-by":"publisher","first-page":"27367","DOI":"10.1038\/s41598-024-78082-2","volume":"14","author":"K Charoensedtasin","year":"2024","unstructured":"Charoensedtasin K, et al. Anticancer effects of pomegranate-derived peptide PG2 on CDK2 and miRNA-339-5p-mediated apoptosis via extracellular vesicles in acute leukemia. Sci Rep. 2024;14(1):27367.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR768","doi-asserted-by":"publisher","first-page":"24795","DOI":"10.1038\/s41598-024-75630-8","volume":"14","author":"S Phuagkhaopong","year":"2024","unstructured":"Phuagkhaopong S, et al. Transcriptome analysis reveals a role of FOXO3 in antileukemia\/lymphoma properties of panduratin A. Sci Rep. 2024;14(1):24795.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR769","doi-asserted-by":"publisher","first-page":"19971","DOI":"10.1038\/s41598-024-70656-4","volume":"14","author":"L Musumeci","year":"2024","unstructured":"Musumeci L, et al. The pro-differentiating capability of a flavonoid-rich extract of Citrus bergamia juice prompts autophagic death in THP-1 cells. Sci Rep. 2024;14(1):19971.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR770","doi-asserted-by":"publisher","first-page":"13737","DOI":"10.1038\/s41598-024-64629-w","volume":"14","author":"G Farruggia","year":"2024","unstructured":"Farruggia G, et al. Nano-fenretinide demonstrates remarkable activity in acute promyeloid leukemia cells. Sci Rep. 2024;14(1):13737.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR771","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1038\/s41467-024-49784-y","volume":"15","author":"E San Jos\u00e9-En\u00e9riz","year":"2024","unstructured":"San Jos\u00e9-En\u00e9riz E, et al. Epigenetic-based differentiation therapy for acute myeloid leukemia. Nat Commun. 2024;15(1):5570.","journal-title":"Nat Commun"},{"issue":"1","key":"1294_CR772","doi-asserted-by":"publisher","first-page":"12868","DOI":"10.1038\/s41598-024-63392-2","volume":"14","author":"DM Sahasrabudhe","year":"2024","unstructured":"Sahasrabudhe DM, et al. In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia. Sci Rep. 2024;14(1):12868.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR773","doi-asserted-by":"publisher","first-page":"29161","DOI":"10.1038\/s41598-024-80496-x","volume":"14","author":"Y Wu","year":"2024","unstructured":"Wu Y, et al. Efficacy and safety of the combination of decitabine and CHAG priming regimen in the relapsed or refractory acute myeloid leukemia. Sci Rep. 2024;14(1):29161.","journal-title":"Sci Rep"},{"issue":"1","key":"1294_CR774","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41420-023-01515-w","volume":"9","author":"G Choukrani","year":"2023","unstructured":"Choukrani G, et al. Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance. Cell Death Discovery. 2023;9(1):228.","journal-title":"Cell Death Discovery"},{"issue":"1","key":"1294_CR775","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41420-022-01071-9","volume":"8","author":"P H\u00e5\u00e5g","year":"2022","unstructured":"H\u00e5\u00e5g P, et al. Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia. Cell Death Discovery. 2022;8(1):284.","journal-title":"Cell Death Discovery"},{"issue":"6","key":"1294_CR776","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41417-021-00358-w","volume":"29","author":"Y-H Fu","year":"2022","unstructured":"Fu Y-H, et al. Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation. Cancer Gene Ther. 2022;29(6):784\u201392.","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"1294_CR777","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/s41374-021-00640-3","volume":"101","author":"J-M Liu","year":"2021","unstructured":"Liu J-M, et al. Curcumin attenuates Adriamycin-resistance of acute myeloid leukemia by inhibiting the lncRNA HOTAIR\/miR-20a-5p\/WT1 axis. Lab Invest. 2021;101(10):1308\u201317.","journal-title":"Lab Invest"},{"key":"1294_CR778","doi-asserted-by":"crossref","unstructured":"Bernasconi-Bisio, F., et al., 2025 Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML. Molecular Therapy Oncology, 33(1).","DOI":"10.1016\/j.omton.2025.200949"},{"key":"1294_CR779","unstructured":"Berisha, N., et al., Directed discovery of high-loading nanoaggregates enabled by drug-matched oligo-peptide excipients. Chem."},{"key":"1294_CR780","doi-asserted-by":"crossref","unstructured":"Bubb, Q.R., et al., Development of multivalent CAR T&#xa0;cells as dual immunotherapy and conditioning agents. Molecular Therapy Oncology, 2025. 33(1).","DOI":"10.1016\/j.omton.2025.200944"},{"key":"1294_CR781","unstructured":"Hu, L., et al., HMPL-306 in relapsed or refractory <em>IDH1-<\/em> and\/or <em>IDH2-<\/em>mutated acute myeloid leukemia: A phase 1 study. Med."},{"key":"1294_CR782","doi-asserted-by":"crossref","unstructured":"Ray, M., et al., 2025 Clofarabine-loaded aptamer-conjugated biodegradable nanoparticle successfully targeted CD117 overexpressed HL60&#xa0;cells and potentially induced apoptosis. Heliyon, 11(4).","DOI":"10.1016\/j.heliyon.2025.e42450"},{"issue":"3","key":"1294_CR783","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ymthe.2025.01.025","volume":"33","author":"L Zhang","year":"2025","unstructured":"Zhang L, et al. Genetically reprogrammed exosomes for immunotherapy of acute myeloid leukemia. Mol Ther. 2025;33(3):1091\u2013104.","journal-title":"Mol Ther"},{"issue":"2","key":"1294_CR784","doi-asserted-by":"publisher","first-page":"100071","DOI":"10.1016\/j.bneo.2025.100071","volume":"2","author":"PL Kropf","year":"2025","unstructured":"Kropf PL, et al. A phase II Study of decitabine with or without carboplatin and arsenic trioxide in MDS and AML patients. Blood Neoplasia. 2025;2(2):100071.","journal-title":"Blood Neoplasia"},{"issue":"1","key":"1294_CR785","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1038\/s41467-020-15817-5","volume":"11","author":"V Barbier","year":"2020","unstructured":"Barbier V, et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nat Commun. 2020;11(1):2042.","journal-title":"Nat Commun"},{"key":"1294_CR786","first-page":"1","volume":"15","author":"SM Abedin","year":"2025","unstructured":"Abedin SM, et al. Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed\/refractory acute myeloid leukemia. Leukemia. 2025;15:1\u20137.","journal-title":"Leukemia"},{"issue":"13","key":"1294_CR787","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1182\/bloodadvances.2022007956","volume":"7","author":"HS Kim","year":"2023","unstructured":"Kim HS, et al. TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently. Blood Adv. 2023;7(13):3155\u201368.","journal-title":"Blood Adv"},{"issue":"4","key":"1294_CR788","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41375-025-02520-x","volume":"39","author":"C Shi","year":"2025","unstructured":"Shi C, et al. Immunotherapy targeting a leader sequence cathepsin G-derived peptide. Leukemia. 2025;39(4):888\u201398.","journal-title":"Leukemia"},{"issue":"1","key":"1294_CR789","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41392-025-02125-x","volume":"10","author":"X Hu","year":"2025","unstructured":"Hu X, et al. Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia. Signal Transduct Target Ther. 2025;10(1):50.","journal-title":"Signal Transduct Target Ther"},{"key":"1294_CR790","first-page":"1","volume":"24","author":"S Ikeda","year":"2025","unstructured":"Ikeda S, et al. CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant. Nat Cancer. 2025;24:1\u20137.","journal-title":"Nat Cancer"},{"issue":"1","key":"1294_CR791","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12906-025-04903-0","volume":"25","author":"KK Gyi","year":"2025","unstructured":"Gyi KK, et al. Anti-leukemia activity of the ethyl acetate extract from Gynostemma pentaphyllum (Thunb.) leaf against FLT3-overexpressing AML cells and its phytochemical characterization. BMC Complement Med Therap. 2025;25(1):172.","journal-title":"BMC Complement Med Therap"},{"key":"1294_CR792","doi-asserted-by":"crossref","unstructured":"Wang, L., et al., 2025 Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia. Investigational New Drugs","DOI":"10.1007\/s10637-025-01541-8"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01294-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01294-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01294-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:03:28Z","timestamp":1759601008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01294-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":792,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1294"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01294-9","relation":{"references":[{"id-type":"doi","id":"10.1042\/BSR20211248","asserted-by":"subject"}]},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"171"}}